Safety and Immunogenicity of H1N1 Vaccine With Trivalent Inactivated Seasonal Influenza Vaccine in Adults

A Study to Evaluate the Safety and Immunogenicity of an A/California/7/2009 (H1N1)V-like Vaccine GSK2340274A or GSK2340273A Co-administered With Trivalent Inactivated Seasonal Influenza Vaccine in Adults 19 to 40 Years of Age

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00985673

Enrollment

611

Registered

2009-09-28

Start date

2009-10-01

Completion date

2010-12-29

Last updated

2018-08-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Influenza

Keywords

GSK Bio's influenza vaccine GSK2340274A, influenza infection, GSK Bio's influenza vaccine GSK2340273A

Brief summary

The purpose of this study is to characterize the safety and immunogenicity of the H1N1 (swine) flu vaccines GSK2340274A and GSK2340273A when co-administered with the seasonal flu vaccine in adults 19 to 40 years of age.

Detailed description

Collaborators: United States Department of Health and Human Services, Office of Biomedical Advanced Research and Development Authority

Interventions

BIOLOGICALGSK2340274A

Two intramuscular injections

BIOLOGICALGSK2340273A

Two intramuscular injections

BIOLOGICALSeasonal trivalent influenza vaccine (TIV)

Single intramuscular injection

BIOLOGICALSaline placebo

Single intramuscular injection

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

PREVENTION

Masking

TRIPLE (Subject, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

19 Years to 40 Years

Healthy volunteers

Yes

Inclusion criteria

* Subjects who the investigator believes can and will comply with the requirements of the protocol. * Written informed consent obtained from the subject. * Male or female adults, 19-40 years of age at the time of the first vaccination. * Safety laboratory tests results within the parameters specified in the protocol. * Satisfactory baseline medical assessment by physical examination. * Comprehension of the study requirements, ability to comprehend and comply with procedures for collection of safety data, expressed availability for the required study period, and ability and willingness to attend scheduled visits as documented by signature on the informed consent document. * Access to a consistent means of telephone contact, which may be either in the home or at the workplace, land line, or mobile, but NOT a pay phone or other multiple-user device. * Female subjects of non-childbearing potential may be enrolled in the study. * Female subjects of childbearing potential may be enrolled in the study, if the subject: * has practiced adequate contraception for 30 days prior to vaccination, and * has a negative pregnancy test on the day of first vaccination, and * has agreed to continue adequate contraception during the entire treatment period and for 2 months after completion of the vaccination series.

Exclusion criteria

* Previous vaccination with an H1N1v-like virus vaccine or a medical history of physician-confirmed infection with an H1N1v-like virus. * Prior receipt at any time of any seasonal influenza vaccine. * Planned administration of any vaccine not foreseen by the study protocol between Day 0 and the Day 63 phlebotomy. * Administration of any licensed vaccine within 4 weeks before the first study vaccine dose. * Use of any investigational or non-registered product other than the study vaccines within 30 days preceding the first dose of study vaccine, or planned use during the study period. * Receipt of systemic glucocorticoids within one month prior to study enrolment, or any other cytotoxic or immunosuppressive drug within six months of study enrolment. Topical, intra-articularly injected, or inhaled glucocorticoids, topical calcineurin inhibitors or imiquimod are allowed. * Receipt of any immunoglobulins and/or any blood products within three months of study enrolment or planned administration of any of these products during the study period. * Presence of evidence of substance abuse or of neurological or psychiatric diagnoses which, even if stable, are deemed by the investigator to render the potential subject unable/unlikely to provide accurate safety reports. * Presence of a temperature \>= 38.0ºC (\>=100.4ºF), or acute symptoms greater than mild severity on the scheduled date of first vaccination. * Diagnosed with cancer, or treatment for cancer, within 3 years. * Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination. * Any significant disorder of coagulation or treatment with warfarin derivatives or heparin. Persons receiving individual doses of low molecular weight heparin outside of 24 hours prior to vaccination are eligible. Persons receiving prophylactic antiplatelet medications, e.g., low-dose acetylsalicylic acid, and without a clinically-apparent bleeding tendency, are eligible. * An acute evolving neurological disorder or history of Guillain-Barré syndrome within six weeks of receipt of seasonal influenza vaccine. * Any known or suspected allergy to any constituent of influenza vaccines; a history of anaphylactic-type reaction to any constituent of influenza vaccines; or a history of severe adverse reaction to a previous influenza vaccine. * Known pregnancy or a positive urine beta-human chorionic gonadotropin test result prior to first vaccination. * Lactating or nursing women.

Design outcomes

Primary

Measure	Time frame	Description
Hemagglutination Inhibition (HI) Antibody Titers Against A/California/7/2009 H1N1 Vaccine Strain.	21 days after the second dose of Arepanrix vaccine (at Day 42).	The A/California vaccine virus-homologous antibody response was measured in subjects having received Flulaval vaccine co-administered with the first dose of Arepanrix vaccine, and in subjects having received two doses of Arepanrix vaccine alone. Titers were expressed as geometric mean antibody titers (GMTs).

Secondary

Measure	Time frame	Description
Number of Influenza-specific Cluster of Differentiation 4 (CD4) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	On Days 0, 7, 21, 28, 42, 63 and 182	Influenza-specific CD4 T-Cells were stimulated in vitro with A/California virus and seasonal Influenza viruses, related antigens or derived peptides. Stimulating antigens were A/Brisbane, A/California, pool peptides H1N1 and pool FLU.
Number of Influenza-specific Cluster of Differentiation 8 (CD8) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	On Days 0, 7, 21, 28, 42, 63 and 182	Influenza-specific CD8 T-Cells were stimulated in vitro with A/California virus and seasonal Influenza viruses, related antigens or derived peptides. Stimulating antigens were A/Brisbane, A/California, pool peptides H1N1 and pool FLU.
Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	On Days 0, 7, 21, 28, 42, 63 and 182	Laboratory parameters assessed were alanine aminotransferase (ALAT), aspartate aminotransferase (ASAT), alkaline phosphatase (AP), bilirubin (BIL) (total (T)), basophils (BAS). For each parameter and for each range it was assessed whether the values of the subjects were in unkown, above, below or within the range.
Number of Subjects Reporting Solicited Local Symptoms.	During a 7-day follow-up period (Days 0-6) post-vaccination period	Solicited local symptoms assessed were pain, redness and swelling
Number of Subjects Reporting Solicited General Symptoms.	During a 7-day follow-up period (Days 0-6) post-vaccination period	Solicited general symptoms assessed were fatigue, headache, joint pain at other location, muscle aches, shivering, sweating and temperature. Temperature is defined as an axillary temperature equal to or above 38.0 degrees Celsius (°C).
Number of Subjects Reporting Unsolicited Adverse Events (AEs).	Within the 84-day (Days 0-83) post-vaccination period.	An unsolicited adverse event is any adverse event (i.e. any untoward medical occurrence in a patient or clinical investigation subject, temporally associated with use of a medicinal product, whether or not considered related to the medicinal product) reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms.
Number of Subjects Reporting Medically Attended Visits (MAEs).	During the entire study period (Days 0-368).	The day 368 was the last contact day for the last subject reporting the event. For each solicited and unsolicited symptom the subject experienced, the subject was asked if they received medical attention defined as hospitalization, an emergency room visit or a visit to or from medical personnel for any reason.
Number of Subjects Reporting Potential Immune Diseases (pIMDs).	During the entire study period (Days 0-406).	The day 406 was the last contact day with the subjects reporting the event. Potential immune-mediated diseases (pIMDs) are a subset of AEs that include both clearly autoimmune diseases and also other inflammatory and/or neurologic disorders which may or may not have an autoimmune etiology.
Number of Subjects Reporting Serious Adverse Events (SAEs).	During the entire study period (Days 0-329).	The day 329 was the last contact day with the subjects reporting serious adverse events. SAEs assessed include medical occurrences that results in death, are life threatening, require hospitalization or prolongation of hospitalization, results in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subjects.
Microneutralization Antibody Titers Against A/California/7/2009 (H1N1) Strain.	On Days 0, 21, 42, 63 and 182	Titers were expressed as geometric mean titers (GMTs) and measured by microneutralization. Arepanrix vaccine strain and the unadjuvanted formulation of Arepanrix vaccine strain was A/California/7/2009 (H1N1). Microneutralization testing was cancelled.
Number of Subjects With a Microneutralization Titer Greater Than or Equal to 1:28 for Antibodies Against A/California/7/2009 (H1N1) Strain.	On Days 0, 21, 42, 63 and 182	Arepanrix vaccine strain and the unadjuvanted formulation of Arepanrix vaccine strain was A/California/7/2009 (H1N1). The antibody cut-off value assessed was a titer of 1:10 and this value was considered as seropositivity. Seronegative subject is a subject whose antibody titer is below the cut-off value, a seropositive subject is a subject whose antibody titer is greater than or equal to the cut-off value. Microneutralization titers \< 1:28 were considered below the cut-off. Microneutralization testing was cancelled.
Vaccine Response Rates (VRR) for Microneutralization Antibody Titers Against A/California/7/2009 (H1N1) Strain.	On Days 0, 21, 42, 63 and 182	Arepanrix vaccine strain and the unadjuvanted formulation of Arepanrix vaccine strain was A/California/7/2009 (H1N1). Vaccine Response Rate for microneutralization titers was defined as the incidence rate of vaccinees with at least a 4-fold increase in post vaccination reciprocal titer relative to Day 0. Microneutralization testing was cancelled.
Hemagglutination Inhibition (HI) Antibody Titers Against A/California/7/2009 H1N1 Vaccine Strain.	21 days after the second dose of Arepanrix vaccine (Day 63 for Flulaval/placebo/Arepanrix Group and Day 42 for Arepanrix/placebo/Flulaval Group)	The A/California vaccine virus-homologous antibody response was measured in subjects having received two doses of Arepanrix vaccine, with prior treatment with Flulaval vaccine 21 days before the first dose and in subjects having received two doses of Arepanrix vaccine alone. Titers were expressed as geometric mean antibody titers (GMTs).
Hemagglutination Inhibition (HI) Antibody Titers Against Each of the Three Flulaval Strains.	21 days after the Flulaval vaccination (at Day 21).	The antibody response against each of the three Flulaval vaccine components in subjects exposed to co-administration of Flulaval vaccine with the first of two doses of Arepanrix vaccine and in subjects exposed to a single dose of Flulaval vaccine. Flulaval vaccine strains were Flu A/Brisbane/59/2007 H1N1, Flu A/Uruguay/716/2007 H3N2 and Flu B/Brisbane/60/2008. Titers were expressed as geometric mean antibody titers (GMTs).
Geometric Mean Antibody Titers (GMTs) for Hemagglutination Inhibition (HI) Antibodies Against Flu A/California H1N1 Strain.	On Days 0, 21, 42 and 63	Titers were expressed as geometric mean antibody titers (GMTs).
Number of Seroconverted Subjects for Antibodies Against A/ California Strain.	At Day 63 from Day 21 for Flulaval/placebo/unadjuvanted Arepanrix and Flulaval/placebo/Arepanrix Groups; At Day 42 from Day 0 for the 4 other groups	Seroconversion rate was defined as the incidence rate of vaccinees who had either a pre-vaccination titer recorded as \< 1:10 and a post-vaccination reciprocal titer ≥ 40 or a pre-vaccination reciprocal titer ≥ 10 and at least a 4-fold increase in post vaccination reciprocal titer. Seroconversion defined as: For initially seronegative subjects, antibody titer ≥ 1:40 after vaccination For initially seropositive subjects, antibody titer after vaccination ≥ 4 fold the pre-vaccination antibody titer
Number of Seroprotected Subjects for Antibodies Against A/California Strain.	At Day 63 for Flulaval/placebo/unadjuvanted Arepanrix and Flulaval/placebo/Arepanrix Groups; At Day 42 for the 4 other groups.	Seroprotection rate was defined as the proportion of subjects with H1N1 reciprocal HI titers ≥ 40 against the tested vaccine virus.
Seroconversion Factor for Antibodies Against A/California Strain.	At Day 63 from Day 21 for Flulaval/placebo/unadjuvanted Arepanrix and Flulaval/placebo/Arepanrix Groups; At Day 42 from Day 0 for the 4 other groups	Seroconversion factor was defined as the geometric mean of the within-subject ratios of the post-vaccination reciprocal HI titer to the prevaccination reciprocal HI titer.
Number of Seroconverted Subjects for Antibodies Against Flulaval Vaccine Strains.	At Day 21 from Day 0 for the pooled group, Flulaval/unadjuvanted Arepanrix/placebo and Flulaval/Arepanrix/placebo Groups; at Day 63 from Day 42 for Unadjuvanted Arepanrix/placebo/Flulaval Group and Arepanrix/placebo/Flulaval Group	Seroconversion defined as: For initially seronegative subjects, antibody titer ≥ 1:40 after vaccination For initially seropositive subjects, antibody titer after vaccination ≥ 4 fold the pre-vaccination antibody titer Flulaval vaccines strains were A/Brisbane/59/2007 H1N1, A/Uruguay/716/2007 H3N2 and B/Brisbane/60/2008. For the analysis the Flulaval/placebo/unadjuvanted Arepanrix Group and the Flulaval/placebo/Arepanrix Group were pooled.
Number of Seroprotected Subjects for Antibodies Against Flulaval Vaccine Strains	At Day 21 for the pooled group, Flulaval/unadjuvanted Arepanrix/placebo and Flulaval/Arepanrix/placebo Groups; at Day 63 for Unadjuvanted Arepanrix/placebo/Flulaval Group and Arepanrix/placebo/Flulaval Group	Seroprotection was defined as the proportion of subjects with H1N1 reciprocal Hemagglutination Inhibition (HI) titers ≥ 1:40 against the tested vaccine virus. Flulaval vaccines strains were A/Brisbane/59/2007 H1N1, A/Uruguay/716/2007 H3N2 and B/Brisbane/60/2008. For the analysis the Flulaval/placebo/unadjuvanted Arepanrix Group and the Flulaval/placebo/Arepanrix Group were pooled.
Seroconversion Factor for Antibodies Against Flulaval Vaccine Strains.	At Day 21 from Day 0 for the pooled group, Flulaval/unadjuvanted Arepanrix/placebo and Flulaval/Arepanrix/placebo Groups; at Day 63 from Day 42 for Unadjuvanted Arepanrix/placebo/Flulaval Group and Arepanrix/placebo/Flulaval Group	Seroconversion factor was defined as the geometric mean of the within-subject ratios of the post-vaccination reciprocal Hemagglutination Inhibition (HI) titer to the prevaccination reciprocal HI titer. Flulaval vaccines strains were A/Brisbane/59/2007 H1N1, A/Uruguay/716/2007 H3N2 and B/Brisbane/60/2008. For the analysis the Flulaval/placebo/unadjuvanted Arepanrix Group and the Flulaval/placebo/Arepanrix Group were pooled.
Number of Seroconverted Subjects for Antibodies Against Flulaval Vaccine Strains	on Days 21 and 63 from Day 0 for the first 4 groups; on Days 42 and 63 from Day 0 for the Unadjuvanted Arepanrix/placebo/Flulaval and Arepanrix/placebo/Flulaval Groups	Seroconversion defined as: For initially seronegative subjects, antibody titer ≥ 1:40 after vaccination For initially seropositive subjects, antibody titer after vaccination ≥ 4 fold the pre-vaccination antibody titer Flulaval vaccines strains were A/Brisbane/59/2007 H1N1, A/Uruguay/716/2007 H3N2 and B/Brisbane/60/2008.
Number of Seroprotected Subjects for Antibodies Against Flulaval Vaccine Strains.	before vaccination and on days 21 and 63 for the first 4 groups and before vaccination and on days 42 and 63 for the Unadjuvanted Arepanrix/placebo/Flulaval and Arepanrix/placebo/Flulaval Groups	Seroprotection rate was defined as the proportion of subjects with H1N1 reciprocal HI titers ≥ 40 against the tested vaccine virus. Flulaval vaccines strains were A/Brisbane/59/2007 H1N1, A/Uruguay/716/2007 H3N2 and B/Brisbane/60/2008.
Geometric Mean Antibody Titers (GMTs) for Hemagglutination Inhibition (HI) Antibodies Against Flulaval Vaccine Strains.	On Days 0, 21 and 63 for the first 4 groups and on Days 0, 42 and 63 for the Unadjuvanted Arepanrix/placebo/Flulaval and Arepanrix/placebo/Flulaval Groups	Titers were expressed as geometric mean titers (GMTs). Flulaval vaccines strains were A/Brisbane/59/2007 H1N1, A/Uruguay/716/2007 H3N2 and B/Brisbane/60/2008.

Countries

Canada, United States

Participant flow

Participants by arm

Arm	Count
Flulaval/Placebo/Unadjuvanted Arepanrix Group subjects received co-administration of Flulaval vaccine and saline placebo on Day 0 followed by the unadjuvanted formulation of Arepanrix vaccine on Day 21 and Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.	102
Flulaval/Placebo/Arepanrix Group subjects received co-administration of Flulaval vaccine and saline placebo on Day 0 followed the administration of Arepanrix vaccine on Day 21 and Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.	104
Flulaval/Unadjuvanted Arepanrix/Placebo Group subjects received co-administration of Flulaval vaccine and the unadjuvanted formulation of Arepanrix vaccine on Day 0 followed by the administration of the unadjuvanted formulation of Arepanrix vaccine on Day 21 and saline placebo on Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.	102
Flulaval/Arepanrix/Placebo Group subjects received co-administration of Flulaval vaccine and Arepanrix vaccine on Day 0 followed by Arepanrix vaccine on Day 21 and saline placebo on Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.	100
Unadjuvanted Arepanrix/Placebo/Flulaval Group subjects received co-administration of the unadjuvanted formulation of Arepanrix vaccine and saline placebo on Day 0 followed by the unadjuvanted formulation of Arepanrix vaccine on Day 21 and Flulaval vaccine on Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.	101
Arepanrix/Placebo/Flulaval Group subjects received co-administration of Arepanrix vaccine and saline placebo on Day 0 followed by Arepanrix vaccine on Day 21 and Flulaval vaccine on Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.	102
Total	611

Withdrawals & dropouts

Period	Reason	FG000	FG001	FG002	FG003	FG004	FG005
Overall Study	Lost to Follow-up	6	7	6	10	5	3
Overall Study	Other	1	0	1	0	1	0
Overall Study	Withdrawal by Subject	0	4	5	2	2	3

Baseline characteristics

Characteristic	Flulaval/Placebo/Unadjuvanted Arepanrix Group	Flulaval/Placebo/Arepanrix Group	Flulaval/Unadjuvanted Arepanrix/Placebo Group	Flulaval/Arepanrix/Placebo Group	Unadjuvanted Arepanrix/Placebo/Flulaval Group	Arepanrix/Placebo/Flulaval Group	Total
Age, Continuous	29.7 Years STANDARD_DEVIATION 6.2	28.6 Years STANDARD_DEVIATION 6.24	28.2 Years STANDARD_DEVIATION 6.32	29.2 Years STANDARD_DEVIATION 6.12	29.3 Years STANDARD_DEVIATION 6.47	28.1 Years STANDARD_DEVIATION 6.08	28.9 Years STANDARD_DEVIATION 6.2
Sex: Female, Male Female	53 Participants	62 Participants	54 Participants	48 Participants	60 Participants	58 Participants	335 Participants
Sex: Female, Male Male	49 Participants	42 Participants	48 Participants	52 Participants	41 Participants	44 Participants	276 Participants

Adverse events

Event type	EG000 affected / at risk	EG001 affected / at risk	EG002 affected / at risk	EG003 affected / at risk	EG004 affected / at risk	EG005 affected / at risk
deaths Total, all-cause mortality	— / —	— / —	— / —	— / —	— / —	— / —
other Total, other adverse events	92 / 102	91 / 104	86 / 102	97 / 100	84 / 101	99 / 102
serious Total, serious adverse events	3 / 102	1 / 104	1 / 102	2 / 100	1 / 101	3 / 102

Outcome results

Primary

Hemagglutination Inhibition (HI) Antibody Titers Against A/California/7/2009 H1N1 Vaccine Strain.

The A/California vaccine virus-homologous antibody response was measured in subjects having received Flulaval vaccine co-administered with the first dose of the unadjuvanted formulation of Arepanrix vaccine, and in subjects having received two doses of the unadjuvanted formulation of Arepanrix vaccine alone. Titers were expressed as geometric mean antibody titers (GMTs).

Time frame: 21 days after the second dose of the unadjuvanted formulation of Arepanrix vaccine (at Day 42)

Population: The According-To-Protocol (ATP) cohort for immunogenicity included evaluable subjects (i.e. those meeting eligibility criteria, with no elimination criteria) who received 2 doses and for whom assay results were available for antibodies against H1N1 antigen 21 days after the 2nd vaccine dose.

Arm	Measure	Value (GEOMETRIC_MEAN)
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Hemagglutination Inhibition (HI) Antibody Titers Against A/California/7/2009 H1N1 Vaccine Strain.	271.2 Titers
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Hemagglutination Inhibition (HI) Antibody Titers Against A/California/7/2009 H1N1 Vaccine Strain.	387.1 Titers

Primary

Hemagglutination Inhibition (HI) Antibody Titers Against A/California/7/2009 H1N1 Vaccine Strain.

The A/California vaccine virus-homologous antibody response was measured in subjects having received Flulaval vaccine co-administered with the first dose of Arepanrix vaccine, and in subjects having received two doses of Arepanrix vaccine alone. Titers were expressed as geometric mean antibody titers (GMTs).

Time frame: 21 days after the second dose of Arepanrix vaccine (at Day 42).

Arm	Measure	Value (GEOMETRIC_MEAN)
Flulaval/Arepanrix/Placebo Group	Hemagglutination Inhibition (HI) Antibody Titers Against A/California/7/2009 H1N1 Vaccine Strain.	589.8 Titers
Arepanrix/Placebo/Flulaval Group	Hemagglutination Inhibition (HI) Antibody Titers Against A/California/7/2009 H1N1 Vaccine Strain.	933.1 Titers

Secondary

Geometric Mean Antibody Titers (GMTs) for Hemagglutination Inhibition (HI) Antibodies Against Flu A/California H1N1 Strain.

Titers were expressed as geometric mean antibody titers (GMTs).

Time frame: On Days 0, 21, 42 and 63

Arm	Measure	Group	Value (GEOMETRIC_MEAN)
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Geometric Mean Antibody Titers (GMTs) for Hemagglutination Inhibition (HI) Antibodies Against Flu A/California H1N1 Strain.	Flu A/Cal H1N1 [at Day 0] (N=92;86;92;88;91;91)	14.6 Titers
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Geometric Mean Antibody Titers (GMTs) for Hemagglutination Inhibition (HI) Antibodies Against Flu A/California H1N1 Strain.	Flu A/Cal H1N1 [at Day 21] (N=92;86;92;89;91;91)	31.1 Titers
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Geometric Mean Antibody Titers (GMTs) for Hemagglutination Inhibition (HI) Antibodies Against Flu A/California H1N1 Strain.	Flu A/Cal H1N1 [at Day 42] (N=92;86;92;89;91;91)	238.6 Titers
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Geometric Mean Antibody Titers (GMTs) for Hemagglutination Inhibition (HI) Antibodies Against Flu A/California H1N1 Strain.	Flu A/Cal H1N1 [at Day 63] (N=92;86;92;89;91;91)	254.2 Titers
Flulaval/Placebo/Arepanrix Group	Geometric Mean Antibody Titers (GMTs) for Hemagglutination Inhibition (HI) Antibodies Against Flu A/California H1N1 Strain.	Flu A/Cal H1N1 [at Day 42] (N=92;86;92;89;91;91)	396.2 Titers
Flulaval/Placebo/Arepanrix Group	Geometric Mean Antibody Titers (GMTs) for Hemagglutination Inhibition (HI) Antibodies Against Flu A/California H1N1 Strain.	Flu A/Cal H1N1 [at Day 21] (N=92;86;92;89;91;91)	26.3 Titers
Flulaval/Placebo/Arepanrix Group	Geometric Mean Antibody Titers (GMTs) for Hemagglutination Inhibition (HI) Antibodies Against Flu A/California H1N1 Strain.	Flu A/Cal H1N1 [at Day 0] (N=92;86;92;88;91;91)	10.9 Titers
Flulaval/Placebo/Arepanrix Group	Geometric Mean Antibody Titers (GMTs) for Hemagglutination Inhibition (HI) Antibodies Against Flu A/California H1N1 Strain.	Flu A/Cal H1N1 [at Day 63] (N=92;86;92;89;91;91)	645.2 Titers
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Geometric Mean Antibody Titers (GMTs) for Hemagglutination Inhibition (HI) Antibodies Against Flu A/California H1N1 Strain.	Flu A/Cal H1N1 [at Day 63] (N=92;86;92;89;91;91)	245.0 Titers
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Geometric Mean Antibody Titers (GMTs) for Hemagglutination Inhibition (HI) Antibodies Against Flu A/California H1N1 Strain.	Flu A/Cal H1N1 [at Day 42] (N=92;86;92;89;91;91)	271.2 Titers
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Geometric Mean Antibody Titers (GMTs) for Hemagglutination Inhibition (HI) Antibodies Against Flu A/California H1N1 Strain.	Flu A/Cal H1N1 [at Day 21] (N=92;86;92;89;91;91)	277.3 Titers
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Geometric Mean Antibody Titers (GMTs) for Hemagglutination Inhibition (HI) Antibodies Against Flu A/California H1N1 Strain.	Flu A/Cal H1N1 [at Day 0] (N=92;86;92;88;91;91)	13.0 Titers
Flulaval/Arepanrix/Placebo Group	Geometric Mean Antibody Titers (GMTs) for Hemagglutination Inhibition (HI) Antibodies Against Flu A/California H1N1 Strain.	Flu A/Cal H1N1 [at Day 0] (N=92;86;92;88;91;91)	10.7 Titers
Flulaval/Arepanrix/Placebo Group	Geometric Mean Antibody Titers (GMTs) for Hemagglutination Inhibition (HI) Antibodies Against Flu A/California H1N1 Strain.	Flu A/Cal H1N1 [at Day 63] (N=92;86;92;89;91;91)	426.9 Titers
Flulaval/Arepanrix/Placebo Group	Geometric Mean Antibody Titers (GMTs) for Hemagglutination Inhibition (HI) Antibodies Against Flu A/California H1N1 Strain.	Flu A/Cal H1N1 [at Day 21] (N=92;86;92;89;91;91)	361.0 Titers
Flulaval/Arepanrix/Placebo Group	Geometric Mean Antibody Titers (GMTs) for Hemagglutination Inhibition (HI) Antibodies Against Flu A/California H1N1 Strain.	Flu A/Cal H1N1 [at Day 42] (N=92;86;92;89;91;91)	589.8 Titers
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Geometric Mean Antibody Titers (GMTs) for Hemagglutination Inhibition (HI) Antibodies Against Flu A/California H1N1 Strain.	Flu A/Cal H1N1 [at Day 42] (N=92;86;92;89;91;91)	387.1 Titers
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Geometric Mean Antibody Titers (GMTs) for Hemagglutination Inhibition (HI) Antibodies Against Flu A/California H1N1 Strain.	Flu A/Cal H1N1 [at Day 63] (N=92;86;92;89;91;91)	345.3 Titers
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Geometric Mean Antibody Titers (GMTs) for Hemagglutination Inhibition (HI) Antibodies Against Flu A/California H1N1 Strain.	Flu A/Cal H1N1 [at Day 21] (N=92;86;92;89;91;91)	358.7 Titers
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Geometric Mean Antibody Titers (GMTs) for Hemagglutination Inhibition (HI) Antibodies Against Flu A/California H1N1 Strain.	Flu A/Cal H1N1 [at Day 0] (N=92;86;92;88;91;91)	9.3 Titers
Arepanrix/Placebo/Flulaval Group	Geometric Mean Antibody Titers (GMTs) for Hemagglutination Inhibition (HI) Antibodies Against Flu A/California H1N1 Strain.	Flu A/Cal H1N1 [at Day 21] (N=92;86;92;89;91;91)	659.8 Titers
Arepanrix/Placebo/Flulaval Group	Geometric Mean Antibody Titers (GMTs) for Hemagglutination Inhibition (HI) Antibodies Against Flu A/California H1N1 Strain.	Flu A/Cal H1N1 [at Day 42] (N=92;86;92;89;91;91)	933.1 Titers
Arepanrix/Placebo/Flulaval Group	Geometric Mean Antibody Titers (GMTs) for Hemagglutination Inhibition (HI) Antibodies Against Flu A/California H1N1 Strain.	Flu A/Cal H1N1 [at Day 63] (N=92;86;92;89;91;91)	704.0 Titers
Arepanrix/Placebo/Flulaval Group	Geometric Mean Antibody Titers (GMTs) for Hemagglutination Inhibition (HI) Antibodies Against Flu A/California H1N1 Strain.	Flu A/Cal H1N1 [at Day 0] (N=92;86;92;88;91;91)	10.1 Titers

Secondary

Geometric Mean Antibody Titers (GMTs) for Hemagglutination Inhibition (HI) Antibodies Against Flu A/California H1N1 Strain.

Titers were expressed as geometric mean antibody titers (GMTs).

Time frame: At Day 182

Population: The According-To-Protocol (ATP) cohort for immunogenicity at Day 182 included evaluable subjects (i.e. those meeting eligibility criteria, with no elimination criteria) for whom 1 dose of Flulaval vaccine and 2 doses of pandemic vaccine were administered and results were available for antibodies against H1N1 antigen at Day 182.

Arm	Measure	Value (GEOMETRIC_MEAN)
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Geometric Mean Antibody Titers (GMTs) for Hemagglutination Inhibition (HI) Antibodies Against Flu A/California H1N1 Strain.	136.6 Titers
Flulaval/Placebo/Arepanrix Group	Geometric Mean Antibody Titers (GMTs) for Hemagglutination Inhibition (HI) Antibodies Against Flu A/California H1N1 Strain.	206.9 Titers
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Geometric Mean Antibody Titers (GMTs) for Hemagglutination Inhibition (HI) Antibodies Against Flu A/California H1N1 Strain.	151.7 Titers
Flulaval/Arepanrix/Placebo Group	Geometric Mean Antibody Titers (GMTs) for Hemagglutination Inhibition (HI) Antibodies Against Flu A/California H1N1 Strain.	171.7 Titers
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Geometric Mean Antibody Titers (GMTs) for Hemagglutination Inhibition (HI) Antibodies Against Flu A/California H1N1 Strain.	218.5 Titers
Arepanrix/Placebo/Flulaval Group	Geometric Mean Antibody Titers (GMTs) for Hemagglutination Inhibition (HI) Antibodies Against Flu A/California H1N1 Strain.	323.6 Titers

Secondary

Geometric Mean Antibody Titers (GMTs) for Hemagglutination Inhibition (HI) Antibodies Against Flulaval Vaccine Strains.

Titers were expressed as geometric mean titers (GMTs). Flulaval vaccines strains were A/Brisbane/59/2007 H1N1, A/Uruguay/716/2007 H3N2 and B/Brisbane/60/2008.

Time frame: At Day 182 after dose 1 vaccination

Arm	Measure	Group	Value (GEOMETRIC_MEAN)
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Geometric Mean Antibody Titers (GMTs) for Hemagglutination Inhibition (HI) Antibodies Against Flulaval Vaccine Strains.	Flu B/Bri/60/08 Victoria	339.9 Titers
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Geometric Mean Antibody Titers (GMTs) for Hemagglutination Inhibition (HI) Antibodies Against Flulaval Vaccine Strains.	Flu A/Bri/59/07 H1N1	68.5 Titers
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Geometric Mean Antibody Titers (GMTs) for Hemagglutination Inhibition (HI) Antibodies Against Flulaval Vaccine Strains.	Flu A/Uru/716/07 H3N2	89.5 Titers
Flulaval/Placebo/Arepanrix Group	Geometric Mean Antibody Titers (GMTs) for Hemagglutination Inhibition (HI) Antibodies Against Flulaval Vaccine Strains.	Flu A/Uru/716/07 H3N2	87.7 Titers
Flulaval/Placebo/Arepanrix Group	Geometric Mean Antibody Titers (GMTs) for Hemagglutination Inhibition (HI) Antibodies Against Flulaval Vaccine Strains.	Flu A/Bri/59/07 H1N1	89.2 Titers
Flulaval/Placebo/Arepanrix Group	Geometric Mean Antibody Titers (GMTs) for Hemagglutination Inhibition (HI) Antibodies Against Flulaval Vaccine Strains.	Flu B/Bri/60/08 Victoria	273.8 Titers
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Geometric Mean Antibody Titers (GMTs) for Hemagglutination Inhibition (HI) Antibodies Against Flulaval Vaccine Strains.	Flu A/Uru/716/07 H3N2	87.1 Titers
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Geometric Mean Antibody Titers (GMTs) for Hemagglutination Inhibition (HI) Antibodies Against Flulaval Vaccine Strains.	Flu A/Bri/59/07 H1N1	87.4 Titers
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Geometric Mean Antibody Titers (GMTs) for Hemagglutination Inhibition (HI) Antibodies Against Flulaval Vaccine Strains.	Flu B/Bri/60/08 Victoria	245.4 Titers
Flulaval/Arepanrix/Placebo Group	Geometric Mean Antibody Titers (GMTs) for Hemagglutination Inhibition (HI) Antibodies Against Flulaval Vaccine Strains.	Flu A/Uru/716/07 H3N2	87.8 Titers
Flulaval/Arepanrix/Placebo Group	Geometric Mean Antibody Titers (GMTs) for Hemagglutination Inhibition (HI) Antibodies Against Flulaval Vaccine Strains.	Flu A/Bri/59/07 H1N1	64.6 Titers
Flulaval/Arepanrix/Placebo Group	Geometric Mean Antibody Titers (GMTs) for Hemagglutination Inhibition (HI) Antibodies Against Flulaval Vaccine Strains.	Flu B/Bri/60/08 Victoria	292.6 Titers
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Geometric Mean Antibody Titers (GMTs) for Hemagglutination Inhibition (HI) Antibodies Against Flulaval Vaccine Strains.	Flu A/Uru/716/07 H3N2	110.0 Titers
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Geometric Mean Antibody Titers (GMTs) for Hemagglutination Inhibition (HI) Antibodies Against Flulaval Vaccine Strains.	Flu A/Bri/59/07 H1N1	64.6 Titers
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Geometric Mean Antibody Titers (GMTs) for Hemagglutination Inhibition (HI) Antibodies Against Flulaval Vaccine Strains.	Flu B/Bri/60/08 Victoria	369.6 Titers
Arepanrix/Placebo/Flulaval Group	Geometric Mean Antibody Titers (GMTs) for Hemagglutination Inhibition (HI) Antibodies Against Flulaval Vaccine Strains.	Flu A/Bri/59/07 H1N1	83.7 Titers
Arepanrix/Placebo/Flulaval Group	Geometric Mean Antibody Titers (GMTs) for Hemagglutination Inhibition (HI) Antibodies Against Flulaval Vaccine Strains.	Flu B/Bri/60/08 Victoria	378.4 Titers
Arepanrix/Placebo/Flulaval Group	Geometric Mean Antibody Titers (GMTs) for Hemagglutination Inhibition (HI) Antibodies Against Flulaval Vaccine Strains.	Flu A/Uru/716/07 H3N2	127.2 Titers

Secondary

Geometric Mean Antibody Titers (GMTs) for Hemagglutination Inhibition (HI) Antibodies Against Flulaval Vaccine Strains.

Titers were expressed as geometric mean titers (GMTs). Flulaval vaccines strains were A/Brisbane/59/2007 H1N1, A/Uruguay/716/2007 H3N2 and B/Brisbane/60/2008.

Time frame: On Days 0, 21 and 63 for the first 4 groups and on Days 0, 42 and 63 for the Unadjuvanted Arepanrix/placebo/Flulaval and Arepanrix/placebo/Flulaval Groups

Arm	Measure	Group	Value (GEOMETRIC_MEAN)
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Geometric Mean Antibody Titers (GMTs) for Hemagglutination Inhibition (HI) Antibodies Against Flulaval Vaccine Strains.	Flu B/Bri/60/08 [at Day 63]	506.7 Titers
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Geometric Mean Antibody Titers (GMTs) for Hemagglutination Inhibition (HI) Antibodies Against Flulaval Vaccine Strains.	Flu A/Bri/59/07 H1N1 [at Day 21 or 42]	145.1 Titers
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Geometric Mean Antibody Titers (GMTs) for Hemagglutination Inhibition (HI) Antibodies Against Flulaval Vaccine Strains.	Flu A/Uru/716/07 H3N2 [at Day 0]	10.1 Titers
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Geometric Mean Antibody Titers (GMTs) for Hemagglutination Inhibition (HI) Antibodies Against Flulaval Vaccine Strains.	Flu B/Bri/60/08 [at Day 0]	52.6 Titers
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Geometric Mean Antibody Titers (GMTs) for Hemagglutination Inhibition (HI) Antibodies Against Flulaval Vaccine Strains.	Flu B/Bri/60/08 [at Day 21 or 42]	662.1 Titers
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Geometric Mean Antibody Titers (GMTs) for Hemagglutination Inhibition (HI) Antibodies Against Flulaval Vaccine Strains.	Flu A/Uru/716/07 H3N2 [at Day 63]	134.4 Titers
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Geometric Mean Antibody Titers (GMTs) for Hemagglutination Inhibition (HI) Antibodies Against Flulaval Vaccine Strains.	Flu A/Bri/59/07 H1N1 [at Day 63]	120.2 Titers
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Geometric Mean Antibody Titers (GMTs) for Hemagglutination Inhibition (HI) Antibodies Against Flulaval Vaccine Strains.	Flu A/Bri/59/07 H1N1 [at Day 0]	17.3 Titers
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Geometric Mean Antibody Titers (GMTs) for Hemagglutination Inhibition (HI) Antibodies Against Flulaval Vaccine Strains.	Flu A/Uru/716/07 H3N2 [at Day 21 or 42]	175.7 Titers
Flulaval/Placebo/Arepanrix Group	Geometric Mean Antibody Titers (GMTs) for Hemagglutination Inhibition (HI) Antibodies Against Flulaval Vaccine Strains.	Flu A/Uru/716/07 H3N2 [at Day 0]	11.8 Titers
Flulaval/Placebo/Arepanrix Group	Geometric Mean Antibody Titers (GMTs) for Hemagglutination Inhibition (HI) Antibodies Against Flulaval Vaccine Strains.	Flu B/Bri/60/08 [at Day 0]	47.3 Titers
Flulaval/Placebo/Arepanrix Group	Geometric Mean Antibody Titers (GMTs) for Hemagglutination Inhibition (HI) Antibodies Against Flulaval Vaccine Strains.	Flu A/Bri/59/07 H1N1 [at Day 63]	186.5 Titers
Flulaval/Placebo/Arepanrix Group	Geometric Mean Antibody Titers (GMTs) for Hemagglutination Inhibition (HI) Antibodies Against Flulaval Vaccine Strains.	Flu A/Bri/59/07 H1N1 [at Day 0]	16.7 Titers
Flulaval/Placebo/Arepanrix Group	Geometric Mean Antibody Titers (GMTs) for Hemagglutination Inhibition (HI) Antibodies Against Flulaval Vaccine Strains.	Flu B/Bri/60/08 [at Day 63]	471.2 Titers
Flulaval/Placebo/Arepanrix Group	Geometric Mean Antibody Titers (GMTs) for Hemagglutination Inhibition (HI) Antibodies Against Flulaval Vaccine Strains.	Flu A/Uru/716/07 H3N2 [at Day 21 or 42]	183.5 Titers
Flulaval/Placebo/Arepanrix Group	Geometric Mean Antibody Titers (GMTs) for Hemagglutination Inhibition (HI) Antibodies Against Flulaval Vaccine Strains.	Flu A/Bri/59/07 H1N1 [at Day 21 or 42]	215.7 Titers
Flulaval/Placebo/Arepanrix Group	Geometric Mean Antibody Titers (GMTs) for Hemagglutination Inhibition (HI) Antibodies Against Flulaval Vaccine Strains.	Flu B/Bri/60/08 [at Day 21 or 42]	658.3 Titers
Flulaval/Placebo/Arepanrix Group	Geometric Mean Antibody Titers (GMTs) for Hemagglutination Inhibition (HI) Antibodies Against Flulaval Vaccine Strains.	Flu A/Uru/716/07 H3N2 [at Day 63]	138.4 Titers
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Geometric Mean Antibody Titers (GMTs) for Hemagglutination Inhibition (HI) Antibodies Against Flulaval Vaccine Strains.	Flu A/Bri/59/07 H1N1 [at Day 63]	157.0 Titers
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Geometric Mean Antibody Titers (GMTs) for Hemagglutination Inhibition (HI) Antibodies Against Flulaval Vaccine Strains.	Flu A/Uru/716/07 H3N2 [at Day 63]	132.0 Titers
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Geometric Mean Antibody Titers (GMTs) for Hemagglutination Inhibition (HI) Antibodies Against Flulaval Vaccine Strains.	Flu A/Uru/716/07 H3N2 [at Day 21 or 42]	181.7 Titers
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Geometric Mean Antibody Titers (GMTs) for Hemagglutination Inhibition (HI) Antibodies Against Flulaval Vaccine Strains.	Flu B/Bri/60/08 [at Day 63]	359.6 Titers
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Geometric Mean Antibody Titers (GMTs) for Hemagglutination Inhibition (HI) Antibodies Against Flulaval Vaccine Strains.	Flu A/Bri/59/07 H1N1 [at Day 0]	18.8 Titers
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Geometric Mean Antibody Titers (GMTs) for Hemagglutination Inhibition (HI) Antibodies Against Flulaval Vaccine Strains.	Flu A/Uru/716/07 H3N2 [at Day 0]	8.8 Titers
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Geometric Mean Antibody Titers (GMTs) for Hemagglutination Inhibition (HI) Antibodies Against Flulaval Vaccine Strains.	Flu B/Bri/60/08 [at Day 0]	45.4 Titers
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Geometric Mean Antibody Titers (GMTs) for Hemagglutination Inhibition (HI) Antibodies Against Flulaval Vaccine Strains.	Flu B/Bri/60/08 [at Day 21 or 42]	478.8 Titers
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Geometric Mean Antibody Titers (GMTs) for Hemagglutination Inhibition (HI) Antibodies Against Flulaval Vaccine Strains.	Flu A/Bri/59/07 H1N1 [at Day 21 or 42]	226.3 Titers
Flulaval/Arepanrix/Placebo Group	Geometric Mean Antibody Titers (GMTs) for Hemagglutination Inhibition (HI) Antibodies Against Flulaval Vaccine Strains.	Flu B/Bri/60/08 [at Day 0]	40.1 Titers
Flulaval/Arepanrix/Placebo Group	Geometric Mean Antibody Titers (GMTs) for Hemagglutination Inhibition (HI) Antibodies Against Flulaval Vaccine Strains.	Flu A/Bri/59/07 H1N1 [at Day 21 or 42]	158.7 Titers
Flulaval/Arepanrix/Placebo Group	Geometric Mean Antibody Titers (GMTs) for Hemagglutination Inhibition (HI) Antibodies Against Flulaval Vaccine Strains.	Flu A/Bri/59/07 H1N1 [at Day 63]	124.3 Titers
Flulaval/Arepanrix/Placebo Group	Geometric Mean Antibody Titers (GMTs) for Hemagglutination Inhibition (HI) Antibodies Against Flulaval Vaccine Strains.	Flu A/Uru/716/07 H3N2 [at Day 0]	10.2 Titers
Flulaval/Arepanrix/Placebo Group	Geometric Mean Antibody Titers (GMTs) for Hemagglutination Inhibition (HI) Antibodies Against Flulaval Vaccine Strains.	Flu A/Uru/716/07 H3N2 [at Day 21 or 42]	191.4 Titers
Flulaval/Arepanrix/Placebo Group	Geometric Mean Antibody Titers (GMTs) for Hemagglutination Inhibition (HI) Antibodies Against Flulaval Vaccine Strains.	Flu A/Uru/716/07 H3N2 [at Day 63]	145.6 Titers
Flulaval/Arepanrix/Placebo Group	Geometric Mean Antibody Titers (GMTs) for Hemagglutination Inhibition (HI) Antibodies Against Flulaval Vaccine Strains.	Flu B/Bri/60/08 [at Day 21 or 42]	576.1 Titers
Flulaval/Arepanrix/Placebo Group	Geometric Mean Antibody Titers (GMTs) for Hemagglutination Inhibition (HI) Antibodies Against Flulaval Vaccine Strains.	Flu B/Bri/60/08 [at Day 63]	433.5 Titers
Flulaval/Arepanrix/Placebo Group	Geometric Mean Antibody Titers (GMTs) for Hemagglutination Inhibition (HI) Antibodies Against Flulaval Vaccine Strains.	Flu A/Bri/59/07 H1N1 [at Day 0]	16.2 Titers
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Geometric Mean Antibody Titers (GMTs) for Hemagglutination Inhibition (HI) Antibodies Against Flulaval Vaccine Strains.	Flu A/Uru/716/07 H3N2 [at Day 63]	216.1 Titers
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Geometric Mean Antibody Titers (GMTs) for Hemagglutination Inhibition (HI) Antibodies Against Flulaval Vaccine Strains.	Flu A/Uru/716/07 H3N2 [at Day 21 or 42]	12.5 Titers
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Geometric Mean Antibody Titers (GMTs) for Hemagglutination Inhibition (HI) Antibodies Against Flulaval Vaccine Strains.	Flu B/Bri/60/08 [at Day 21 or 42]	74.7 Titers
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Geometric Mean Antibody Titers (GMTs) for Hemagglutination Inhibition (HI) Antibodies Against Flulaval Vaccine Strains.	Flu A/Uru/716/07 H3N2 [at Day 0]	10.4 Titers
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Geometric Mean Antibody Titers (GMTs) for Hemagglutination Inhibition (HI) Antibodies Against Flulaval Vaccine Strains.	Flu A/Bri/59/07 H1N1 [at Day 21 or 42]	32.9 Titers
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Geometric Mean Antibody Titers (GMTs) for Hemagglutination Inhibition (HI) Antibodies Against Flulaval Vaccine Strains.	Flu B/Bri/60/08 [at Day 63]	644.9 Titers
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Geometric Mean Antibody Titers (GMTs) for Hemagglutination Inhibition (HI) Antibodies Against Flulaval Vaccine Strains.	Flu A/Bri/59/07 H1N1 [at Day 63]	137.4 Titers
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Geometric Mean Antibody Titers (GMTs) for Hemagglutination Inhibition (HI) Antibodies Against Flulaval Vaccine Strains.	Flu A/Bri/59/07 H1N1 [at Day 0]	14.6 Titers
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Geometric Mean Antibody Titers (GMTs) for Hemagglutination Inhibition (HI) Antibodies Against Flulaval Vaccine Strains.	Flu B/Bri/60/08 [at Day 0]	56.7 Titers
Arepanrix/Placebo/Flulaval Group	Geometric Mean Antibody Titers (GMTs) for Hemagglutination Inhibition (HI) Antibodies Against Flulaval Vaccine Strains.	Flu B/Bri/60/08 [at Day 0]	58.0 Titers
Arepanrix/Placebo/Flulaval Group	Geometric Mean Antibody Titers (GMTs) for Hemagglutination Inhibition (HI) Antibodies Against Flulaval Vaccine Strains.	Flu A/Uru/716/07 H3N2 [at Day 21 or 42]	19.1 Titers
Arepanrix/Placebo/Flulaval Group	Geometric Mean Antibody Titers (GMTs) for Hemagglutination Inhibition (HI) Antibodies Against Flulaval Vaccine Strains.	Flu A/Bri/59/07 H1N1 [at Day 0]	16.6 Titers
Arepanrix/Placebo/Flulaval Group	Geometric Mean Antibody Titers (GMTs) for Hemagglutination Inhibition (HI) Antibodies Against Flulaval Vaccine Strains.	Flu A/Bri/59/07 H1N1 [at Day 21 or 42]	53.2 Titers
Arepanrix/Placebo/Flulaval Group	Geometric Mean Antibody Titers (GMTs) for Hemagglutination Inhibition (HI) Antibodies Against Flulaval Vaccine Strains.	Flu B/Bri/60/08 [at Day 63]	688.1 Titers
Arepanrix/Placebo/Flulaval Group	Geometric Mean Antibody Titers (GMTs) for Hemagglutination Inhibition (HI) Antibodies Against Flulaval Vaccine Strains.	Flu B/Bri/60/08 [at Day 21 or 42]	139.5 Titers
Arepanrix/Placebo/Flulaval Group	Geometric Mean Antibody Titers (GMTs) for Hemagglutination Inhibition (HI) Antibodies Against Flulaval Vaccine Strains.	Flu A/Uru/716/07 H3N2 [at Day 0]	11.5 Titers
Arepanrix/Placebo/Flulaval Group	Geometric Mean Antibody Titers (GMTs) for Hemagglutination Inhibition (HI) Antibodies Against Flulaval Vaccine Strains.	Flu A/Uru/716/07 H3N2 [at Day 63]	221.9 Titers
Arepanrix/Placebo/Flulaval Group	Geometric Mean Antibody Titers (GMTs) for Hemagglutination Inhibition (HI) Antibodies Against Flulaval Vaccine Strains.	Flu A/Bri/59/07 H1N1 [at Day 63]	166.9 Titers

Secondary

Hemagglutination Inhibition (HI) Antibody Titers Against A/California/7/2009 H1N1 Vaccine Strain.

The A/California vaccine virus-homologous antibody response was measured in subjects having received two doses of Arepanrix vaccine, with prior treatment with Flulaval vaccine 21 days before the first dose and in subjects having received two doses of Arepanrix vaccine alone. Titers were expressed as geometric mean antibody titers (GMTs).

Time frame: 21 days after the second dose of Arepanrix vaccine (Day 63 for Flulaval/placebo/Arepanrix Group and Day 42 for Arepanrix/placebo/Flulaval Group)

Arm	Measure	Value (GEOMETRIC_MEAN)
Flulaval/Placebo/Arepanrix Group	Hemagglutination Inhibition (HI) Antibody Titers Against A/California/7/2009 H1N1 Vaccine Strain.	645.2 Titers
Arepanrix/Placebo/Flulaval Group	Hemagglutination Inhibition (HI) Antibody Titers Against A/California/7/2009 H1N1 Vaccine Strain.	933.1 Titers

Secondary

Hemagglutination Inhibition (HI) Antibody Titers Against A/California/7/2009 H1N1 Vaccine Strain.

The A/California vaccine virus-homologous antibody response was measured in subjects pre-treated with Flulaval who subsequently received two doses of the unadjuvanted formulation of Arepanrix vaccine compared to subjects pre-treated with Flulaval vaccine who subsequently received two doses of Arepanrix vaccine. Titers were expressed as geometric mean antibody titers (GMTs).

Time frame: 21 days after the second dose of the pandemic vaccine (at Day 63)

Arm	Measure	Value (GEOMETRIC_MEAN)
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Hemagglutination Inhibition (HI) Antibody Titers Against A/California/7/2009 H1N1 Vaccine Strain.	254.2 Titers
Flulaval/Placebo/Arepanrix Group	Hemagglutination Inhibition (HI) Antibody Titers Against A/California/7/2009 H1N1 Vaccine Strain.	645.2 Titers

Secondary

Hemagglutination Inhibition (HI) Antibody Titers Against A/California/7/2009 H1N1 Vaccine Strain.

The A/California vaccine virus-homologous antibody response was measured in subjects having received two doses of the unadjuvanted formulation of Arepanrix vaccine, with prior treatment with Flulaval vaccine 21 days before the first dose and in subjects having received two doses of the unadjuvanted formulation of Arepanrix vaccine alone. Titers were expressed as geometric mean antibody titers (GMTs).

Time frame: 21 days after the second dose of the unadjuvanted formulation of Arepanrix vaccine (Day 63 for Flulaval/placebo/unadjuvanted Arepanrix Group and Day 42 for Unadjuvanted Arepanrix/placebo/Flulaval Group)

Arm	Measure	Value (GEOMETRIC_MEAN)
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Hemagglutination Inhibition (HI) Antibody Titers Against A/California/7/2009 H1N1 Vaccine Strain.	254.2 Titers
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Hemagglutination Inhibition (HI) Antibody Titers Against A/California/7/2009 H1N1 Vaccine Strain.	387.1 Titers

Secondary

Hemagglutination Inhibition (HI) Antibody Titers Against Each of the Three Flulaval Strains.

The antibody response against each of the three Flulaval vaccine components in subjects exposed to co-administration of Flulaval vaccine with the first of two doses of the unadjuvanted formulation of Arepanrix vaccine and in subjects exposed to a single dose of Flulaval vaccine. Flulaval vaccine strains were Flu A/Brisbane/59/2007 H1N1, Flu A/Uruguay/716/2007 H3N2 and Flu B/Brisbane/60/2008. Titers were expressed as geometric mean antibody titers (GMTs).

Time frame: 21 days after the Flulaval vaccination (at Day 21).

Arm	Measure	Group	Value (GEOMETRIC_MEAN)
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Hemagglutination Inhibition (HI) Antibody Titers Against Each of the Three Flulaval Strains.	Flu A/Uru/716/07 H3N2	175.7 Titers
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Hemagglutination Inhibition (HI) Antibody Titers Against Each of the Three Flulaval Strains.	Flu A/Brisbane/59/07 H1N1	145.1 Titers
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Hemagglutination Inhibition (HI) Antibody Titers Against Each of the Three Flulaval Strains.	Flu B/Brisbane/60/08	662.1 Titers
Flulaval/Placebo/Arepanrix Group	Hemagglutination Inhibition (HI) Antibody Titers Against Each of the Three Flulaval Strains.	Flu A/Uru/716/07 H3N2	183.5 Titers
Flulaval/Placebo/Arepanrix Group	Hemagglutination Inhibition (HI) Antibody Titers Against Each of the Three Flulaval Strains.	Flu A/Brisbane/59/07 H1N1	215.7 Titers
Flulaval/Placebo/Arepanrix Group	Hemagglutination Inhibition (HI) Antibody Titers Against Each of the Three Flulaval Strains.	Flu B/Brisbane/60/08	658.3 Titers
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Hemagglutination Inhibition (HI) Antibody Titers Against Each of the Three Flulaval Strains.	Flu A/Brisbane/59/07 H1N1	226.3 Titers
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Hemagglutination Inhibition (HI) Antibody Titers Against Each of the Three Flulaval Strains.	Flu B/Brisbane/60/08	478.8 Titers
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Hemagglutination Inhibition (HI) Antibody Titers Against Each of the Three Flulaval Strains.	Flu A/Uru/716/07 H3N2	181.7 Titers

Secondary

Hemagglutination Inhibition (HI) Antibody Titers Against Each of the Three Flulaval Strains.

The antibody response against each of the three Flulaval vaccine components in subjects exposed to pre-treatment with two doses of the unadjuvanted formulation of Arepanrix vaccine and in subjects exposed to a single dose of Flulaval vaccine. Flulaval vaccine strains were Flu A/Brisbane/59/2007 H1N1, Flu A/Uruguay/716/2007 H3N2 and Flu B/Brisbane/60/2008. Titers were expressed as geometric mean antibody titers (GMTs).

Time frame: 21 days after the Flulaval vaccination (Day 63 for Unadjuvanted Arepanrix/placebo/Flulaval Group and Day 21 for Flulaval/placebo/unadjuvanted Arepanrix and Flulaval/placebo/Arepanrix Groups)

Arm	Measure	Group	Value (GEOMETRIC_MEAN)
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Hemagglutination Inhibition (HI) Antibody Titers Against Each of the Three Flulaval Strains.	Flu A/Uru/716/07 H3N2	175.7 Titers
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Hemagglutination Inhibition (HI) Antibody Titers Against Each of the Three Flulaval Strains.	Flu A/Bri/59/07 H1N1	145.1 Titers
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Hemagglutination Inhibition (HI) Antibody Titers Against Each of the Three Flulaval Strains.	Flu B/Bri/60/08	662.1 Titers
Flulaval/Placebo/Arepanrix Group	Hemagglutination Inhibition (HI) Antibody Titers Against Each of the Three Flulaval Strains.	Flu A/Uru/716/07 H3N2	183.5 Titers
Flulaval/Placebo/Arepanrix Group	Hemagglutination Inhibition (HI) Antibody Titers Against Each of the Three Flulaval Strains.	Flu A/Bri/59/07 H1N1	215.7 Titers
Flulaval/Placebo/Arepanrix Group	Hemagglutination Inhibition (HI) Antibody Titers Against Each of the Three Flulaval Strains.	Flu B/Bri/60/08	658.3 Titers
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Hemagglutination Inhibition (HI) Antibody Titers Against Each of the Three Flulaval Strains.	Flu A/Bri/59/07 H1N1	137.4 Titers
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Hemagglutination Inhibition (HI) Antibody Titers Against Each of the Three Flulaval Strains.	Flu B/Bri/60/08	644.9 Titers
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Hemagglutination Inhibition (HI) Antibody Titers Against Each of the Three Flulaval Strains.	Flu A/Uru/716/07 H3N2	216.1 Titers

Secondary

Hemagglutination Inhibition (HI) Antibody Titers Against Each of the Three Flulaval Strains.

The antibody response against each of the three Flulaval vaccine components in subjects exposed to pre-treatment with two doses of Arepanrix vaccine and in subjects exposed to a single dose of Flulaval vaccine. Flulaval vaccine strains were Flu A/Brisbane/59/2007 H1N1, Flu A/Uruguay/716/2007 H3N2 and Flu B/Brisbane/60/2008. Titers were expressed as geometric mean antibody titers (GMTs).

Time frame: 21 days after the Flulaval vaccination (Day 63 for Arepanrix/placebo/Flulaval Group and Day 21 for Flulaval/placebo/unadjuvanted Arepanrix and Flulaval/placebo/Arepanrix Groups)

Arm	Measure	Group	Value (GEOMETRIC_MEAN)
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Hemagglutination Inhibition (HI) Antibody Titers Against Each of the Three Flulaval Strains.	Flu A/Uru/716/07 H3N2	175.7 Titers
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Hemagglutination Inhibition (HI) Antibody Titers Against Each of the Three Flulaval Strains.	Flu A/BRI/59/07 H1N1	145.1 Titers
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Hemagglutination Inhibition (HI) Antibody Titers Against Each of the Three Flulaval Strains.	Flu B/Bri/60/08	662.1 Titers
Flulaval/Placebo/Arepanrix Group	Hemagglutination Inhibition (HI) Antibody Titers Against Each of the Three Flulaval Strains.	Flu A/Uru/716/07 H3N2	183.5 Titers
Flulaval/Placebo/Arepanrix Group	Hemagglutination Inhibition (HI) Antibody Titers Against Each of the Three Flulaval Strains.	Flu A/BRI/59/07 H1N1	215.7 Titers
Flulaval/Placebo/Arepanrix Group	Hemagglutination Inhibition (HI) Antibody Titers Against Each of the Three Flulaval Strains.	Flu B/Bri/60/08	658.3 Titers
Arepanrix/Placebo/Flulaval Group	Hemagglutination Inhibition (HI) Antibody Titers Against Each of the Three Flulaval Strains.	Flu A/BRI/59/07 H1N1	166.9 Titers
Arepanrix/Placebo/Flulaval Group	Hemagglutination Inhibition (HI) Antibody Titers Against Each of the Three Flulaval Strains.	Flu B/Bri/60/08	688.1 Titers
Arepanrix/Placebo/Flulaval Group	Hemagglutination Inhibition (HI) Antibody Titers Against Each of the Three Flulaval Strains.	Flu A/Uru/716/07 H3N2	221.9 Titers

Secondary

Hemagglutination Inhibition (HI) Antibody Titers Against Each of the Three Flulaval Strains.

The antibody response against each of the three Flulaval vaccine components in subjects exposed to co-administration of Flulaval vaccine with the first of two doses of Arepanrix vaccine and in subjects exposed to a single dose of Flulaval vaccine. Flulaval vaccine strains were Flu A/Brisbane/59/2007 H1N1, Flu A/Uruguay/716/2007 H3N2 and Flu B/Brisbane/60/2008. Titers were expressed as geometric mean antibody titers (GMTs).

Time frame: 21 days after the Flulaval vaccination (at Day 21).

Arm	Measure	Group	Value (GEOMETRIC_MEAN)
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Hemagglutination Inhibition (HI) Antibody Titers Against Each of the Three Flulaval Strains.	Flu A/Uru/716/07 H3N2	175.7 Titers
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Hemagglutination Inhibition (HI) Antibody Titers Against Each of the Three Flulaval Strains.	Flu A/BRI/59/07 H1N1	145.1 Titers
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Hemagglutination Inhibition (HI) Antibody Titers Against Each of the Three Flulaval Strains.	Flu B/Bri/60/08	662.1 Titers
Flulaval/Placebo/Arepanrix Group	Hemagglutination Inhibition (HI) Antibody Titers Against Each of the Three Flulaval Strains.	Flu A/Uru/716/07 H3N2	183.5 Titers
Flulaval/Placebo/Arepanrix Group	Hemagglutination Inhibition (HI) Antibody Titers Against Each of the Three Flulaval Strains.	Flu A/BRI/59/07 H1N1	215.7 Titers
Flulaval/Placebo/Arepanrix Group	Hemagglutination Inhibition (HI) Antibody Titers Against Each of the Three Flulaval Strains.	Flu B/Bri/60/08	658.3 Titers
Flulaval/Arepanrix/Placebo Group	Hemagglutination Inhibition (HI) Antibody Titers Against Each of the Three Flulaval Strains.	Flu A/BRI/59/07 H1N1	158.7 Titers
Flulaval/Arepanrix/Placebo Group	Hemagglutination Inhibition (HI) Antibody Titers Against Each of the Three Flulaval Strains.	Flu B/Bri/60/08	576.1 Titers
Flulaval/Arepanrix/Placebo Group	Hemagglutination Inhibition (HI) Antibody Titers Against Each of the Three Flulaval Strains.	Flu A/Uru/716/07 H3N2	191.4 Titers

Secondary

Microneutralization Antibody Titers Against A/California/7/2009 (H1N1) Strain.

Titers were expressed as geometric mean titers (GMTs) and measured by microneutralization. Arepanrix vaccine strain and the unadjuvanted formulation of Arepanrix vaccine strain was A/California/7/2009 (H1N1). Microneutralization testing was cancelled.

Time frame: On Days 0, 21, 42, 63 and 182

Population: Microneutralization testing was cancelled.

Secondary

Number of Influenza-specific Cluster of Differentiation 4 (CD4) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).

Influenza-specific CD4 T-Cells were stimulated in vitro with A/California virus and seasonal Influenza viruses, related antigens or derived peptides. Stimulating antigens were A/Brisbane, A/California, pool peptides H1N1 and pool FLU.

Time frame: On Days 0, 7, 21, 28, 42, 63 and 182

Arm	Measure	Group	Value (MEAN)	Dispersion
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Influenza-specific Cluster of Differentiation 4 (CD4) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	Pool Flu [D0] (N=24,25,24,25,25,24)	3286.63 Number of T cells/million	Standard Deviation 1710
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Influenza-specific Cluster of Differentiation 4 (CD4) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	Pool peptides H1 [D7] (N=24,27,24,23,24,25)	596.42 Number of T cells/million	Standard Deviation 500.15
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Influenza-specific Cluster of Differentiation 4 (CD4) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	A/Brisbane [D7] (N=24,27,24,23,24,26)	4437.33 Number of T cells/million	Standard Deviation 1930.3
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Influenza-specific Cluster of Differentiation 4 (CD4) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	Pool peptides H1 [D28] (N=26,27,27,26,25,27)	480.42 Number of T cells/million	Standard Deviation 392.81
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Influenza-specific Cluster of Differentiation 4 (CD4) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	A/Brisbane [D0] (N=25,25,24,25,25,26)	2533.40 Number of T cells/million	Standard Deviation 1225.9
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Influenza-specific Cluster of Differentiation 4 (CD4) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	A/Brisbane [D63] (N=26,26,25,25,24,26)	3407.62 Number of T cells/million	Standard Deviation 1114.62
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Influenza-specific Cluster of Differentiation 4 (CD4) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	Pool peptides H1 [D42] (N=27,27,27,27,24,28)	467.70 Number of T cells/million	Standard Deviation 302.91
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Influenza-specific Cluster of Differentiation 4 (CD4) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	A/California [D182] (N=26,24,26,26,25,25)	1461.88 Number of T cells/million	Standard Deviation 735.77
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Influenza-specific Cluster of Differentiation 4 (CD4) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	A/Brisbane [D28] (N=27,27,27,26,25,27)	3500.22 Number of T cells/million	Standard Deviation 1615.89
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Influenza-specific Cluster of Differentiation 4 (CD4) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	A/California [D0] (N=25,25,24,25,25,26)	2176.28 Number of T cells/million	Standard Deviation 1226.08
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Influenza-specific Cluster of Differentiation 4 (CD4) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	Pool Flu [D42] (N=26,27,27,26,24,27)	4734.42 Number of T cells/million	Standard Deviation 1823.28
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Influenza-specific Cluster of Differentiation 4 (CD4) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	Pool Flu [D182] (N=26,24,26,26,25,25)	3304.50 Number of T cells/million	Standard Deviation 1393.44
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Influenza-specific Cluster of Differentiation 4 (CD4) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	Pool Flu [D63] (N=25,26,25,25,24,24)	4405.96 Number of T cells/million	Standard Deviation 1586.42
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Influenza-specific Cluster of Differentiation 4 (CD4) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	Pool peptides H1 [D63] (N=26,26,25,25,24,26)	504.92 Number of T cells/million	Standard Deviation 321.17
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Influenza-specific Cluster of Differentiation 4 (CD4) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	A/California [D63] (N=26,26,25,25,24,26)	2768.15 Number of T cells/million	Standard Deviation 1109.96
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Influenza-specific Cluster of Differentiation 4 (CD4) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	Pool peptides H1 [D0] (N=25,24,24,25,23,25)	349.64 Number of T cells/million	Standard Deviation 336.13
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Influenza-specific Cluster of Differentiation 4 (CD4) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	Pool Flu [D28] (N=25,27,27,26,25,26)	4767.36 Number of T cells/million	Standard Deviation 2217.82
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Influenza-specific Cluster of Differentiation 4 (CD4) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	A/Brisbane [D182] (N=26,24,26,26,25,25)	3190.31 Number of T cells/million	Standard Deviation 1086.38
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Influenza-specific Cluster of Differentiation 4 (CD4) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	A/California [D7] (N=24,27,24,23,24,26)	4089.25 Number of T cells/million	Standard Deviation 2131.69
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Influenza-specific Cluster of Differentiation 4 (CD4) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	Pool peptides H1 [D21] (N=26,24,27,24,24,26)	465.42 Number of T cells/million	Standard Deviation 352.18
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Influenza-specific Cluster of Differentiation 4 (CD4) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	A/California [D21] (N=26,25,27,24,24,26)	3144.62 Number of T cells/million	Standard Deviation 1723.51
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Influenza-specific Cluster of Differentiation 4 (CD4) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	Pool Flu [D21] (N=25,25,27,24,24,25)	5234.16 Number of T cells/million	Standard Deviation 2513.78
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Influenza-specific Cluster of Differentiation 4 (CD4) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	Pool Flu [D7] (N=24,27,24,23,24,25)	6574.50 Number of T cells/million	Standard Deviation 3399.35
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Influenza-specific Cluster of Differentiation 4 (CD4) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	A/Brisbane [D42] (N=27,26,27,27,24,28)	3595.11 Number of T cells/million	Standard Deviation 1268.17
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Influenza-specific Cluster of Differentiation 4 (CD4) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	A/Brisbane [D21] (N=26,25,27,24,24,26)	3561.00 Number of T cells/million	Standard Deviation 1502.24
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Influenza-specific Cluster of Differentiation 4 (CD4) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	Pool peptides H1 [D182] (N=26,24,26,26,25,25)	554.65 Number of T cells/million	Standard Deviation 439.3
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Influenza-specific Cluster of Differentiation 4 (CD4) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	A/California [D42] (N=27,27,27,27,24,28)	2931.04 Number of T cells/million	Standard Deviation 1276.42
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Influenza-specific Cluster of Differentiation 4 (CD4) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	A/California [D28] (N=27,27,27,26,25,27)	3061.63 Number of T cells/million	Standard Deviation 1632.58
Flulaval/Placebo/Arepanrix Group	Number of Influenza-specific Cluster of Differentiation 4 (CD4) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	Pool peptides H1 [D21] (N=26,24,27,24,24,26)	589.79 Number of T cells/million	Standard Deviation 459.57
Flulaval/Placebo/Arepanrix Group	Number of Influenza-specific Cluster of Differentiation 4 (CD4) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	A/California [D182] (N=26,24,26,26,25,25)	2333.88 Number of T cells/million	Standard Deviation 925.38
Flulaval/Placebo/Arepanrix Group	Number of Influenza-specific Cluster of Differentiation 4 (CD4) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	A/California [D28] (N=27,27,27,26,25,27)	3770.44 Number of T cells/million	Standard Deviation 1460.62
Flulaval/Placebo/Arepanrix Group	Number of Influenza-specific Cluster of Differentiation 4 (CD4) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	Pool Flu [D28] (N=25,27,27,26,25,26)	5256.07 Number of T cells/million	Standard Deviation 2292.16
Flulaval/Placebo/Arepanrix Group	Number of Influenza-specific Cluster of Differentiation 4 (CD4) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	A/California [D42] (N=27,27,27,27,24,28)	4381.48 Number of T cells/million	Standard Deviation 2053.51
Flulaval/Placebo/Arepanrix Group	Number of Influenza-specific Cluster of Differentiation 4 (CD4) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	A/California [D63] (N=26,26,25,25,24,26)	5328.19 Number of T cells/million	Standard Deviation 2436.59
Flulaval/Placebo/Arepanrix Group	Number of Influenza-specific Cluster of Differentiation 4 (CD4) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	A/Brisbane [D182] (N=26,24,26,26,25,25)	4631.00 Number of T cells/million	Standard Deviation 1834.57
Flulaval/Placebo/Arepanrix Group	Number of Influenza-specific Cluster of Differentiation 4 (CD4) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	A/Brisbane [D7] (N=24,27,24,23,24,26)	4595.26 Number of T cells/million	Standard Deviation 2058.76
Flulaval/Placebo/Arepanrix Group	Number of Influenza-specific Cluster of Differentiation 4 (CD4) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	Pool peptides H1 [D182] (N=26,24,26,26,25,25)	824.17 Number of T cells/million	Standard Deviation 565.53
Flulaval/Placebo/Arepanrix Group	Number of Influenza-specific Cluster of Differentiation 4 (CD4) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	Pool Flu [D0] (N=24,25,24,25,25,24)	3531.36 Number of T cells/million	Standard Deviation 1972.37
Flulaval/Placebo/Arepanrix Group	Number of Influenza-specific Cluster of Differentiation 4 (CD4) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	Pool Flu [D7] (N=24,27,24,23,24,25)	6921.85 Number of T cells/million	Standard Deviation 4366.14
Flulaval/Placebo/Arepanrix Group	Number of Influenza-specific Cluster of Differentiation 4 (CD4) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	Pool Flu [D21] (N=25,25,27,24,24,25)	5124.60 Number of T cells/million	Standard Deviation 2268.53
Flulaval/Placebo/Arepanrix Group	Number of Influenza-specific Cluster of Differentiation 4 (CD4) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	Pool Flu [D182] (N=26,24,26,26,25,25)	4325.63 Number of T cells/million	Standard Deviation 1541.34
Flulaval/Placebo/Arepanrix Group	Number of Influenza-specific Cluster of Differentiation 4 (CD4) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	Pool peptides H1 [D63] (N=26,26,25,25,24,26)	1248.54 Number of T cells/million	Standard Deviation 1175.35
Flulaval/Placebo/Arepanrix Group	Number of Influenza-specific Cluster of Differentiation 4 (CD4) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	Pool Flu [D63] (N=25,26,25,25,24,24)	6639.92 Number of T cells/million	Standard Deviation 3131.66
Flulaval/Placebo/Arepanrix Group	Number of Influenza-specific Cluster of Differentiation 4 (CD4) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	Pool peptides H1 [D42] (N=27,27,27,27,24,28)	1049.96 Number of T cells/million	Standard Deviation 865.58
Flulaval/Placebo/Arepanrix Group	Number of Influenza-specific Cluster of Differentiation 4 (CD4) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	A/Brisbane [D0] (N=25,25,24,25,25,26)	2604.64 Number of T cells/million	Standard Deviation 1435.48
Flulaval/Placebo/Arepanrix Group	Number of Influenza-specific Cluster of Differentiation 4 (CD4) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	Pool peptides H1 [D28] (N=26,27,27,26,25,27)	704.59 Number of T cells/million	Standard Deviation 518.63
Flulaval/Placebo/Arepanrix Group	Number of Influenza-specific Cluster of Differentiation 4 (CD4) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	A/Brisbane [D21] (N=26,25,27,24,24,26)	3756.72 Number of T cells/million	Standard Deviation 1379.69
Flulaval/Placebo/Arepanrix Group	Number of Influenza-specific Cluster of Differentiation 4 (CD4) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	Pool Flu [D42] (N=26,27,27,26,24,27)	5881.78 Number of T cells/million	Standard Deviation 2641.14
Flulaval/Placebo/Arepanrix Group	Number of Influenza-specific Cluster of Differentiation 4 (CD4) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	A/Brisbane [D28] (N=27,27,27,26,25,27)	4269.11 Number of T cells/million	Standard Deviation 1482.01
Flulaval/Placebo/Arepanrix Group	Number of Influenza-specific Cluster of Differentiation 4 (CD4) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	A/California [D21] (N=26,25,27,24,24,26)	3032.52 Number of T cells/million	Standard Deviation 1342.3
Flulaval/Placebo/Arepanrix Group	Number of Influenza-specific Cluster of Differentiation 4 (CD4) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	A/Brisbane [D63] (N=26,26,25,25,24,26)	6444.50 Number of T cells/million	Standard Deviation 2681.5
Flulaval/Placebo/Arepanrix Group	Number of Influenza-specific Cluster of Differentiation 4 (CD4) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	A/Brisbane [D42] (N=27,26,27,27,24,28)	5246.88 Number of T cells/million	Standard Deviation 2407.94
Flulaval/Placebo/Arepanrix Group	Number of Influenza-specific Cluster of Differentiation 4 (CD4) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	Pool peptides H1 [D7] (N=24,27,24,23,24,25)	581.63 Number of T cells/million	Standard Deviation 527.07
Flulaval/Placebo/Arepanrix Group	Number of Influenza-specific Cluster of Differentiation 4 (CD4) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	A/California [D0] (N=25,25,24,25,25,26)	1988.24 Number of T cells/million	Standard Deviation 1072.73
Flulaval/Placebo/Arepanrix Group	Number of Influenza-specific Cluster of Differentiation 4 (CD4) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	A/California [D7] (N=24,27,24,23,24,26)	3852.44 Number of T cells/million	Standard Deviation 1970.35
Flulaval/Placebo/Arepanrix Group	Number of Influenza-specific Cluster of Differentiation 4 (CD4) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	Pool peptides H1 [D0] (N=25,24,24,25,23,25)	428.00 Number of T cells/million	Standard Deviation 296.76
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Influenza-specific Cluster of Differentiation 4 (CD4) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	A/Brisbane [D7] (N=24,27,24,23,24,26)	5560.33 Number of T cells/million	Standard Deviation 3301.9
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Influenza-specific Cluster of Differentiation 4 (CD4) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	A/Brisbane [D21] (N=26,25,27,24,24,26)	5581.78 Number of T cells/million	Standard Deviation 3123.38
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Influenza-specific Cluster of Differentiation 4 (CD4) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	A/California [D42] (N=27,27,27,27,24,28)	3720.07 Number of T cells/million	Standard Deviation 2261.08
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Influenza-specific Cluster of Differentiation 4 (CD4) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	Pool peptides H1 [D21] (N=26,24,27,24,24,26)	728.15 Number of T cells/million	Standard Deviation 623.89
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Influenza-specific Cluster of Differentiation 4 (CD4) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	Pool peptides H1 [D0] (N=25,24,24,25,23,25)	356.79 Number of T cells/million	Standard Deviation 206.44
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Influenza-specific Cluster of Differentiation 4 (CD4) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	A/Brisbane [D28] (N=27,27,27,26,25,27)	5102.78 Number of T cells/million	Standard Deviation 2856.77
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Influenza-specific Cluster of Differentiation 4 (CD4) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	Pool peptides H1 [D28] (N=26,27,27,26,25,27)	528.78 Number of T cells/million	Standard Deviation 322.1
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Influenza-specific Cluster of Differentiation 4 (CD4) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	A/California [D28] (N=27,27,27,26,25,27)	4058.63 Number of T cells/million	Standard Deviation 2349.19
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Influenza-specific Cluster of Differentiation 4 (CD4) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	A/California [D182] (N=26,24,26,26,25,25)	1838.96 Number of T cells/million	Standard Deviation 842.26
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Influenza-specific Cluster of Differentiation 4 (CD4) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	A/Brisbane [D63] (N=26,26,25,25,24,26)	4169.32 Number of T cells/million	Standard Deviation 2216.49
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Influenza-specific Cluster of Differentiation 4 (CD4) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	A/California [D7] (N=24,27,24,23,24,26)	4780.21 Number of T cells/million	Standard Deviation 2828.25
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Influenza-specific Cluster of Differentiation 4 (CD4) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	A/Brisbane [D182] (N=26,24,26,26,25,25)	4132.81 Number of T cells/million	Standard Deviation 1816.7
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Influenza-specific Cluster of Differentiation 4 (CD4) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	A/Brisbane [D42] (N=27,26,27,27,24,28)	4791.41 Number of T cells/million	Standard Deviation 2706.43
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Influenza-specific Cluster of Differentiation 4 (CD4) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	Pool peptides H1 [D7] (N=24,27,24,23,24,25)	708.96 Number of T cells/million	Standard Deviation 518.87
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Influenza-specific Cluster of Differentiation 4 (CD4) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	Pool Flu [D28] (N=25,27,27,26,25,26)	6090.00 Number of T cells/million	Standard Deviation 3336.49
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Influenza-specific Cluster of Differentiation 4 (CD4) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	Pool Flu [D63] (N=25,26,25,25,24,24)	4893.88 Number of T cells/million	Standard Deviation 2322.1
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Influenza-specific Cluster of Differentiation 4 (CD4) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	Pool peptides H1 [D42] (N=27,27,27,27,24,28)	514.78 Number of T cells/million	Standard Deviation 296.67
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Influenza-specific Cluster of Differentiation 4 (CD4) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	Pool Flu [D42] (N=26,27,27,26,24,27)	5721.70 Number of T cells/million	Standard Deviation 3058.63
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Influenza-specific Cluster of Differentiation 4 (CD4) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	Pool peptides H1 [D63] (N=26,26,25,25,24,26)	460.28 Number of T cells/million	Standard Deviation 267.85
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Influenza-specific Cluster of Differentiation 4 (CD4) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	A/California [D63] (N=26,26,25,25,24,26)	3149.00 Number of T cells/million	Standard Deviation 1844.25
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Influenza-specific Cluster of Differentiation 4 (CD4) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	Pool Flu [D21] (N=25,25,27,24,24,25)	6579.26 Number of T cells/million	Standard Deviation 3489.2
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Influenza-specific Cluster of Differentiation 4 (CD4) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	Pool peptides H1 [D182] (N=26,24,26,26,25,25)	531.73 Number of T cells/million	Standard Deviation 481.91
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Influenza-specific Cluster of Differentiation 4 (CD4) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	A/California [D21] (N=26,25,27,24,24,26)	4455.00 Number of T cells/million	Standard Deviation 2768.12
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Influenza-specific Cluster of Differentiation 4 (CD4) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	A/Brisbane [D0] (N=25,25,24,25,25,26)	3521.33 Number of T cells/million	Standard Deviation 1922.24
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Influenza-specific Cluster of Differentiation 4 (CD4) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	A/California [D0] (N=25,25,24,25,25,26)	2804.63 Number of T cells/million	Standard Deviation 1912.94
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Influenza-specific Cluster of Differentiation 4 (CD4) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	Pool Flu [D182] (N=26,24,26,26,25,25)	4006.46 Number of T cells/million	Standard Deviation 1836.3
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Influenza-specific Cluster of Differentiation 4 (CD4) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	Pool Flu [D7] (N=24,27,24,23,24,25)	7096.46 Number of T cells/million	Standard Deviation 3777.79
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Influenza-specific Cluster of Differentiation 4 (CD4) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	Pool Flu [D0] (N=24,25,24,25,25,24)	4315.71 Number of T cells/million	Standard Deviation 2499.77
Flulaval/Arepanrix/Placebo Group	Number of Influenza-specific Cluster of Differentiation 4 (CD4) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	Pool peptides H1 [D21] (N=26,24,27,24,24,26)	974.67 Number of T cells/million	Standard Deviation 579.23
Flulaval/Arepanrix/Placebo Group	Number of Influenza-specific Cluster of Differentiation 4 (CD4) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	A/Brisbane [D7] (N=24,27,24,23,24,26)	6242.30 Number of T cells/million	Standard Deviation 2773.6
Flulaval/Arepanrix/Placebo Group	Number of Influenza-specific Cluster of Differentiation 4 (CD4) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	A/Brisbane [D42] (N=27,26,27,27,24,28)	5607.96 Number of T cells/million	Standard Deviation 2773.17
Flulaval/Arepanrix/Placebo Group	Number of Influenza-specific Cluster of Differentiation 4 (CD4) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	A/California [D21] (N=26,25,27,24,24,26)	4986.71 Number of T cells/million	Standard Deviation 2398.42
Flulaval/Arepanrix/Placebo Group	Number of Influenza-specific Cluster of Differentiation 4 (CD4) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	Pool Flu [D7] (N=24,27,24,23,24,25)	7682.43 Number of T cells/million	Standard Deviation 2951.47
Flulaval/Arepanrix/Placebo Group	Number of Influenza-specific Cluster of Differentiation 4 (CD4) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	Pool Flu [D21] (N=25,25,27,24,24,25)	6949.96 Number of T cells/million	Standard Deviation 3006.25
Flulaval/Arepanrix/Placebo Group	Number of Influenza-specific Cluster of Differentiation 4 (CD4) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	Pool Flu [D42] (N=26,27,27,26,24,27)	6239.38 Number of T cells/million	Standard Deviation 2542.17
Flulaval/Arepanrix/Placebo Group	Number of Influenza-specific Cluster of Differentiation 4 (CD4) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	Pool Flu [D182] (N=26,24,26,26,25,25)	3937.67 Number of T cells/million	Standard Deviation 1413.94
Flulaval/Arepanrix/Placebo Group	Number of Influenza-specific Cluster of Differentiation 4 (CD4) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	A/Brisbane [D21] (N=26,25,27,24,24,26)	6069.67 Number of T cells/million	Standard Deviation 3306.79
Flulaval/Arepanrix/Placebo Group	Number of Influenza-specific Cluster of Differentiation 4 (CD4) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	A/Brisbane [D28] (N=27,27,27,26,25,27)	6989.15 Number of T cells/million	Standard Deviation 3950.45
Flulaval/Arepanrix/Placebo Group	Number of Influenza-specific Cluster of Differentiation 4 (CD4) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	A/Brisbane [D63] (N=26,26,25,25,24,26)	5020.88 Number of T cells/million	Standard Deviation 2346.39
Flulaval/Arepanrix/Placebo Group	Number of Influenza-specific Cluster of Differentiation 4 (CD4) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	A/Brisbane [D182] (N=26,24,26,26,25,25)	3988.04 Number of T cells/million	Standard Deviation 1606.16
Flulaval/Arepanrix/Placebo Group	Number of Influenza-specific Cluster of Differentiation 4 (CD4) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	A/California [D0] (N=25,25,24,25,25,26)	2055.44 Number of T cells/million	Standard Deviation 1053.95
Flulaval/Arepanrix/Placebo Group	Number of Influenza-specific Cluster of Differentiation 4 (CD4) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	A/California [D7] (N=24,27,24,23,24,26)	5265.74 Number of T cells/million	Standard Deviation 2008.41
Flulaval/Arepanrix/Placebo Group	Number of Influenza-specific Cluster of Differentiation 4 (CD4) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	A/California [D28] (N=27,27,27,26,25,27)	5979.12 Number of T cells/million	Standard Deviation 3448.84
Flulaval/Arepanrix/Placebo Group	Number of Influenza-specific Cluster of Differentiation 4 (CD4) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	A/California [D42] (N=27,27,27,27,24,28)	4658.07 Number of T cells/million	Standard Deviation 1939.82
Flulaval/Arepanrix/Placebo Group	Number of Influenza-specific Cluster of Differentiation 4 (CD4) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	A/California [D63] (N=26,26,25,25,24,26)	3967.12 Number of T cells/million	Standard Deviation 1655.09
Flulaval/Arepanrix/Placebo Group	Number of Influenza-specific Cluster of Differentiation 4 (CD4) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	A/California [D182] (N=26,24,26,26,25,25)	2068.73 Number of T cells/million	Standard Deviation 939.92
Flulaval/Arepanrix/Placebo Group	Number of Influenza-specific Cluster of Differentiation 4 (CD4) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	Pool peptides H1 [D0] (N=25,24,24,25,23,25)	320.52 Number of T cells/million	Standard Deviation 216.19
Flulaval/Arepanrix/Placebo Group	Number of Influenza-specific Cluster of Differentiation 4 (CD4) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	Pool peptides H1 [D7] (N=24,27,24,23,24,25)	857.04 Number of T cells/million	Standard Deviation 474.48
Flulaval/Arepanrix/Placebo Group	Number of Influenza-specific Cluster of Differentiation 4 (CD4) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	A/Brisbane [D0] (N=25,25,24,25,25,26)	2612.56 Number of T cells/million	Standard Deviation 1256.47
Flulaval/Arepanrix/Placebo Group	Number of Influenza-specific Cluster of Differentiation 4 (CD4) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	Pool peptides H1 [D28] (N=26,27,27,26,25,27)	1345.69 Number of T cells/million	Standard Deviation 1536.94
Flulaval/Arepanrix/Placebo Group	Number of Influenza-specific Cluster of Differentiation 4 (CD4) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	Pool peptides H1 [D42] (N=27,27,27,27,24,28)	1080.93 Number of T cells/million	Standard Deviation 669.26
Flulaval/Arepanrix/Placebo Group	Number of Influenza-specific Cluster of Differentiation 4 (CD4) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	Pool peptides H1 [D63] (N=26,26,25,25,24,26)	815.24 Number of T cells/million	Standard Deviation 634.45
Flulaval/Arepanrix/Placebo Group	Number of Influenza-specific Cluster of Differentiation 4 (CD4) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	Pool peptides H1 [D182] (N=26,24,26,26,25,25)	648.69 Number of T cells/million	Standard Deviation 557.34
Flulaval/Arepanrix/Placebo Group	Number of Influenza-specific Cluster of Differentiation 4 (CD4) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	Pool Flu [D0] (N=24,25,24,25,25,24)	3056.80 Number of T cells/million	Standard Deviation 1096.38
Flulaval/Arepanrix/Placebo Group	Number of Influenza-specific Cluster of Differentiation 4 (CD4) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	Pool Flu [D28] (N=25,27,27,26,25,26)	7265.23 Number of T cells/million	Standard Deviation 3520.63
Flulaval/Arepanrix/Placebo Group	Number of Influenza-specific Cluster of Differentiation 4 (CD4) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	Pool Flu [D63] (N=25,26,25,25,24,24)	5323.84 Number of T cells/million	Standard Deviation 2132.52
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Influenza-specific Cluster of Differentiation 4 (CD4) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	Pool peptides H1 [D21] (N=26,24,27,24,24,26)	619.50 Number of T cells/million	Standard Deviation 391.47
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Influenza-specific Cluster of Differentiation 4 (CD4) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	Pool peptides H1 [D0] (N=25,24,24,25,23,25)	443.35 Number of T cells/million	Standard Deviation 356.02
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Influenza-specific Cluster of Differentiation 4 (CD4) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	A/California [D0] (N=25,25,24,25,25,26)	2109.52 Number of T cells/million	Standard Deviation 828.11
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Influenza-specific Cluster of Differentiation 4 (CD4) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	A/Brisbane [D182] (N=26,24,26,26,25,25)	3672.16 Number of T cells/million	Standard Deviation 1191.85
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Influenza-specific Cluster of Differentiation 4 (CD4) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	A/Brisbane [D42] (N=27,26,27,27,24,28)	3872.67 Number of T cells/million	Standard Deviation 1270.26
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Influenza-specific Cluster of Differentiation 4 (CD4) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	Pool peptides H1 [D7] (N=24,27,24,23,24,25)	692.29 Number of T cells/million	Standard Deviation 454.48
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Influenza-specific Cluster of Differentiation 4 (CD4) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	A/Brisbane [D63] (N=26,26,25,25,24,26)	4074.38 Number of T cells/million	Standard Deviation 1639.45
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Influenza-specific Cluster of Differentiation 4 (CD4) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	A/Brisbane [D28] (N=27,27,27,26,25,27)	3816.20 Number of T cells/million	Standard Deviation 1290.25
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Influenza-specific Cluster of Differentiation 4 (CD4) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	A/Brisbane [D21] (N=26,25,27,24,24,26)	3894.54 Number of T cells/million	Standard Deviation 1596.44
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Influenza-specific Cluster of Differentiation 4 (CD4) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	A/Brisbane [D0] (N=25,25,24,25,25,26)	2644.40 Number of T cells/million	Standard Deviation 1219.04
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Influenza-specific Cluster of Differentiation 4 (CD4) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	Pool peptides H1 [D28] (N=26,27,27,26,25,27)	642.00 Number of T cells/million	Standard Deviation 379.9
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Influenza-specific Cluster of Differentiation 4 (CD4) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	Pool Flu [D182] (N=26,24,26,26,25,25)	3918.28 Number of T cells/million	Standard Deviation 1284.32
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Influenza-specific Cluster of Differentiation 4 (CD4) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	Pool peptides H1 [D42] (N=27,27,27,27,24,28)	600.04 Number of T cells/million	Standard Deviation 496.71
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Influenza-specific Cluster of Differentiation 4 (CD4) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	Pool Flu [D42] (N=26,27,27,26,24,27)	4167.63 Number of T cells/million	Standard Deviation 1351.74
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Influenza-specific Cluster of Differentiation 4 (CD4) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	Pool Flu [D28] (N=25,27,27,26,25,26)	4047.92 Number of T cells/million	Standard Deviation 1219
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Influenza-specific Cluster of Differentiation 4 (CD4) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	Pool peptides H1 [D63] (N=26,26,25,25,24,26)	508.58 Number of T cells/million	Standard Deviation 316.75
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Influenza-specific Cluster of Differentiation 4 (CD4) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	Pool Flu [D7] (N=24,27,24,23,24,25)	4668.17 Number of T cells/million	Standard Deviation 1675.47
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Influenza-specific Cluster of Differentiation 4 (CD4) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	A/Brisbane [D7] (N=24,27,24,23,24,26)	4269.96 Number of T cells/million	Standard Deviation 1744.37
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Influenza-specific Cluster of Differentiation 4 (CD4) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	Pool peptides H1 [D182] (N=26,24,26,26,25,25)	552.52 Number of T cells/million	Standard Deviation 528.46
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Influenza-specific Cluster of Differentiation 4 (CD4) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	Pool Flu [D63] (N=25,26,25,25,24,24)	4900.17 Number of T cells/million	Standard Deviation 2016.61
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Influenza-specific Cluster of Differentiation 4 (CD4) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	Pool Flu [D0] (N=24,25,24,25,25,24)	3308.08 Number of T cells/million	Standard Deviation 1124.49
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Influenza-specific Cluster of Differentiation 4 (CD4) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	A/California [D28] (N=27,27,27,26,25,27)	2875.52 Number of T cells/million	Standard Deviation 837.73
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Influenza-specific Cluster of Differentiation 4 (CD4) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	Pool Flu [D21] (N=25,25,27,24,24,25)	4329.96 Number of T cells/million	Standard Deviation 1672.2
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Influenza-specific Cluster of Differentiation 4 (CD4) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	A/California [D63] (N=26,26,25,25,24,26)	3246.71 Number of T cells/million	Standard Deviation 1379.49
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Influenza-specific Cluster of Differentiation 4 (CD4) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	A/California [D42] (N=27,27,27,27,24,28)	2838.00 Number of T cells/million	Standard Deviation 1008.2
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Influenza-specific Cluster of Differentiation 4 (CD4) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	A/California [D21] (N=26,25,27,24,24,26)	2975.38 Number of T cells/million	Standard Deviation 1058.31
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Influenza-specific Cluster of Differentiation 4 (CD4) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	A/California [D182] (N=26,24,26,26,25,25)	1630.40 Number of T cells/million	Standard Deviation 592.23
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Influenza-specific Cluster of Differentiation 4 (CD4) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	A/California [D7] (N=24,27,24,23,24,26)	3224.42 Number of T cells/million	Standard Deviation 1238.08
Arepanrix/Placebo/Flulaval Group	Number of Influenza-specific Cluster of Differentiation 4 (CD4) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	A/California [D21] (N=26,25,27,24,24,26)	4793.35 Number of T cells/million	Standard Deviation 2194.74
Arepanrix/Placebo/Flulaval Group	Number of Influenza-specific Cluster of Differentiation 4 (CD4) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	A/Brisbane [D42] (N=27,26,27,27,24,28)	6200.64 Number of T cells/million	Standard Deviation 2733.75
Arepanrix/Placebo/Flulaval Group	Number of Influenza-specific Cluster of Differentiation 4 (CD4) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	A/Brisbane [D21] (N=26,25,27,24,24,26)	5590.23 Number of T cells/million	Standard Deviation 2407.32
Arepanrix/Placebo/Flulaval Group	Number of Influenza-specific Cluster of Differentiation 4 (CD4) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	Pool peptides H1 [D0] (N=25,24,24,25,23,25)	271.76 Number of T cells/million	Standard Deviation 180.44
Arepanrix/Placebo/Flulaval Group	Number of Influenza-specific Cluster of Differentiation 4 (CD4) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	A/California [D182] (N=26,24,26,26,25,25)	2513.48 Number of T cells/million	Standard Deviation 1232.2
Arepanrix/Placebo/Flulaval Group	Number of Influenza-specific Cluster of Differentiation 4 (CD4) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	A/Brisbane [D182] (N=26,24,26,26,25,25)	4568.16 Number of T cells/million	Standard Deviation 2043.61
Arepanrix/Placebo/Flulaval Group	Number of Influenza-specific Cluster of Differentiation 4 (CD4) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	Pool peptides H1 [D63] (N=26,26,25,25,24,26)	910.81 Number of T cells/million	Standard Deviation 482.86
Arepanrix/Placebo/Flulaval Group	Number of Influenza-specific Cluster of Differentiation 4 (CD4) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	A/California [D42] (N=27,27,27,27,24,28)	5622.14 Number of T cells/million	Standard Deviation 2870.26
Arepanrix/Placebo/Flulaval Group	Number of Influenza-specific Cluster of Differentiation 4 (CD4) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	Pool Flu [D21] (N=25,25,27,24,24,25)	5691.08 Number of T cells/million	Standard Deviation 2047.1
Arepanrix/Placebo/Flulaval Group	Number of Influenza-specific Cluster of Differentiation 4 (CD4) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	Pool peptides H1 [D7] (N=24,27,24,23,24,25)	718.76 Number of T cells/million	Standard Deviation 663.81
Arepanrix/Placebo/Flulaval Group	Number of Influenza-specific Cluster of Differentiation 4 (CD4) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	A/Brisbane [D63] (N=26,26,25,25,24,26)	5757.04 Number of T cells/million	Standard Deviation 3131.86
Arepanrix/Placebo/Flulaval Group	Number of Influenza-specific Cluster of Differentiation 4 (CD4) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	Pool peptides H1 [D182] (N=26,24,26,26,25,25)	757.68 Number of T cells/million	Standard Deviation 638.4
Arepanrix/Placebo/Flulaval Group	Number of Influenza-specific Cluster of Differentiation 4 (CD4) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	Pool peptides H1 [D42] (N=27,27,27,27,24,28)	1228.25 Number of T cells/million	Standard Deviation 637.35
Arepanrix/Placebo/Flulaval Group	Number of Influenza-specific Cluster of Differentiation 4 (CD4) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	A/Brisbane [D7] (N=24,27,24,23,24,26)	4674.88 Number of T cells/million	Standard Deviation 2325.77
Arepanrix/Placebo/Flulaval Group	Number of Influenza-specific Cluster of Differentiation 4 (CD4) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	A/California [D0] (N=25,25,24,25,25,26)	1641.04 Number of T cells/million	Standard Deviation 799.39
Arepanrix/Placebo/Flulaval Group	Number of Influenza-specific Cluster of Differentiation 4 (CD4) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	Pool peptides H1 [D21] (N=26,24,27,24,24,26)	1022.38 Number of T cells/million	Standard Deviation 572.5
Arepanrix/Placebo/Flulaval Group	Number of Influenza-specific Cluster of Differentiation 4 (CD4) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	A/Brisbane [D0] (N=25,25,24,25,25,26)	2016.31 Number of T cells/million	Standard Deviation 822.34
Arepanrix/Placebo/Flulaval Group	Number of Influenza-specific Cluster of Differentiation 4 (CD4) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	A/California [D63] (N=26,26,25,25,24,26)	5151.62 Number of T cells/million	Standard Deviation 3008.33
Arepanrix/Placebo/Flulaval Group	Number of Influenza-specific Cluster of Differentiation 4 (CD4) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	A/Brisbane [D28] (N=27,27,27,26,25,27)	7083.19 Number of T cells/million	Standard Deviation 3227.04
Arepanrix/Placebo/Flulaval Group	Number of Influenza-specific Cluster of Differentiation 4 (CD4) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	A/California [D7] (N=24,27,24,23,24,26)	3590.08 Number of T cells/million	Standard Deviation 1912.94
Arepanrix/Placebo/Flulaval Group	Number of Influenza-specific Cluster of Differentiation 4 (CD4) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	Pool peptides H1 [D28] (N=26,27,27,26,25,27)	1251.07 Number of T cells/million	Standard Deviation 695.04
Arepanrix/Placebo/Flulaval Group	Number of Influenza-specific Cluster of Differentiation 4 (CD4) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	Pool Flu [D182] (N=26,24,26,26,25,25)	4277.76 Number of T cells/million	Standard Deviation 1655.16
Arepanrix/Placebo/Flulaval Group	Number of Influenza-specific Cluster of Differentiation 4 (CD4) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	Pool Flu [D0] (N=24,25,24,25,25,24)	2775.50 Number of T cells/million	Standard Deviation 1214.18
Arepanrix/Placebo/Flulaval Group	Number of Influenza-specific Cluster of Differentiation 4 (CD4) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	Pool Flu [D63] (N=25,26,25,25,24,24)	6455.25 Number of T cells/million	Standard Deviation 2694.48
Arepanrix/Placebo/Flulaval Group	Number of Influenza-specific Cluster of Differentiation 4 (CD4) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	Pool Flu [D42] (N=26,27,27,26,24,27)	6215.93 Number of T cells/million	Standard Deviation 2389.59
Arepanrix/Placebo/Flulaval Group	Number of Influenza-specific Cluster of Differentiation 4 (CD4) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	A/California [D28] (N=27,27,27,26,25,27)	6689.44 Number of T cells/million	Standard Deviation 3501.59
Arepanrix/Placebo/Flulaval Group	Number of Influenza-specific Cluster of Differentiation 4 (CD4) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	Pool Flu [D7] (N=24,27,24,23,24,25)	4713.28 Number of T cells/million	Standard Deviation 2161.14
Arepanrix/Placebo/Flulaval Group	Number of Influenza-specific Cluster of Differentiation 4 (CD4) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	Pool Flu [D28] (N=25,27,27,26,25,26)	6804.42 Number of T cells/million	Standard Deviation 2824.8

Secondary

Number of Influenza-specific Cluster of Differentiation 8 (CD8) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).

Influenza-specific CD8 T-Cells were stimulated in vitro with A/California virus and seasonal Influenza viruses, related antigens or derived peptides. Stimulating antigens were A/Brisbane, A/California, pool peptides H1N1 and pool FLU.

Time frame: On Days 0, 7, 21, 28, 42, 63 and 182

Arm	Measure	Group	Value (MEAN)	Dispersion
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Influenza-specific Cluster of Differentiation 8 (CD8) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	Pool Flu [D42] (N=26,27,27,26,24,27)	506.35 Number of T cells/million	Standard Deviation 560.83
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Influenza-specific Cluster of Differentiation 8 (CD8) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	A/Brisbane [D182] (N=26,24,26,26,25,25)	550.27 Number of T cells/million	Standard Deviation 1948.06
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Influenza-specific Cluster of Differentiation 8 (CD8) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	Pool peptides H1 [D42] (N=27,27,27,27,24,28)	143.67 Number of T cells/million	Standard Deviation 189.28
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Influenza-specific Cluster of Differentiation 8 (CD8) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	A/California [D21] (N=26,25,27,24,24,26)	332.00 Number of T cells/million	Standard Deviation 539.48
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Influenza-specific Cluster of Differentiation 8 (CD8) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	A/California [D7] (N=24,27,24,23,24,26)	610.29 Number of T cells/million	Standard Deviation 744.7
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Influenza-specific Cluster of Differentiation 8 (CD8) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	A/Brisbane [D21] (N=26,25,27,24,24,26)	601.31 Number of T cells/million	Standard Deviation 1154.73
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Influenza-specific Cluster of Differentiation 8 (CD8) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	Pool Flu [D63] (N=25,26,25,25,24,24)	461.20 Number of T cells/million	Standard Deviation 698.48
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Influenza-specific Cluster of Differentiation 8 (CD8) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	A/California [D0] (N=25,25,24,25,25,26)	357.40 Number of T cells/million	Standard Deviation 800.46
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Influenza-specific Cluster of Differentiation 8 (CD8) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	Pool peptides H1 [D182] (N=26,24,26,26,25,25)	287.31 Number of T cells/million	Standard Deviation 511.19
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Influenza-specific Cluster of Differentiation 8 (CD8) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	Pool peptides H1 [D28] (N=26,27,27,26,25,27)	100.08 Number of T cells/million	Standard Deviation 132.13
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Influenza-specific Cluster of Differentiation 8 (CD8) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	A/Brisbane [D0] (N=25,25,24,25,25,26)	515.36 Number of T cells/million	Standard Deviation 1191.1
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Influenza-specific Cluster of Differentiation 8 (CD8) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	Pool peptides H1 [D21] (N=26,24,27,24,24,26)	103.81 Number of T cells/million	Standard Deviation 160.76
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Influenza-specific Cluster of Differentiation 8 (CD8) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	Pool Flu [D7] (N=24,27,24,23,24,25)	986.92 Number of T cells/million	Standard Deviation 863.16
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Influenza-specific Cluster of Differentiation 8 (CD8) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	Pool Flu [D21] (N=25,25,27,24,24,25)	586.32 Number of T cells/million	Standard Deviation 876.08
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Influenza-specific Cluster of Differentiation 8 (CD8) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	Pool Flu [D0] (N=24,25,24,25,25,24)	351.38 Number of T cells/million	Standard Deviation 467.93
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Influenza-specific Cluster of Differentiation 8 (CD8) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	Pool Flu [D182] (N=26,24,26,26,25,25)	404.77 Number of T cells/million	Standard Deviation 981.01
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Influenza-specific Cluster of Differentiation 8 (CD8) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	Pool peptides H1 [D7] (N=24,27,24,23,24,25)	205.33 Number of T cells/million	Standard Deviation 288.67
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Influenza-specific Cluster of Differentiation 8 (CD8) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	A/California [D28] (N=27,27,27,26,25,27)	470.33 Number of T cells/million	Standard Deviation 655.02
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Influenza-specific Cluster of Differentiation 8 (CD8) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	Pool peptides H1 [D0] (N=25,24,24,25,23,25)	110.48 Number of T cells/million	Standard Deviation 140.31
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Influenza-specific Cluster of Differentiation 8 (CD8) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	A/Brisbane [D28] (N=27,27,27,26,25,27)	629.22 Number of T cells/million	Standard Deviation 964.11
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Influenza-specific Cluster of Differentiation 8 (CD8) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	A/Brisbane [D63] (N=26,26,25,25,24,26)	620.00 Number of T cells/million	Standard Deviation 1393.77
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Influenza-specific Cluster of Differentiation 8 (CD8) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	A/California [D182] (N=26,24,26,26,25,25)	214.85 Number of T cells/million	Standard Deviation 326.43
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Influenza-specific Cluster of Differentiation 8 (CD8) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	A/Brisbane [D7] (N=24,27,24,23,24,26)	772.96 Number of T cells/million	Standard Deviation 716.4
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Influenza-specific Cluster of Differentiation 8 (CD8) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	A/Brisbane [D42] (N=27,26,27,27,24,28)	666.67 Number of T cells/million	Standard Deviation 1180.05
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Influenza-specific Cluster of Differentiation 8 (CD8) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	Pool peptides H1 [D63] (N=26,26,25,25,24,26)	85.96 Number of T cells/million	Standard Deviation 97.66
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Influenza-specific Cluster of Differentiation 8 (CD8) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	A/California [D63] (N=26,2625,25,24,26)	203.62 Number of T cells/million	Standard Deviation 197.89
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Influenza-specific Cluster of Differentiation 8 (CD8) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	Pool Flu [D28] (N=25,27,27,26,25,26)	484.48 Number of T cells/million	Standard Deviation 587.46
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Influenza-specific Cluster of Differentiation 8 (CD8) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	A/California [D42] (N=27,27,27,27,24,28)	314.89 Number of T cells/million	Standard Deviation 289.95
Flulaval/Placebo/Arepanrix Group	Number of Influenza-specific Cluster of Differentiation 8 (CD8) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	Pool Flu [D63] (N=25,26,25,25,24,24)	325.12 Number of T cells/million	Standard Deviation 270.84
Flulaval/Placebo/Arepanrix Group	Number of Influenza-specific Cluster of Differentiation 8 (CD8) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	Pool Flu [D21] (N=25,25,27,24,24,25)	268.24 Number of T cells/million	Standard Deviation 324.48
Flulaval/Placebo/Arepanrix Group	Number of Influenza-specific Cluster of Differentiation 8 (CD8) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	Pool Flu [D28] (N=25,27,27,26,25,26)	508.11 Number of T cells/million	Standard Deviation 559.97
Flulaval/Placebo/Arepanrix Group	Number of Influenza-specific Cluster of Differentiation 8 (CD8) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	A/Brisbane [D0] (N=25,25,24,25,25,26)	382.84 Number of T cells/million	Standard Deviation 595.58
Flulaval/Placebo/Arepanrix Group	Number of Influenza-specific Cluster of Differentiation 8 (CD8) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	A/California [D28] (N=27,27,27,26,25,27)	452.93 Number of T cells/million	Standard Deviation 547.61
Flulaval/Placebo/Arepanrix Group	Number of Influenza-specific Cluster of Differentiation 8 (CD8) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	A/Brisbane [D7] (N=24,27,24,23,24,26)	884.81 Number of T cells/million	Standard Deviation 1225.9
Flulaval/Placebo/Arepanrix Group	Number of Influenza-specific Cluster of Differentiation 8 (CD8) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	A/Brisbane [D63] (N=26,26,25,25,24,26)	420.50 Number of T cells/million	Standard Deviation 486.62
Flulaval/Placebo/Arepanrix Group	Number of Influenza-specific Cluster of Differentiation 8 (CD8) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	A/Brisbane [D182] (N=26,24,26,26,25,25)	436.79 Number of T cells/million	Standard Deviation 653.5
Flulaval/Placebo/Arepanrix Group	Number of Influenza-specific Cluster of Differentiation 8 (CD8) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	A/California [D0] (N=25,25,24,25,25,26)	189.28 Number of T cells/million	Standard Deviation 197.92
Flulaval/Placebo/Arepanrix Group	Number of Influenza-specific Cluster of Differentiation 8 (CD8) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	A/Brisbane [D21] (N=26,25,27,24,24,26)	517.44 Number of T cells/million	Standard Deviation 799.2
Flulaval/Placebo/Arepanrix Group	Number of Influenza-specific Cluster of Differentiation 8 (CD8) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	A/California [D7] (N=24,27,24,23,24,26)	466.93 Number of T cells/million	Standard Deviation 573.69
Flulaval/Placebo/Arepanrix Group	Number of Influenza-specific Cluster of Differentiation 8 (CD8) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	Pool Flu [D42] (N=26,27,27,26,24,27)	356.41 Number of T cells/million	Standard Deviation 392.23
Flulaval/Placebo/Arepanrix Group	Number of Influenza-specific Cluster of Differentiation 8 (CD8) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	A/California [D21] (N=26,25,27,24,24,26)	275.04 Number of T cells/million	Standard Deviation 334.83
Flulaval/Placebo/Arepanrix Group	Number of Influenza-specific Cluster of Differentiation 8 (CD8) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	A/California [D42] (N=27,27,27,27,24,28)	304.00 Number of T cells/million	Standard Deviation 255.38
Flulaval/Placebo/Arepanrix Group	Number of Influenza-specific Cluster of Differentiation 8 (CD8) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	A/California [D63] (N=26,2625,25,24,26)	260.54 Number of T cells/million	Standard Deviation 359.88
Flulaval/Placebo/Arepanrix Group	Number of Influenza-specific Cluster of Differentiation 8 (CD8) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	A/California [D182] (N=26,24,26,26,25,25)	220.71 Number of T cells/million	Standard Deviation 330.88
Flulaval/Placebo/Arepanrix Group	Number of Influenza-specific Cluster of Differentiation 8 (CD8) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	Pool peptides H1 [D0] (N=25,24,24,25,23,25)	180.38 Number of T cells/million	Standard Deviation 359.58
Flulaval/Placebo/Arepanrix Group	Number of Influenza-specific Cluster of Differentiation 8 (CD8) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	A/Brisbane [D28] (N=27,27,27,26,25,27)	642.22 Number of T cells/million	Standard Deviation 850.79
Flulaval/Placebo/Arepanrix Group	Number of Influenza-specific Cluster of Differentiation 8 (CD8) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	Pool Flu [D7] (N=24,27,24,23,24,25)	843.44 Number of T cells/million	Standard Deviation 826.65
Flulaval/Placebo/Arepanrix Group	Number of Influenza-specific Cluster of Differentiation 8 (CD8) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	Pool peptides H1 [D7] (N=24,27,24,23,24,25)	185.15 Number of T cells/million	Standard Deviation 243.88
Flulaval/Placebo/Arepanrix Group	Number of Influenza-specific Cluster of Differentiation 8 (CD8) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	Pool peptides H1 [D21] (N=26,24,27,24,24,26)	194.92 Number of T cells/million	Standard Deviation 384.18
Flulaval/Placebo/Arepanrix Group	Number of Influenza-specific Cluster of Differentiation 8 (CD8) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	Pool peptides H1 [D28] (N=26,27,27,26,25,27)	170.04 Number of T cells/million	Standard Deviation 385.99
Flulaval/Placebo/Arepanrix Group	Number of Influenza-specific Cluster of Differentiation 8 (CD8) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	Pool peptides H1 [D42] (N=27,27,27,27,24,28)	157.41 Number of T cells/million	Standard Deviation 350.83
Flulaval/Placebo/Arepanrix Group	Number of Influenza-specific Cluster of Differentiation 8 (CD8) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	Pool Flu [D182] (N=26,24,26,26,25,25)	315.75 Number of T cells/million	Standard Deviation 441.5
Flulaval/Placebo/Arepanrix Group	Number of Influenza-specific Cluster of Differentiation 8 (CD8) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	Pool peptides H1 [D63] (N=26,26,25,25,24,26)	173.88 Number of T cells/million	Standard Deviation 244.91
Flulaval/Placebo/Arepanrix Group	Number of Influenza-specific Cluster of Differentiation 8 (CD8) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	Pool Flu [D0] (N=24,25,24,25,25,24)	224.60 Number of T cells/million	Standard Deviation 251.59
Flulaval/Placebo/Arepanrix Group	Number of Influenza-specific Cluster of Differentiation 8 (CD8) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	Pool peptides H1 [D182] (N=26,24,26,26,25,25)	265.63 Number of T cells/million	Standard Deviation 343.36
Flulaval/Placebo/Arepanrix Group	Number of Influenza-specific Cluster of Differentiation 8 (CD8) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	A/Brisbane [D42] (N=27,26,27,27,24,28)	551.88 Number of T cells/million	Standard Deviation 911.02
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Influenza-specific Cluster of Differentiation 8 (CD8) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	A/California [D42] (N=27,27,27,27,24,28)	247.89 Number of T cells/million	Standard Deviation 459.58
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Influenza-specific Cluster of Differentiation 8 (CD8) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	A/Brisbane [D7] (N=24,27,24,23,24,26)	1115.96 Number of T cells/million	Standard Deviation 1545.07
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Influenza-specific Cluster of Differentiation 8 (CD8) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	A/Brisbane [D63] (N=26,26,25,25,24,26)	428.92 Number of T cells/million	Standard Deviation 687.17
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Influenza-specific Cluster of Differentiation 8 (CD8) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	A/California [D63] (N=26,2625,25,24,26)	242.36 Number of T cells/million	Standard Deviation 357.21
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Influenza-specific Cluster of Differentiation 8 (CD8) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	Pool Flu [D182] (N=26,24,26,26,25,25)	334.23 Number of T cells/million	Standard Deviation 447.12
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Influenza-specific Cluster of Differentiation 8 (CD8) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	A/California [D28] (N=27,27,27,26,25,27)	332.63 Number of T cells/million	Standard Deviation 553.07
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Influenza-specific Cluster of Differentiation 8 (CD8) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	A/California [D182] (N=26,24,26,26,25,25)	225.50 Number of T cells/million	Standard Deviation 366.51
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Influenza-specific Cluster of Differentiation 8 (CD8) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	Pool Flu [D7] (N=24,27,24,23,24,25)	1042.17 Number of T cells/million	Standard Deviation 1237.44
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Influenza-specific Cluster of Differentiation 8 (CD8) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	A/Brisbane [D0] (N=25,25,24,25,25,26)	489.08 Number of T cells/million	Standard Deviation 520.3
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Influenza-specific Cluster of Differentiation 8 (CD8) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	Pool Flu [D0] (N=24,25,24,25,25,24)	478.42 Number of T cells/million	Standard Deviation 463.43
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Influenza-specific Cluster of Differentiation 8 (CD8) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	Pool peptides H1 [D0] (N=25,24,24,25,23,25)	101.04 Number of T cells/million	Standard Deviation 158.31
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Influenza-specific Cluster of Differentiation 8 (CD8) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	Pool Flu [D63] (N=25,26,25,25,24,24)	402.24 Number of T cells/million	Standard Deviation 418.89
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Influenza-specific Cluster of Differentiation 8 (CD8) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	Pool peptides H1 [D63] (N=26,26,25,25,24,26)	113.20 Number of T cells/million	Standard Deviation 193.78
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Influenza-specific Cluster of Differentiation 8 (CD8) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	Pool peptides H1 [D7] (N=24,27,24,23,24,25)	202.13 Number of T cells/million	Standard Deviation 293.11
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Influenza-specific Cluster of Differentiation 8 (CD8) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	A/Brisbane [D28] (N=27,27,27,26,25,27)	498.33 Number of T cells/million	Standard Deviation 730.34
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Influenza-specific Cluster of Differentiation 8 (CD8) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	Pool Flu [D42] (N=26,27,27,26,24,27)	471.30 Number of T cells/million	Standard Deviation 610.38
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Influenza-specific Cluster of Differentiation 8 (CD8) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	Pool peptides H1 [D21] (N=26,24,27,24,24,26)	101.30 Number of T cells/million	Standard Deviation 148.62
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Influenza-specific Cluster of Differentiation 8 (CD8) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	Pool Flu [D28] (N=25,27,27,26,25,26)	505.33 Number of T cells/million	Standard Deviation 595.15
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Influenza-specific Cluster of Differentiation 8 (CD8) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	Pool Flu [D21] (N=25,25,27,24,24,25)	609.07 Number of T cells/million	Standard Deviation 997.1
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Influenza-specific Cluster of Differentiation 8 (CD8) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	Pool peptides H1 [D28] (N=26,27,27,26,25,27)	124.56 Number of T cells/million	Standard Deviation 181.86
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Influenza-specific Cluster of Differentiation 8 (CD8) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	A/California [D0] (N=25,25,24,25,25,26)	271.58 Number of T cells/million	Standard Deviation 192.68
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Influenza-specific Cluster of Differentiation 8 (CD8) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	A/California [D7] (N=24,27,24,23,24,26)	716.88 Number of T cells/million	Standard Deviation 1251.2
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Influenza-specific Cluster of Differentiation 8 (CD8) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	A/Brisbane [D21] (N=26,25,27,24,24,26)	655.22 Number of T cells/million	Standard Deviation 1327
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Influenza-specific Cluster of Differentiation 8 (CD8) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	A/Brisbane [D42] (N=27,26,27,27,24,28)	525.07 Number of T cells/million	Standard Deviation 938.18
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Influenza-specific Cluster of Differentiation 8 (CD8) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	A/Brisbane [D182] (N=26,24,26,26,25,25)	377.65 Number of T cells/million	Standard Deviation 426.59
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Influenza-specific Cluster of Differentiation 8 (CD8) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	Pool peptides H1 [D182] (N=26,24,26,26,25,25)	306.04 Number of T cells/million	Standard Deviation 630.16
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Influenza-specific Cluster of Differentiation 8 (CD8) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	A/California [D21] (N=26,25,27,24,24,26)	324.37 Number of T cells/million	Standard Deviation 668.77
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Influenza-specific Cluster of Differentiation 8 (CD8) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	Pool peptides H1 [D42] (N=27,27,27,27,24,28)	87.41 Number of T cells/million	Standard Deviation 115.12
Flulaval/Arepanrix/Placebo Group	Number of Influenza-specific Cluster of Differentiation 8 (CD8) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	Pool peptides H1 [D63] (N=26,26,25,25,24,26)	88.28 Number of T cells/million	Standard Deviation 162.1
Flulaval/Arepanrix/Placebo Group	Number of Influenza-specific Cluster of Differentiation 8 (CD8) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	A/California [D7] (N=24,27,24,23,24,26)	553.78 Number of T cells/million	Standard Deviation 639.15
Flulaval/Arepanrix/Placebo Group	Number of Influenza-specific Cluster of Differentiation 8 (CD8) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	A/Brisbane [D63] (N=26,26,25,25,24,26)	230.84 Number of T cells/million	Standard Deviation 226.1
Flulaval/Arepanrix/Placebo Group	Number of Influenza-specific Cluster of Differentiation 8 (CD8) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	Pool peptides H1 [D21] (N=26,24,27,24,24,26)	140.75 Number of T cells/million	Standard Deviation 155.63
Flulaval/Arepanrix/Placebo Group	Number of Influenza-specific Cluster of Differentiation 8 (CD8) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	Pool peptides H1 [D42] (N=27,27,27,27,24,28)	103.89 Number of T cells/million	Standard Deviation 139.95
Flulaval/Arepanrix/Placebo Group	Number of Influenza-specific Cluster of Differentiation 8 (CD8) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	A/Brisbane [D28] (N=27,27,27,26,25,27)	508.88 Number of T cells/million	Standard Deviation 540.73
Flulaval/Arepanrix/Placebo Group	Number of Influenza-specific Cluster of Differentiation 8 (CD8) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	A/California [D63] (N=26,2625,25,24,26)	114.24 Number of T cells/million	Standard Deviation 165.15
Flulaval/Arepanrix/Placebo Group	Number of Influenza-specific Cluster of Differentiation 8 (CD8) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	Pool Flu [D28] (N=25,27,27,26,25,26)	458.12 Number of T cells/million	Standard Deviation 496.69
Flulaval/Arepanrix/Placebo Group	Number of Influenza-specific Cluster of Differentiation 8 (CD8) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	Pool Flu [D7] (N=24,27,24,23,24,25)	788.78 Number of T cells/million	Standard Deviation 947.53
Flulaval/Arepanrix/Placebo Group	Number of Influenza-specific Cluster of Differentiation 8 (CD8) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	A/Brisbane [D42] (N=27,26,27,27,24,28)	209.07 Number of T cells/million	Standard Deviation 171.21
Flulaval/Arepanrix/Placebo Group	Number of Influenza-specific Cluster of Differentiation 8 (CD8) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	A/California [D21] (N=26,25,27,24,24,26)	183.00 Number of T cells/million	Standard Deviation 146.43
Flulaval/Arepanrix/Placebo Group	Number of Influenza-specific Cluster of Differentiation 8 (CD8) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	A/Brisbane [D21] (N=26,25,27,24,24,26)	319.17 Number of T cells/million	Standard Deviation 315.86
Flulaval/Arepanrix/Placebo Group	Number of Influenza-specific Cluster of Differentiation 8 (CD8) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	A/California [D182] (N=26,24,26,26,25,25)	139.50 Number of T cells/million	Standard Deviation 273.43
Flulaval/Arepanrix/Placebo Group	Number of Influenza-specific Cluster of Differentiation 8 (CD8) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	A/Brisbane [D0] (N=25,25,24,25,25,26)	183.96 Number of T cells/million	Standard Deviation 226.54
Flulaval/Arepanrix/Placebo Group	Number of Influenza-specific Cluster of Differentiation 8 (CD8) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	A/California [D28] (N=27,27,27,26,25,27)	344.54 Number of T cells/million	Standard Deviation 288.96
Flulaval/Arepanrix/Placebo Group	Number of Influenza-specific Cluster of Differentiation 8 (CD8) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	Pool peptides H1 [D28] (N=26,27,27,26,25,27)	277.77 Number of T cells/million	Standard Deviation 329.71
Flulaval/Arepanrix/Placebo Group	Number of Influenza-specific Cluster of Differentiation 8 (CD8) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	Pool Flu [D182] (N=26,24,26,26,25,25)	291.73 Number of T cells/million	Standard Deviation 790.15
Flulaval/Arepanrix/Placebo Group	Number of Influenza-specific Cluster of Differentiation 8 (CD8) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	A/California [D0] (N=25,25,24,25,25,26)	365.72 Number of T cells/million	Standard Deviation 985.87
Flulaval/Arepanrix/Placebo Group	Number of Influenza-specific Cluster of Differentiation 8 (CD8) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	Pool peptides H1 [D0] (N=25,24,24,25,23,25)	150.08 Number of T cells/million	Standard Deviation 215.56
Flulaval/Arepanrix/Placebo Group	Number of Influenza-specific Cluster of Differentiation 8 (CD8) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	Pool Flu [D21] (N=25,25,27,24,24,25)	266.63 Number of T cells/million	Standard Deviation 252.28
Flulaval/Arepanrix/Placebo Group	Number of Influenza-specific Cluster of Differentiation 8 (CD8) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	Pool peptides H1 [D182] (N=26,24,26,26,25,25)	241.42 Number of T cells/million	Standard Deviation 353.02
Flulaval/Arepanrix/Placebo Group	Number of Influenza-specific Cluster of Differentiation 8 (CD8) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	A/Brisbane [D7] (N=24,27,24,23,24,26)	725.39 Number of T cells/million	Standard Deviation 585.98
Flulaval/Arepanrix/Placebo Group	Number of Influenza-specific Cluster of Differentiation 8 (CD8) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	Pool Flu [D42] (N=26,27,27,26,24,27)	344.77 Number of T cells/million	Standard Deviation 709.66
Flulaval/Arepanrix/Placebo Group	Number of Influenza-specific Cluster of Differentiation 8 (CD8) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	A/Brisbane [D182] (N=26,24,26,26,25,25)	86.81 Number of T cells/million	Standard Deviation 99.38
Flulaval/Arepanrix/Placebo Group	Number of Influenza-specific Cluster of Differentiation 8 (CD8) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	Pool peptides H1 [D7] (N=24,27,24,23,24,25)	254.65 Number of T cells/million	Standard Deviation 417.53
Flulaval/Arepanrix/Placebo Group	Number of Influenza-specific Cluster of Differentiation 8 (CD8) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	Pool Flu [D0] (N=24,25,24,25,25,24)	344.60 Number of T cells/million	Standard Deviation 641.98
Flulaval/Arepanrix/Placebo Group	Number of Influenza-specific Cluster of Differentiation 8 (CD8) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	Pool Flu [D63] (N=25,26,25,25,24,24)	296.08 Number of T cells/million	Standard Deviation 624.75
Flulaval/Arepanrix/Placebo Group	Number of Influenza-specific Cluster of Differentiation 8 (CD8) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	A/California [D42] (N=27,27,27,27,24,28)	157.67 Number of T cells/million	Standard Deviation 192.15
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Influenza-specific Cluster of Differentiation 8 (CD8) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	Pool Flu [D0] (N=24,25,24,25,25,24)	761.68 Number of T cells/million	Standard Deviation 2411
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Influenza-specific Cluster of Differentiation 8 (CD8) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	A/Brisbane [D7] (N=24,27,24,23,24,26)	1611.96 Number of T cells/million	Standard Deviation 4894.45
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Influenza-specific Cluster of Differentiation 8 (CD8) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	A/Brisbane [D21] (N=26,25,27,24,24,26)	1184.17 Number of T cells/million	Standard Deviation 4146.13
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Influenza-specific Cluster of Differentiation 8 (CD8) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	A/Brisbane [D28] (N=27,27,27,26,25,27)	1466.76 Number of T cells/million	Standard Deviation 5768.96
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Influenza-specific Cluster of Differentiation 8 (CD8) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	A/Brisbane [D42] (N=27,26,27,27,24,28)	1737.50 Number of T cells/million	Standard Deviation 6861.67
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Influenza-specific Cluster of Differentiation 8 (CD8) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	A/Brisbane [D63] (N=26,26,25,25,24,26)	1493.46 Number of T cells/million	Standard Deviation 5828.76
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Influenza-specific Cluster of Differentiation 8 (CD8) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	A/Brisbane [D182] (N=26,24,26,26,25,25)	1474.56 Number of T cells/million	Standard Deviation 6012.19
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Influenza-specific Cluster of Differentiation 8 (CD8) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	A/California [D0] (N=25,25,24,25,25,26)	482.64 Number of T cells/million	Standard Deviation 1286.27
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Influenza-specific Cluster of Differentiation 8 (CD8) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	A/California [D7] (N=24,27,24,23,24,26)	834.50 Number of T cells/million	Standard Deviation 2063.34
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Influenza-specific Cluster of Differentiation 8 (CD8) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	A/California [D21] (N=26,25,27,24,24,26)	428.92 Number of T cells/million	Standard Deviation 1071.57
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Influenza-specific Cluster of Differentiation 8 (CD8) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	A/California [D42] (N=27,27,27,27,24,28)	702.50 Number of T cells/million	Standard Deviation 2209.62
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Influenza-specific Cluster of Differentiation 8 (CD8) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	A/California [D63] (N=26,2625,25,24,26)	853.83 Number of T cells/million	Standard Deviation 3236.11
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Influenza-specific Cluster of Differentiation 8 (CD8) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	A/California [D182] (N=26,24,26,26,25,25)	598.92 Number of T cells/million	Standard Deviation 2344.64
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Influenza-specific Cluster of Differentiation 8 (CD8) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	Pool peptides H1 [D0] (N=25,24,24,25,23,25)	111.26 Number of T cells/million	Standard Deviation 162.75
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Influenza-specific Cluster of Differentiation 8 (CD8) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	Pool peptides H1 [D7] (N=24,27,24,23,24,25)	243.46 Number of T cells/million	Standard Deviation 382.39
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Influenza-specific Cluster of Differentiation 8 (CD8) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	Pool peptides H1 [D21] (N=26,24,27,24,24,26)	211.96 Number of T cells/million	Standard Deviation 482.54
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Influenza-specific Cluster of Differentiation 8 (CD8) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	Pool peptides H1 [D28] (N=26,27,27,26,25,27)	160.80 Number of T cells/million	Standard Deviation 216.87
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Influenza-specific Cluster of Differentiation 8 (CD8) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	Pool peptides H1 [D42] (N=27,27,27,27,24,28)	266.75 Number of T cells/million	Standard Deviation 481.5
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Influenza-specific Cluster of Differentiation 8 (CD8) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	Pool peptides H1 [D63] (N=26,26,25,25,24,26)	210.33 Number of T cells/million	Standard Deviation 403.19
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Influenza-specific Cluster of Differentiation 8 (CD8) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	Pool peptides H1 [D182] (N=26,24,26,26,25,25)	255.44 Number of T cells/million	Standard Deviation 425.71
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Influenza-specific Cluster of Differentiation 8 (CD8) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	Pool Flu [D21] (N=25,25,27,24,24,25)	693.88 Number of T cells/million	Standard Deviation 2082.82
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Influenza-specific Cluster of Differentiation 8 (CD8) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	Pool Flu [D63] (N=25,26,25,25,24,24)	1123.13 Number of T cells/million	Standard Deviation 4008.27
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Influenza-specific Cluster of Differentiation 8 (CD8) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	Pool Flu [D182] (N=26,24,26,26,25,25)	926.40 Number of T cells/million	Standard Deviation 3463.27
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Influenza-specific Cluster of Differentiation 8 (CD8) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	A/Brisbane [D0] (N=25,25,24,25,25,26)	1222.40 Number of T cells/million	Standard Deviation 4485.04
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Influenza-specific Cluster of Differentiation 8 (CD8) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	A/California [D28] (N=27,27,27,26,25,27)	973.96 Number of T cells/million	Standard Deviation 3644.93
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Influenza-specific Cluster of Differentiation 8 (CD8) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	Pool Flu [D7] (N=24,27,24,23,24,25)	1094.96 Number of T cells/million	Standard Deviation 3111.41
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Influenza-specific Cluster of Differentiation 8 (CD8) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	Pool Flu [D28] (N=25,27,27,26,25,26)	963.20 Number of T cells/million	Standard Deviation 3548.16
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Influenza-specific Cluster of Differentiation 8 (CD8) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	Pool Flu [D42] (N=26,27,27,26,24,27)	996.67 Number of T cells/million	Standard Deviation 3648.68
Arepanrix/Placebo/Flulaval Group	Number of Influenza-specific Cluster of Differentiation 8 (CD8) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	Pool Flu [D7] (N=24,27,24,23,24,25)	522.84 Number of T cells/million	Standard Deviation 514.35
Arepanrix/Placebo/Flulaval Group	Number of Influenza-specific Cluster of Differentiation 8 (CD8) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	Pool peptides H1 [D182] (N=26,24,26,26,25,25)	198.44 Number of T cells/million	Standard Deviation 561.99
Arepanrix/Placebo/Flulaval Group	Number of Influenza-specific Cluster of Differentiation 8 (CD8) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	A/Brisbane [D42] (N=27,26,27,27,24,28)	501.54 Number of T cells/million	Standard Deviation 1329.9
Arepanrix/Placebo/Flulaval Group	Number of Influenza-specific Cluster of Differentiation 8 (CD8) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	Pool peptides H1 [D63] (N=26,26,25,25,24,26)	88.19 Number of T cells/million	Standard Deviation 206.24
Arepanrix/Placebo/Flulaval Group	Number of Influenza-specific Cluster of Differentiation 8 (CD8) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	Pool peptides H1 [D42] (N=27,27,27,27,24,28)	145.96 Number of T cells/million	Standard Deviation 261.67
Arepanrix/Placebo/Flulaval Group	Number of Influenza-specific Cluster of Differentiation 8 (CD8) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	Pool peptides H1 [D28] (N=26,27,27,26,25,27)	187.37 Number of T cells/million	Standard Deviation 361.53
Arepanrix/Placebo/Flulaval Group	Number of Influenza-specific Cluster of Differentiation 8 (CD8) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	Pool peptides H1 [D21] (N=26,24,27,24,24,26)	173.77 Number of T cells/million	Standard Deviation 432.74
Arepanrix/Placebo/Flulaval Group	Number of Influenza-specific Cluster of Differentiation 8 (CD8) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	Pool Flu [D0] (N=24,25,24,25,25,24)	157.63 Number of T cells/million	Standard Deviation 166.45
Arepanrix/Placebo/Flulaval Group	Number of Influenza-specific Cluster of Differentiation 8 (CD8) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	Pool peptides H1 [D7] (N=24,27,24,23,24,25)	173.48 Number of T cells/million	Standard Deviation 202.67
Arepanrix/Placebo/Flulaval Group	Number of Influenza-specific Cluster of Differentiation 8 (CD8) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	Pool peptides H1 [D0] (N=25,24,24,25,23,25)	70.92 Number of T cells/million	Standard Deviation 113.24
Arepanrix/Placebo/Flulaval Group	Number of Influenza-specific Cluster of Differentiation 8 (CD8) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	A/California [D182] (N=26,24,26,26,25,25)	138.52 Number of T cells/million	Standard Deviation 245.14
Arepanrix/Placebo/Flulaval Group	Number of Influenza-specific Cluster of Differentiation 8 (CD8) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	A/California [D63] (N=26,2625,25,24,26)	194.73 Number of T cells/million	Standard Deviation 453.09
Arepanrix/Placebo/Flulaval Group	Number of Influenza-specific Cluster of Differentiation 8 (CD8) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	A/Brisbane [D28] (N=27,27,27,26,25,27)	1735.48 Number of T cells/million	Standard Deviation 5219.43
Arepanrix/Placebo/Flulaval Group	Number of Influenza-specific Cluster of Differentiation 8 (CD8) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	Pool Flu [D21] (N=25,25,27,24,24,25)	406.28 Number of T cells/million	Standard Deviation 620.1
Arepanrix/Placebo/Flulaval Group	Number of Influenza-specific Cluster of Differentiation 8 (CD8) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	A/California [D42] (N=27,27,27,27,24,28)	291.96 Number of T cells/million	Standard Deviation 654.16
Arepanrix/Placebo/Flulaval Group	Number of Influenza-specific Cluster of Differentiation 8 (CD8) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	A/Brisbane [D21] (N=26,25,27,24,24,26)	501.08 Number of T cells/million	Standard Deviation 1319.91
Arepanrix/Placebo/Flulaval Group	Number of Influenza-specific Cluster of Differentiation 8 (CD8) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	Pool Flu [D28] (N=25,27,27,26,25,26)	423.62 Number of T cells/million	Standard Deviation 430.29
Arepanrix/Placebo/Flulaval Group	Number of Influenza-specific Cluster of Differentiation 8 (CD8) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	A/California [D28] (N=27,27,27,26,25,27)	497.67 Number of T cells/million	Standard Deviation 612.95
Arepanrix/Placebo/Flulaval Group	Number of Influenza-specific Cluster of Differentiation 8 (CD8) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	A/California [D7] (N=24,27,24,23,24,26)	348.69 Number of T cells/million	Standard Deviation 326.74
Arepanrix/Placebo/Flulaval Group	Number of Influenza-specific Cluster of Differentiation 8 (CD8) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	A/California [D0] (N=25,25,24,25,25,26)	93.50 Number of T cells/million	Standard Deviation 114.9
Arepanrix/Placebo/Flulaval Group	Number of Influenza-specific Cluster of Differentiation 8 (CD8) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	A/Brisbane [D7] (N=24,27,24,23,24,26)	529.73 Number of T cells/million	Standard Deviation 416.76
Arepanrix/Placebo/Flulaval Group	Number of Influenza-specific Cluster of Differentiation 8 (CD8) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	Pool Flu [D42] (N=26,27,27,26,24,27)	391.11 Number of T cells/million	Standard Deviation 755.53
Arepanrix/Placebo/Flulaval Group	Number of Influenza-specific Cluster of Differentiation 8 (CD8) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	A/Brisbane [D182] (N=26,24,26,26,25,25)	370.64 Number of T cells/million	Standard Deviation 955.57
Arepanrix/Placebo/Flulaval Group	Number of Influenza-specific Cluster of Differentiation 8 (CD8) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	A/Brisbane [D63] (N=26,26,25,25,24,26)	529.81 Number of T cells/million	Standard Deviation 1383.73
Arepanrix/Placebo/Flulaval Group	Number of Influenza-specific Cluster of Differentiation 8 (CD8) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	A/Brisbane [D0] (N=25,25,24,25,25,26)	119.46 Number of T cells/million	Standard Deviation 113.79
Arepanrix/Placebo/Flulaval Group	Number of Influenza-specific Cluster of Differentiation 8 (CD8) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	A/California [D21] (N=26,25,27,24,24,26)	351.69 Number of T cells/million	Standard Deviation 713.52
Arepanrix/Placebo/Flulaval Group	Number of Influenza-specific Cluster of Differentiation 8 (CD8) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	Pool Flu [D182] (N=26,24,26,26,25,25)	234.92 Number of T cells/million	Standard Deviation 398.06
Arepanrix/Placebo/Flulaval Group	Number of Influenza-specific Cluster of Differentiation 8 (CD8) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	Pool Flu [D63] (N=25,26,25,25,24,24)	432.08 Number of T cells/million	Standard Deviation 1145.71

Secondary

Number of Seroconverted Subjects for Antibodies Against A/ California Strain.

Seroconversion rate was defined as the incidence rate of vaccinees who had either a pre-vaccination titer recorded as \< 1:10 and a post-vaccination reciprocal titer ≥ 40 or a pre-vaccination reciprocal titer ≥ 10 and at least a 4-fold increase in post vaccination reciprocal titer. Seroconversion defined as: For initially seronegative subjects, antibody titer ≥ 1:40 after vaccination For initially seropositive subjects, antibody titer after vaccination ≥ 4 fold the pre-vaccination antibody titer

Time frame: At Day 63 from Day 21 for Flulaval/placebo/unadjuvanted Arepanrix and Flulaval/placebo/Arepanrix Groups; At Day 42 from Day 0 for the 4 other groups

Arm	Measure	Value (NUMBER)
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Seroconverted Subjects for Antibodies Against A/ California Strain.	66 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Seroconverted Subjects for Antibodies Against A/ California Strain.	77 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Seroconverted Subjects for Antibodies Against A/ California Strain.	84 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Seroconverted Subjects for Antibodies Against A/ California Strain.	85 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Seroconverted Subjects for Antibodies Against A/ California Strain.	88 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Seroconverted Subjects for Antibodies Against A/ California Strain.	90 Subjects

Secondary

Number of Seroconverted Subjects for Antibodies Against Flulaval Vaccine Strains

Seroconversion defined as: For initially seronegative subjects, antibody titer ≥ 1:40 after vaccination For initially seropositive subjects, antibody titer after vaccination ≥ 4 fold the pre-vaccination antibody titer Flulaval vaccines strains were A/Brisbane/59/2007 H1N1, A/Uruguay/716/2007 H3N2 and B/Brisbane/60/2008.

Time frame: on Days 21 and 63 from Day 0 for the first 4 groups; on Days 42 and 63 from Day 0 for the Unadjuvanted Arepanrix/placebo/Flulaval and Arepanrix/placebo/Flulaval Groups

Arm	Measure	Group	Value (NUMBER)
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Seroconverted Subjects for Antibodies Against Flulaval Vaccine Strains	Flu A/Bri/59/07 H1N1 [Day 21 or 42 after dose 1]	71 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Seroconverted Subjects for Antibodies Against Flulaval Vaccine Strains	Flu B/Bri/60/08 [Day 21 or 42 after dose 1]	76 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Seroconverted Subjects for Antibodies Against Flulaval Vaccine Strains	Flu A/Uru/716/07 H3N2 [Day 63 after dose 1]	71 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Seroconverted Subjects for Antibodies Against Flulaval Vaccine Strains	Flu A/Uru/716/07 H3N2 [Day 21 or 42 after dose 1]	72 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Seroconverted Subjects for Antibodies Against Flulaval Vaccine Strains	Flu A/Bri/59/07 H1N1 [Day 63 after dose 1]	63 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Seroconverted Subjects for Antibodies Against Flulaval Vaccine Strains	Flu B/Bri/60/08 [Day 63 after dose 1]	73 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Seroconverted Subjects for Antibodies Against Flulaval Vaccine Strains	Flu B/Bri/60/08 [Day 21 or 42 after dose 1]	76 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Seroconverted Subjects for Antibodies Against Flulaval Vaccine Strains	Flu A/Bri/59/07 H1N1 [Day 63 after dose 1]	76 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Seroconverted Subjects for Antibodies Against Flulaval Vaccine Strains	Flu A/Uru/716/07 H3N2 [Day 63 after dose 1]	69 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Seroconverted Subjects for Antibodies Against Flulaval Vaccine Strains	Flu A/Bri/59/07 H1N1 [Day 21 or 42 after dose 1]	74 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Seroconverted Subjects for Antibodies Against Flulaval Vaccine Strains	Flu A/Uru/716/07 H3N2 [Day 21 or 42 after dose 1]	73 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Seroconverted Subjects for Antibodies Against Flulaval Vaccine Strains	Flu B/Bri/60/08 [Day 63 after dose 1]	73 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Seroconverted Subjects for Antibodies Against Flulaval Vaccine Strains	Flu B/Bri/60/08 [Day 21 or 42 after dose 1]	74 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Seroconverted Subjects for Antibodies Against Flulaval Vaccine Strains	Flu A/Bri/59/07 H1N1 [Day 21 or 42 after dose 1]	76 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Seroconverted Subjects for Antibodies Against Flulaval Vaccine Strains	Flu A/Bri/59/07 H1N1 [Day 63 after dose 1]	69 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Seroconverted Subjects for Antibodies Against Flulaval Vaccine Strains	Flu A/Uru/716/07 H3N2 [Day 21 or 42 after dose 1]	72 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Seroconverted Subjects for Antibodies Against Flulaval Vaccine Strains	Flu A/Uru/716/07 H3N2 [Day 63 after dose 1]	69 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Seroconverted Subjects for Antibodies Against Flulaval Vaccine Strains	Flu B/Bri/60/08 [Day 63 after dose 1]	67 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Seroconverted Subjects for Antibodies Against Flulaval Vaccine Strains	Flu B/Bri/60/08 [Day 21 or 42 after dose 1]	78 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Seroconverted Subjects for Antibodies Against Flulaval Vaccine Strains	Flu B/Bri/60/08 [Day 63 after dose 1]	73 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Seroconverted Subjects for Antibodies Against Flulaval Vaccine Strains	Flu A/Bri/59/07 H1N1 [Day 21 or 42 after dose 1]	70 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Seroconverted Subjects for Antibodies Against Flulaval Vaccine Strains	Flu A/Bri/59/07 H1N1 [Day 63 after dose 1]	64 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Seroconverted Subjects for Antibodies Against Flulaval Vaccine Strains	Flu A/Uru/716/07 H3N2 [Day 21 or 42 after dose 1]	76 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Seroconverted Subjects for Antibodies Against Flulaval Vaccine Strains	Flu A/Uru/716/07 H3N2 [Day 63 after dose 1]	69 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Seroconverted Subjects for Antibodies Against Flulaval Vaccine Strains	Flu A/Uru/716/07 H3N2 [Day 21 or 42 after dose 1]	3 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Seroconverted Subjects for Antibodies Against Flulaval Vaccine Strains	Flu A/Uru/716/07 H3N2 [Day 63 after dose 1]	75 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Seroconverted Subjects for Antibodies Against Flulaval Vaccine Strains	Flu A/Bri/59/07 H1N1 [Day 63 after dose 1]	71 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Seroconverted Subjects for Antibodies Against Flulaval Vaccine Strains	Flu B/Bri/60/08 [Day 21 or 42 after dose 1]	6 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Seroconverted Subjects for Antibodies Against Flulaval Vaccine Strains	Flu B/Bri/60/08 [Day 63 after dose 1]	78 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Seroconverted Subjects for Antibodies Against Flulaval Vaccine Strains	Flu A/Bri/59/07 H1N1 [Day 21 or 42 after dose 1]	17 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Seroconverted Subjects for Antibodies Against Flulaval Vaccine Strains	Flu A/Uru/716/07 H3N2 [Day 63 after dose 1]	78 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Seroconverted Subjects for Antibodies Against Flulaval Vaccine Strains	Flu A/Uru/716/07 H3N2 [Day 21 or 42 after dose 1]	6 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Seroconverted Subjects for Antibodies Against Flulaval Vaccine Strains	Flu B/Bri/60/08 [Day 63 after dose 1]	76 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Seroconverted Subjects for Antibodies Against Flulaval Vaccine Strains	Flu A/Bri/59/07 H1N1 [Day 63 after dose 1]	76 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Seroconverted Subjects for Antibodies Against Flulaval Vaccine Strains	Flu A/Bri/59/07 H1N1 [Day 21 or 42 after dose 1]	28 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Seroconverted Subjects for Antibodies Against Flulaval Vaccine Strains	Flu B/Bri/60/08 [Day 21 or 42 after dose 1]	24 Subjects

Secondary

Number of Seroconverted Subjects for Antibodies Against Flulaval Vaccine Strains

Time frame: At Day 182 from Day 0

Arm	Measure	Group	Value (NUMBER)
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Seroconverted Subjects for Antibodies Against Flulaval Vaccine Strains	Flu A/Uru/716/07 H3N2	58 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Seroconverted Subjects for Antibodies Against Flulaval Vaccine Strains	Flu A/Bri/59/07 H1N1	45 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Seroconverted Subjects for Antibodies Against Flulaval Vaccine Strains	Flu B/Bri/60/08 Victoria	68 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Seroconverted Subjects for Antibodies Against Flulaval Vaccine Strains	Flu A/Uru/716/07 H3N2	56 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Seroconverted Subjects for Antibodies Against Flulaval Vaccine Strains	Flu A/Bri/59/07 H1N1	57 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Seroconverted Subjects for Antibodies Against Flulaval Vaccine Strains	Flu B/Bri/60/08 Victoria	54 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Seroconverted Subjects for Antibodies Against Flulaval Vaccine Strains	Flu A/Uru/716/07 H3N2	54 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Seroconverted Subjects for Antibodies Against Flulaval Vaccine Strains	Flu A/Bri/59/07 H1N1	45 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Seroconverted Subjects for Antibodies Against Flulaval Vaccine Strains	Flu B/Bri/60/08 Victoria	48 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Seroconverted Subjects for Antibodies Against Flulaval Vaccine Strains	Flu A/Uru/716/07 H3N2	56 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Seroconverted Subjects for Antibodies Against Flulaval Vaccine Strains	Flu A/Bri/59/07 H1N1	38 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Seroconverted Subjects for Antibodies Against Flulaval Vaccine Strains	Flu B/Bri/60/08 Victoria	64 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Seroconverted Subjects for Antibodies Against Flulaval Vaccine Strains	Flu A/Uru/716/07 H3N2	60 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Seroconverted Subjects for Antibodies Against Flulaval Vaccine Strains	Flu A/Bri/59/07 H1N1	46 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Seroconverted Subjects for Antibodies Against Flulaval Vaccine Strains	Flu B/Bri/60/08 Victoria	67 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Seroconverted Subjects for Antibodies Against Flulaval Vaccine Strains	Flu A/Bri/59/07 H1N1	54 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Seroconverted Subjects for Antibodies Against Flulaval Vaccine Strains	Flu B/Bri/60/08 Victoria	62 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Seroconverted Subjects for Antibodies Against Flulaval Vaccine Strains	Flu A/Uru/716/07 H3N2	61 Subjects

Secondary

Number of Seroconverted Subjects for Antibodies Against Flulaval Vaccine Strains.

Time frame: At Day 21 from Day 0 for the pooled group, Flulaval/unadjuvanted Arepanrix/placebo and Flulaval/Arepanrix/placebo Groups; at Day 63 from Day 42 for Unadjuvanted Arepanrix/placebo/Flulaval Group and Arepanrix/placebo/Flulaval Group

Arm	Measure	Group	Value (NUMBER)
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Seroconverted Subjects for Antibodies Against Flulaval Vaccine Strains.	Flu A/Bri/59/07 H1N1	76 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Seroconverted Subjects for Antibodies Against Flulaval Vaccine Strains.	Flu B/Bri/60/08	74 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Seroconverted Subjects for Antibodies Against Flulaval Vaccine Strains.	Flu A/Uru/716/07 H3N2	72 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Seroconverted Subjects for Antibodies Against Flulaval Vaccine Strains.	Flu A/Uru/716/07 H3N2	76 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Seroconverted Subjects for Antibodies Against Flulaval Vaccine Strains.	Flu A/Bri/59/07 H1N1	70 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Seroconverted Subjects for Antibodies Against Flulaval Vaccine Strains.	Flu B/Bri/60/08	78 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Seroconverted Subjects for Antibodies Against Flulaval Vaccine Strains.	Flu A/Uru/716/07 H3N2	73 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Seroconverted Subjects for Antibodies Against Flulaval Vaccine Strains.	Flu A/Bri/59/07 H1N1	50 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Seroconverted Subjects for Antibodies Against Flulaval Vaccine Strains.	Flu B/Bri/60/08	71 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Seroconverted Subjects for Antibodies Against Flulaval Vaccine Strains.	Flu A/Bri/59/07 H1N1	33 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Seroconverted Subjects for Antibodies Against Flulaval Vaccine Strains.	Flu B/Bri/60/08	57 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Seroconverted Subjects for Antibodies Against Flulaval Vaccine Strains.	Flu A/Uru/716/07 H3N2	72 Subjects
Flulaval/Placebo/(Unadjuvanted) Arepanrix Pooled Group	Number of Seroconverted Subjects for Antibodies Against Flulaval Vaccine Strains.	Flu A/Uru/716/07 H3N2	145 Subjects
Flulaval/Placebo/(Unadjuvanted) Arepanrix Pooled Group	Number of Seroconverted Subjects for Antibodies Against Flulaval Vaccine Strains.	Flu A/Bri/59/07 H1N1	145 Subjects
Flulaval/Placebo/(Unadjuvanted) Arepanrix Pooled Group	Number of Seroconverted Subjects for Antibodies Against Flulaval Vaccine Strains.	Flu B/Bri/60/08	152 Subjects

Secondary

Number of Seroprotected Subjects for Antibodies Against A/California Strain.

Seroprotection rate was defined as the proportion of subjects with H1N1 reciprocal HI titers ≥ 40 against the tested vaccine virus.

Time frame: At Day 63 for Flulaval/placebo/unadjuvanted Arepanrix and Flulaval/placebo/Arepanrix Groups; At Day 42 for the 4 other groups.

Arm	Measure	Value (NUMBER)
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Seroprotected Subjects for Antibodies Against A/California Strain.	90 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Seroprotected Subjects for Antibodies Against A/California Strain.	86 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Seroprotected Subjects for Antibodies Against A/California Strain.	92 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Seroprotected Subjects for Antibodies Against A/California Strain.	89 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Seroprotected Subjects for Antibodies Against A/California Strain.	91 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Seroprotected Subjects for Antibodies Against A/California Strain.	91 Subjects

Secondary

Number of Seroprotected Subjects for Antibodies Against Flulaval Vaccine Strains

Seroprotection was defined as the proportion of subjects with H1N1 reciprocal Hemagglutination Inhibition (HI) titers ≥ 1:40 against the tested vaccine virus. Flulaval vaccines strains were A/Brisbane/59/2007 H1N1, A/Uruguay/716/2007 H3N2 and B/Brisbane/60/2008. For the analysis the Flulaval/placebo/unadjuvanted Arepanrix Group and the Flulaval/placebo/Arepanrix Group were pooled.

Time frame: At Day 21 for the pooled group, Flulaval/unadjuvanted Arepanrix/placebo and Flulaval/Arepanrix/placebo Groups; at Day 63 for Unadjuvanted Arepanrix/placebo/Flulaval Group and Arepanrix/placebo/Flulaval Group

Arm	Measure	Group	Value (NUMBER)
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Seroprotected Subjects for Antibodies Against Flulaval Vaccine Strains	Flu A/Bri/59/07 H1N1	89 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Seroprotected Subjects for Antibodies Against Flulaval Vaccine Strains	Flu B/Bri/60/08	90 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Seroprotected Subjects for Antibodies Against Flulaval Vaccine Strains	Flu A/Uru/716/07 H3N2	77 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Seroprotected Subjects for Antibodies Against Flulaval Vaccine Strains	Flu A/Uru/716/07 H3N2	79 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Seroprotected Subjects for Antibodies Against Flulaval Vaccine Strains	Flu A/Bri/59/07 H1N1	82 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Seroprotected Subjects for Antibodies Against Flulaval Vaccine Strains	Flu B/Bri/60/08	89 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Seroprotected Subjects for Antibodies Against Flulaval Vaccine Strains	Flu A/Uru/716/07 H3N2	81 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Seroprotected Subjects for Antibodies Against Flulaval Vaccine Strains	Flu A/Bri/59/07 H1N1	81 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Seroprotected Subjects for Antibodies Against Flulaval Vaccine Strains	Flu B/Bri/60/08	91 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Seroprotected Subjects for Antibodies Against Flulaval Vaccine Strains	Flu A/Bri/59/07 H1N1	87 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Seroprotected Subjects for Antibodies Against Flulaval Vaccine Strains	Flu B/Bri/60/08	91 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Seroprotected Subjects for Antibodies Against Flulaval Vaccine Strains	Flu A/Uru/716/07 H3N2	83 Subjects
Flulaval/Placebo/(Unadjuvanted) Arepanrix Pooled Group	Number of Seroprotected Subjects for Antibodies Against Flulaval Vaccine Strains	Flu A/Uru/716/07 H3N2	155 Subjects
Flulaval/Placebo/(Unadjuvanted) Arepanrix Pooled Group	Number of Seroprotected Subjects for Antibodies Against Flulaval Vaccine Strains	Flu A/Bri/59/07 H1N1	170 Subjects
Flulaval/Placebo/(Unadjuvanted) Arepanrix Pooled Group	Number of Seroprotected Subjects for Antibodies Against Flulaval Vaccine Strains	Flu B/Bri/60/08	176 Subjects

Secondary

Number of Seroprotected Subjects for Antibodies Against Flulaval Vaccine Strains.

Seroprotection rate was defined as the proportion of subjects with H1N1 reciprocal HI titers ≥ 40 against the tested vaccine virus. Flulaval vaccines strains were A/Brisbane/59/2007 H1N1, A/Uruguay/716/2007 H3N2 and B/Brisbane/60/2008.

Time frame: At Day 182 after the first dose

Arm	Measure	Group	Value (NUMBER)
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Seroprotected Subjects for Antibodies Against Flulaval Vaccine Strains.	Flu A/Bri/59/07 H1N1	63 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Seroprotected Subjects for Antibodies Against Flulaval Vaccine Strains.	Flu A/Uru/716/07 H3N2	66 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Seroprotected Subjects for Antibodies Against Flulaval Vaccine Strains.	Flu B/Bri/60/08 Victoria	90 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Seroprotected Subjects for Antibodies Against Flulaval Vaccine Strains.	Flu A/Uru/716/07 H3N2	64 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Seroprotected Subjects for Antibodies Against Flulaval Vaccine Strains.	Flu A/Bri/59/07 H1N1	74 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Seroprotected Subjects for Antibodies Against Flulaval Vaccine Strains.	Flu B/Bri/60/08 Victoria	88 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Seroprotected Subjects for Antibodies Against Flulaval Vaccine Strains.	Flu A/Bri/59/07 H1N1	66 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Seroprotected Subjects for Antibodies Against Flulaval Vaccine Strains.	Flu A/Uru/716/07 H3N2	60 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Seroprotected Subjects for Antibodies Against Flulaval Vaccine Strains.	Flu B/Bri/60/08 Victoria	79 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Seroprotected Subjects for Antibodies Against Flulaval Vaccine Strains.	Flu B/Bri/60/08 Victoria	89 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Seroprotected Subjects for Antibodies Against Flulaval Vaccine Strains.	Flu A/Bri/59/07 H1N1	61 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Seroprotected Subjects for Antibodies Against Flulaval Vaccine Strains.	Flu A/Uru/716/07 H3N2	64 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Seroprotected Subjects for Antibodies Against Flulaval Vaccine Strains.	Flu A/Uru/716/07 H3N2	68 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Seroprotected Subjects for Antibodies Against Flulaval Vaccine Strains.	Flu A/Bri/59/07 H1N1	67 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Seroprotected Subjects for Antibodies Against Flulaval Vaccine Strains.	Flu B/Bri/60/08 Victoria	88 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Seroprotected Subjects for Antibodies Against Flulaval Vaccine Strains.	Flu B/Bri/60/08 Victoria	91 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Seroprotected Subjects for Antibodies Against Flulaval Vaccine Strains.	Flu A/Bri/59/07 H1N1	71 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Seroprotected Subjects for Antibodies Against Flulaval Vaccine Strains.	Flu A/Uru/716/07 H3N2	70 Subjects

Secondary

Number of Seroprotected Subjects for Antibodies Against Flulaval Vaccine Strains.

Time frame: before vaccination and on days 21 and 63 for the first 4 groups and before vaccination and on days 42 and 63 for the Unadjuvanted Arepanrix/placebo/Flulaval and Arepanrix/placebo/Flulaval Groups

Arm	Measure	Group	Value (NUMBER)
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Seroprotected Subjects for Antibodies Against Flulaval Vaccine Strains.	Flu A/Bri/59/07 H1N1 [Days 21 or 42 post dose 1]	86 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Seroprotected Subjects for Antibodies Against Flulaval Vaccine Strains.	Flu B/Bri/60/08 [Days 21 or 42 post dose 1]	91 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Seroprotected Subjects for Antibodies Against Flulaval Vaccine Strains.	Flu A/Bri/59/07 H1N1 [at Day 63 post dose 1]	84 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Seroprotected Subjects for Antibodies Against Flulaval Vaccine Strains.	Flu A/Uru/716/07 H3N2 [Days 21 or 42 post dose 1]	78 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Seroprotected Subjects for Antibodies Against Flulaval Vaccine Strains.	Flu B/Bri/60/08 [at Day 0]	62 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Seroprotected Subjects for Antibodies Against Flulaval Vaccine Strains.	Flu A/Uru/716/07 H3N2 [at Day 63 post dose 1]	78 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Seroprotected Subjects for Antibodies Against Flulaval Vaccine Strains.	Flu A/Bri/59/07 H1N1 [at Day 0]	20 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Seroprotected Subjects for Antibodies Against Flulaval Vaccine Strains.	Flu B/Bri/60/08 [at Day 63 post dose 1]	91 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Seroprotected Subjects for Antibodies Against Flulaval Vaccine Strains.	Flu A/Uru/716/07 H3N2 [at Day 0]	12 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Seroprotected Subjects for Antibodies Against Flulaval Vaccine Strains.	Flu A/Uru/716/07 H3N2 [at Day 63 post dose 1]	75 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Seroprotected Subjects for Antibodies Against Flulaval Vaccine Strains.	Flu A/Bri/59/07 H1N1 [Days 21 or 42 post dose 1]	84 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Seroprotected Subjects for Antibodies Against Flulaval Vaccine Strains.	Flu A/Uru/716/07 H3N2 [Days 21 or 42 post dose 1]	77 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Seroprotected Subjects for Antibodies Against Flulaval Vaccine Strains.	Flu B/Bri/60/08 [Days 21 or 42 post dose 1]	85 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Seroprotected Subjects for Antibodies Against Flulaval Vaccine Strains.	Flu A/Uru/716/07 H3N2 [at Day 0]	16 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Seroprotected Subjects for Antibodies Against Flulaval Vaccine Strains.	Flu A/Bri/59/07 H1N1 [at Day 63 post dose 1]	86 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Seroprotected Subjects for Antibodies Against Flulaval Vaccine Strains.	Flu B/Bri/60/08 [at Day 0]	50 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Seroprotected Subjects for Antibodies Against Flulaval Vaccine Strains.	Flu A/Bri/59/07 H1N1 [at Day 0]	18 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Seroprotected Subjects for Antibodies Against Flulaval Vaccine Strains.	Flu B/Bri/60/08 [at Day 63 post dose 1]	86 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Seroprotected Subjects for Antibodies Against Flulaval Vaccine Strains.	Flu A/Bri/59/07 H1N1 [at Day 63 post dose 1]	85 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Seroprotected Subjects for Antibodies Against Flulaval Vaccine Strains.	Flu A/Uru/716/07 H3N2 [at Day 63 post dose 1]	73 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Seroprotected Subjects for Antibodies Against Flulaval Vaccine Strains.	Flu A/Bri/59/07 H1N1 [Days 21 or 42 post dose 1]	89 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Seroprotected Subjects for Antibodies Against Flulaval Vaccine Strains.	Flu A/Bri/59/07 H1N1 [at Day 0]	26 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Seroprotected Subjects for Antibodies Against Flulaval Vaccine Strains.	Flu B/Bri/60/08 [at Day 0]	56 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Seroprotected Subjects for Antibodies Against Flulaval Vaccine Strains.	Flu A/Uru/716/07 H3N2 [at Day 0]	8 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Seroprotected Subjects for Antibodies Against Flulaval Vaccine Strains.	Flu B/Bri/60/08 [at Day 63 post dose 1]	91 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Seroprotected Subjects for Antibodies Against Flulaval Vaccine Strains.	Flu B/Bri/60/08 [Days 21 or 42 post dose 1]	90 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Seroprotected Subjects for Antibodies Against Flulaval Vaccine Strains.	Flu A/Uru/716/07 H3N2 [Days 21 or 42 post dose 1]	77 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Seroprotected Subjects for Antibodies Against Flulaval Vaccine Strains.	Flu B/Bri/60/08 [Days 21 or 42 post dose 1]	89 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Seroprotected Subjects for Antibodies Against Flulaval Vaccine Strains.	Flu A/Bri/59/07 H1N1 [at Day 0]	18 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Seroprotected Subjects for Antibodies Against Flulaval Vaccine Strains.	Flu A/Bri/59/07 H1N1 [Days 21 or 42 post dose 1]	82 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Seroprotected Subjects for Antibodies Against Flulaval Vaccine Strains.	Flu A/Bri/59/07 H1N1 [at Day 63 post dose 1]	79 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Seroprotected Subjects for Antibodies Against Flulaval Vaccine Strains.	Flu A/Uru/716/07 H3N2 [at Day 0]	13 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Seroprotected Subjects for Antibodies Against Flulaval Vaccine Strains.	Flu A/Uru/716/07 H3N2 [Days 21 or 42 post dose 1]	79 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Seroprotected Subjects for Antibodies Against Flulaval Vaccine Strains.	Flu A/Uru/716/07 H3N2 [at Day 63 post dose 1]	75 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Seroprotected Subjects for Antibodies Against Flulaval Vaccine Strains.	Flu B/Bri/60/08 [at Day 0]	49 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Seroprotected Subjects for Antibodies Against Flulaval Vaccine Strains.	Flu B/Bri/60/08 [at Day 63 post dose 1]	89 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Seroprotected Subjects for Antibodies Against Flulaval Vaccine Strains.	Flu A/Uru/716/07 H3N2 [at Day 63 post dose 1]	81 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Seroprotected Subjects for Antibodies Against Flulaval Vaccine Strains.	Flu A/Uru/716/07 H3N2 [Days 21 or 42 post dose 1]	18 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Seroprotected Subjects for Antibodies Against Flulaval Vaccine Strains.	Flu B/Bri/60/08 [at Day 0]	66 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Seroprotected Subjects for Antibodies Against Flulaval Vaccine Strains.	Flu A/Uru/716/07 H3N2 [at Day 0]	15 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Seroprotected Subjects for Antibodies Against Flulaval Vaccine Strains.	Flu B/Bri/60/08 [Days 21 or 42 post dose 1]	75 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Seroprotected Subjects for Antibodies Against Flulaval Vaccine Strains.	Flu A/Bri/59/07 H1N1 [at Day 63 post dose 1]	81 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Seroprotected Subjects for Antibodies Against Flulaval Vaccine Strains.	Flu A/Bri/59/07 H1N1 [at Day 0]	23 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Seroprotected Subjects for Antibodies Against Flulaval Vaccine Strains.	Flu B/Bri/60/08 [at Day 63 post dose 1]	91 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Seroprotected Subjects for Antibodies Against Flulaval Vaccine Strains.	Flu A/Bri/59/07 H1N1 [Days 21 or 42 post dose 1]	47 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Seroprotected Subjects for Antibodies Against Flulaval Vaccine Strains.	Flu B/Bri/60/08 [at Day 0]	62 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Seroprotected Subjects for Antibodies Against Flulaval Vaccine Strains.	Flu A/Bri/59/07 H1N1 [Days 21 or 42 post dose 1]	62 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Seroprotected Subjects for Antibodies Against Flulaval Vaccine Strains.	Flu A/Bri/59/07 H1N1 [at Day 0]	20 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Seroprotected Subjects for Antibodies Against Flulaval Vaccine Strains.	Flu A/Uru/716/07 H3N2 [at Day 63 post dose 1]	83 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Seroprotected Subjects for Antibodies Against Flulaval Vaccine Strains.	Flu A/Uru/716/07 H3N2 [at Day 0]	17 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Seroprotected Subjects for Antibodies Against Flulaval Vaccine Strains.	Flu B/Bri/60/08 [at Day 63 post dose 1]	91 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Seroprotected Subjects for Antibodies Against Flulaval Vaccine Strains.	Flu A/Uru/716/07 H3N2 [Days 21 or 42 post dose 1]	28 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Seroprotected Subjects for Antibodies Against Flulaval Vaccine Strains.	Flu B/Bri/60/08 [Days 21 or 42 post dose 1]	89 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Seroprotected Subjects for Antibodies Against Flulaval Vaccine Strains.	Flu A/Bri/59/07 H1N1 [at Day 63 post dose 1]	87 Subjects

Secondary

Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed

Laboratory parameters assessed were creatinine (CREA), bilirubin (BIL) (direct (D)), eosinophils (EOS), hemoglobin (Hgb), hematocrit (Hct). For each parameter and for each range it was assessed whether the values of the subjects were unknown, in above, below or within the range.

Time frame: On Days 0, 7, 21, 28, 42, 63 and 182

Population: The Total Vaccinated cohort included all vaccinated subjects

Arm	Measure	Group	Value (NUMBER)
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	EOS [D0] Unknown (N=102,104,102,100,101,102)	2 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	EOS [D0] Above (N=102,104,102,100,101,102)	1 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	CREA [D42] Below (N=101,97,95,95,96,97)	6 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hct [D7] Below (N=102,101,100,99,100,99)	7 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	EOS [D0] Within (N=102,104,102,100,101,102)	97 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	CREA [D182] Above (N=99,91,88,91,93,97)	1 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	CREA [D182] Within (N=99,91,88,91,93,97)	84 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	CREA [D182] Below (N=99,91,88,91,93,97)	14 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	CREA [D42] Within (N=101,97,95,95,96,97)	95 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	CREA [D7] Within (N=102,101,100,99,100,99)	94 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	CREA [D63] Unknown (N=100,95,95,95,97,97)	1 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	CREA [D63] Above (N=100,95,95,95,97,97)	0 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	CREA [D63] Within (N=100,95,95,95,97,97)	92 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	CREA [D63] Below (N=100,95,95,95,97,97)	7 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	CREA [D42] Above (N=101,97,95,95,96,97)	0 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL D [D42] Below (N=101,97,95,95,96,97)	0 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	CREA [D42] Unknown (N=101,97,95,95,96,97)	0 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL D [D21] Unknown (N=101,100,97,97,99,99)	0 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL D [D7] Above (N=102,101,100,99,100,99)	0 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hct [D63] Below (N=100,95,95,95,97,97)	8 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL D [D21] Above (N=101,100,97,97,99,99)	0 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL D [D21] Within (N=101,100,97,97,99,99)	101 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	CREA [D0] Below (N=102,104,102,100,101,102)	8 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL D [D21] Below (N=101,100,97,97,99,99)	0 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL D [D0] Unknown (N=102,104,102,100,101,102)	1 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL D [D0] Above (N=102,104,102,100,101,102)	0 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL D [D0] Within (N=102,104,102,100,101,102)	101 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	CREA [D7] Unknown (N=102,101,100,99,100,99)	0 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	EOS [D21] Within (N=101,100,97,97,99,99)	97 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL D [D0] Below (N=102,104,102,100,101,102)	0 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hgb [D182] Within (N=99,91,88,91,93,97)	89 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hgb [D63] Unknown (N=100,95,95,95,97,97)	0 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hgb [D63] Above (N=100,95,95,95,97,97)	0 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	CREA [D21] Below (N=101,100,97,97,99,99)	12 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	EOS [D28] Below (N=101,98,96,98,98,97)	4 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hgb [D63] Below (N=100,95,95,95,97,97)	8 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hgb [D42] Unknown (N=101,97,95,95,96,97)	0 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hgb [D42] Above (N=101,97,95,95,96,97)	0 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hgb [D42] Below (N=101,97,95,95,96,97)	7 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	CREA [D21] Within (N=101,100,97,97,99,99)	88 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	CREA [D7] Above (N=102,101,100,99,100,99)	0 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hgb [D28] Unknown (N=101,98,96,98,98,97)	1 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hgb [D28] Within (N=101,98,96,98,98,97)	90 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hgb [D21] Unknown (N=101,100,97,97,99,99)	0 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hgb [D21] Above (N=101,100,97,97,99,99)	2 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	CREA [D21] Above (N=101,100,97,97,99,99)	1 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL D [D182] Unknown (N=99,91,88,91,93,97)	0 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hgb [D21] Below (N=101,100,97,97,99,99)	6 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hgb [D7] Unknown (N=102,101,100,99,100,99)	0 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hgb [D0] Within (N=102,104,102,100,101,102)	97 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hct [D182] Above (N=99,91,88,91,93,97)	2 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	CREA [D21] Unknown (N=101,100,97,97,99,99)	0 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL D [D182] Above (N=99,91,88,91,93,97)	0 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hct [D63] Unknown (N=100,95,95,95,97,97)	0 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hct [D63] Above (N=100,95,95,95,97,97)	0 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hct [D42] Within (N=101,97,95,95,96,97)	90 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hct [D42] Below (N=101,97,95,95,96,97)	11 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	CREA [D28] Below (N=101,98,96,98,98,97)	5 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	EOS [D42] Unknown (N=101,97,95,95,96,97)	0 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hct [D28] Unknown (N=101,98,96,98,98,97)	1 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hct [D28] Above (N=101,98,96,98,98,97)	1 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hct [D28] Within (N=101,98,96,98,98,97)	89 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hct [D28] Below (N=101,98,96,98,98,97)	10 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	CREA [D28] Within (N=101,98,96,98,98,97)	95 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL D [D182] Within (N=99,91,88,91,93,97)	99 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	EOS [D182] Unknown (N=99,91,88,91,93,97)	0 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	EOS [D63] Unknown (N=100,95,95,95,97,97)	0 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	EOS [D63] Above (N=100,95,95,95,97,97)	1 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	EOS [D42] Above (N=101,97,95,95,96,97)	1 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	CREA [D28] Above (N=101,98,96,98,98,97)	0 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL D [D182] Below (N=99,91,88,91,93,97)	0 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	EOS [D42] Within (N=101,97,95,95,96,97)	96 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	EOS [D42] Below (N=101,97,95,95,96,97)	4 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	EOS [D28] Unknown (N=101,98,96,98,98,97)	2 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	EOS [D28] Above (N=101,98,96,98,98,97)	1 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	CREA [D28] Unknown (N=101,98,96,98,98,97)	1 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL D [D63] Below (N=100,95,95,95,97,97)	0 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	EOS [D21] Below (N=101,100,97,97,99,99)	2 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	EOS [D7] Unknown (N=102,101,100,99,100,99)	0 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	EOS [D63] Below (N=100,95,95,95,97,97)	2 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL D [D42] Unknown (N=101,97,95,95,96,97)	0 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hct [D7] Above (N=102,101,100,99,100,99)	2 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hct [D7] Within (N=102,101,100,99,100,99)	93 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hct [D0] Unknown (N=102,104,102,100,101,102)	2 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hct [D0] Above (N=102,104,102,100,101,102)	2 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	EOS [D63] Within (N=100,95,95,95,97,97)	97 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	EOS [D0] Below (N=102,104,102,100,101,102)	2 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hct [D0] Within (N=102,104,102,100,101,102)	94 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hct [D0] Below (N=102,104,102,100,101,102)	4 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	EOS [D182] Above (N=99,91,88,91,93,97)	2 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	EOS [D182] Within (N=99,91,88,91,93,97)	94 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	EOS [D182] Below (N=99,91,88,91,93,97)	3 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	CREA [D0] Unknown (N=102,104,102,100,101,102)	0 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL D [D42] Above (N=101,97,95,95,96,97)	0 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL D [D42] Within (N=101,97,95,95,96,97)	101 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL D [D28] Unknown (N=101,98,96,98,98,97)	1 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL D [D28] Above (N=101,98,96,98,98,97)	0 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	EOS [D7] Below (N=102,101,100,99,100,99)	7 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	CREA [D0] Above (N=102,104,102,100,101,102)	1 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL D [D28] Within (N=101,98,96,98,98,97)	100 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL D [D28] Below (N=101,98,96,98,98,97)	0 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL D [D7] Unknown(N=102,101,100,99,100,99)	0 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL D [D7] Within (N=102,101,100,99,100,99)	102 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	EOS [D7] Within (N=102,101,100,99,100,99)	93 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	CREA [D0] Within (N=102,104,102,100,101,102)	93 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL D [D7] Below (N=102,101,100,99,100,99)	0 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hgb [D182] Unknown (N=99,91,88,91,93,97)	0 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hgb [D182] Above (N=99,91,88,91,93,97)	1 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hgb [D182] Below (N=99,91,88,91,93,97)	9 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	EOS [D7] Above (N=102,101,100,99,100,99)	2 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	CREA [D182] Unknown (N=99,91,88,91,93,97)	0 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hgb [D63] Within (N=100,95,95,95,97,97)	92 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hgb [D42] Within (N=101,97,95,95,96,97)	94 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hgb [D28] Above (N=101,98,96,98,98,97)	0 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	EOS [D21] Above (N=101,100,97,97,99,99)	2 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	CREA [D7] Below (N=102,101,100,99,100,99)	8 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hgb [D28] Below (N=101,98,96,98,98,97)	10 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hgb [D21] Within (N=101,100,97,97,99,99)	93 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hgb [D7] Above (N=102,101,100,99,100,99)	2 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hgb [D7] Within (N=102,101,100,99,100,99)	94 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	EOS [D21] Unknown (N=101,100,97,97,99,99)	0 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL D [D63] Unknown (N=100,95,95,95,97,97)	1 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hgb [D7] Below (N=102,101,100,99,100,99)	6 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hgb [D0] Unknown (N=102,104,102,100,101,102)	2 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hgb [D0] Above (N=102,104,102,100,101,102)	1 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hgb [D0] Below (N=102,104,102,100,101,102)	2 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hct [D182] Unknown (N=99,91,88,91,93,97)	0 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hct [D182] Within (N=99,91,88,91,93,97)	93 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hct [D182] Below (N=99,91,88,91,93,97)	4 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	EOS [D28] Within (N=101,98,96,98,98,97)	94 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL D [D63] Above (N=100,95,95,95,97,97)	0 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hct [D63] Within (N=100,95,95,95,97,97)	92 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hct [D42] Unknown (N=101,97,95,95,96,97)	0 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hct [D42] Above (N=101,97,95,95,96,97)	0 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hct [D21] Unknown (N=101,100,97,97,99,99)	0 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL D [D63] Within (N=100,95,95,95,97,97)	99 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hct [D21] Above (N=101,100,97,97,99,99)	1 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hct [D21] Within (N=101,100,97,97,99,99)	92 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hct [D21] Below (N=101,100,97,97,99,99)	8 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hct [D7] Unknown (N=102,101,100,99,100,99)	0 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hct [D21] Within (N=101,100,97,97,99,99)	94 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	CREA [D182] Above (N=99,91,88,91,93,97)	1 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	CREA [D182] Unknown (N=99,91,88,91,93,97)	1 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	EOS [D0] Below (N=102,104,102,100,101,102)	6 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	EOS [D7] Below (N=102,101,100,99,100,99)	4 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	EOS [D7] Within (N=102,101,100,99,100,99)	93 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	EOS [D7] Above (N=102,101,100,99,100,99)	3 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	EOS [D21] Above (N=101,100,97,97,99,99)	4 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	EOS [D21] Unknown (N=101,100,97,97,99,99)	1 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	EOS [D28] Within (N=101,98,96,98,98,97)	90 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	EOS [D42] Unknown (N=101,97,95,95,96,97)	0 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	EOS [D63] Below (N=100,95,95,95,97,97)	9 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	EOS [D63] Within (N=100,95,95,95,97,97)	82 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	EOS [D182] Below (N=99,91,88,91,93,97)	4 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	EOS [D182] Within (N=99,91,88,91,93,97)	86 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	EOS [D182] Above (N=99,91,88,91,93,97)	1 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hct [D0] Below (N=102,104,102,100,101,102)	2 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hct [D0] Within (N=102,104,102,100,101,102)	99 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hct [D0] Above (N=102,104,102,100,101,102)	3 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hct [D0] Unknown (N=102,104,102,100,101,102)	0 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hct [D7] Below (N=102,101,100,99,100,99)	7 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hct [D7] Above (N=102,101,100,99,100,99)	2 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hct [D7] Unknown (N=102,101,100,99,100,99)	1 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hct [D21] Below (N=101,100,97,97,99,99)	4 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hct [D21] Above (N=101,100,97,97,99,99)	1 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hct [D21] Unknown (N=101,100,97,97,99,99)	1 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hct [D42] Below (N=101,97,95,95,96,97)	9 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hct [D42] Within (N=101,97,95,95,96,97)	86 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hct [D63] Below (N=100,95,95,95,97,97)	10 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hct [D63] Within (N=100,95,95,95,97,97)	84 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hct [D182] Below (N=99,91,88,91,93,97)	6 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hct [D182] Within (N=99,91,88,91,93,97)	84 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hct [D182] Unknown (N=99,91,88,91,93,97)	0 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hgb [D0] Above (N=102,104,102,100,101,102)	1 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hgb [D0] Unknown (N=102,104,102,100,101,102)	0 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hgb [D7] Below (N=102,101,100,99,100,99)	7 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hgb [D7] Within (N=102,101,100,99,100,99)	91 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hgb [D7] Above (N=102,101,100,99,100,99)	2 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hgb [D21] Within (N=101,100,97,97,99,99)	94 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hgb [D21] Unknown (N=101,100,97,97,99,99)	1 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hgb [D28] Below (N=101,98,96,98,98,97)	7 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hgb [D28] Above (N=101,98,96,98,98,97)	1 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hgb [D42] Within (N=101,97,95,95,96,97)	87 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hgb [D63] Within (N=100,95,95,95,97,97)	83 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hgb [D63] Unknown (N=100,95,95,95,97,97)	0 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hgb [D182] Below (N=99,91,88,91,93,97)	6 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hgb [D182] Within (N=99,91,88,91,93,97)	84 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hgb [D182] Above (N=99,91,88,91,93,97)	1 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hgb [D182] Unknown (N=99,91,88,91,93,97)	0 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL D [D7] Below (N=102,101,100,99,100,99)	0 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL D [D7] Within (N=102,101,100,99,100,99)	101 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL D [D7] Above (N=102,101,100,99,100,99)	0 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL D [D7] Unknown(N=102,101,100,99,100,99)	0 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL D [D28] Below (N=101,98,96,98,98,97)	0 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL D [D28] Within (N=101,98,96,98,98,97)	98 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL D [D28] Above (N=101,98,96,98,98,97)	0 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL D [D42] Within (N=101,97,95,95,96,97)	97 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL D [D42] Above (N=101,97,95,95,96,97)	0 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL D [D63] Within (N=100,95,95,95,97,97)	94 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL D [D63] Above (N=100,95,95,95,97,97)	0 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL D [D63] Unknown (N=100,95,95,95,97,97)	1 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	CREA [D0] Within (N=102,104,102,100,101,102)	97 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	CREA [D0] Above (N=102,104,102,100,101,102)	1 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	CREA [D0] Unknown (N=102,104,102,100,101,102)	0 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hct [D7] Within (N=102,101,100,99,100,99)	91 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	EOS [D28] Below (N=101,98,96,98,98,97)	4 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hct [D28] Below (N=101,98,96,98,98,97)	6 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hct [D42] Unknown (N=101,97,95,95,96,97)	0 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	CREA [D7] Above (N=102,101,100,99,100,99)	2 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	CREA [D7] Unknown (N=102,101,100,99,100,99)	0 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	CREA [D21] Below (N=101,100,97,97,99,99)	6 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	CREA [D21] Within (N=101,100,97,97,99,99)	92 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	CREA [D21] Above (N=101,100,97,97,99,99)	2 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	CREA [D21] Unknown (N=101,100,97,97,99,99)	0 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	CREA [D28] Below (N=101,98,96,98,98,97)	8 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	CREA [D28] Within (N=101,98,96,98,98,97)	90 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	CREA [D28] Above (N=101,98,96,98,98,97)	0 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	CREA [D28] Unknown (N=101,98,96,98,98,97)	0 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	CREA [D42] Below (N=101,97,95,95,96,97)	5 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	CREA [D42] Within (N=101,97,95,95,96,97)	90 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	CREA [D42] Above (N=101,97,95,95,96,97)	2 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	CREA [D42] Unknown (N=101,97,95,95,96,97)	0 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	CREA [D63] Below (N=100,95,95,95,97,97)	7 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	CREA [D63] Within (N=100,95,95,95,97,97)	86 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	CREA [D63] Above (N=100,95,95,95,97,97)	1 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	CREA [D63] Unknown (N=100,95,95,95,97,97)	1 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	CREA [D182] Below (N=99,91,88,91,93,97)	7 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	CREA [D182] Within (N=99,91,88,91,93,97)	82 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	EOS [D0] Within (N=102,104,102,100,101,102)	96 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	EOS [D0] Above (N=102,104,102,100,101,102)	2 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	EOS [D0] Unknown (N=102,104,102,100,101,102)	0 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	EOS [D7] Unknown (N=102,101,100,99,100,99)	1 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	EOS [D21] Below (N=101,100,97,97,99,99)	8 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	EOS [D21] Within (N=101,100,97,97,99,99)	87 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	EOS [D28] Above (N=101,98,96,98,98,97)	2 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	EOS [D28] Unknown (N=101,98,96,98,98,97)	2 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	EOS [D42] Below (N=101,97,95,95,96,97)	9 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	EOS [D42] Within (N=101,97,95,95,96,97)	86 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	EOS [D42] Above (N=101,97,95,95,96,97)	2 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	EOS [D63] Above (N=100,95,95,95,97,97)	4 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	EOS [D63] Unknown (N=100,95,95,95,97,97)	0 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	EOS [D182] Unknown (N=99,91,88,91,93,97)	0 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hct [D28] Within (N=101,98,96,98,98,97)	88 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hct [D28] Above (N=101,98,96,98,98,97)	2 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hct [D28] Unknown (N=101,98,96,98,98,97)	2 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hct [D42] Above (N=101,97,95,95,96,97)	2 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hct [D63] Above (N=100,95,95,95,97,97)	1 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hct [D63] Unknown (N=100,95,95,95,97,97)	0 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hct [D182] Above (N=99,91,88,91,93,97)	1 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hgb [D0] Below (N=102,104,102,100,101,102)	6 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hgb [D0] Within (N=102,104,102,100,101,102)	97 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hgb [D7] Unknown (N=102,101,100,99,100,99)	1 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hgb [D21] Below (N=101,100,97,97,99,99)	5 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hgb [D21] Above (N=101,100,97,97,99,99)	0 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hgb [D28] Within (N=101,98,96,98,98,97)	88 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hgb [D28] Unknown (N=101,98,96,98,98,97)	2 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hgb [D42] Below (N=101,97,95,95,96,97)	8 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hgb [D42] Above (N=101,97,95,95,96,97)	2 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hgb [D42] Unknown (N=101,97,95,95,96,97)	0 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hgb [D63] Below (N=100,95,95,95,97,97)	10 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hgb [D63] Above (N=100,95,95,95,97,97)	2 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL D [D0] Below (N=102,104,102,100,101,102)	0 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL D [D0] Within (N=102,104,102,100,101,102)	104 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL D [D0] Above (N=102,104,102,100,101,102)	0 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL D [D0] Unknown (N=102,104,102,100,101,102)	0 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL D [D21] Below (N=101,100,97,97,99,99)	0 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL D [D21] Within (N=101,100,97,97,99,99)	100 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL D [D21] Above (N=101,100,97,97,99,99)	0 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL D [D21] Unknown (N=101,100,97,97,99,99)	0 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL D [D28] Unknown (N=101,98,96,98,98,97)	0 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL D [D42] Below (N=101,97,95,95,96,97)	0 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL D [D42] Unknown (N=101,97,95,95,96,97)	0 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL D [D63] Below (N=100,95,95,95,97,97)	0 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL D [D182] Below (N=99,91,88,91,93,97)	0 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL D [D182] Within (N=99,91,88,91,93,97)	90 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL D [D182] Above (N=99,91,88,91,93,97)	0 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL D [D182] Unknown (N=99,91,88,91,93,97)	1 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	CREA [D0] Below (N=102,104,102,100,101,102)	6 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	CREA [D7] Below (N=102,101,100,99,100,99)	6 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	CREA [D7] Within (N=102,101,100,99,100,99)	93 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hgb [D28] Below (N=101,98,96,98,98,97)	5 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	CREA [D182] Below (N=99,91,88,91,93,97)	7 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	CREA [D7] Within (N=102,101,100,99,100,99)	91 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hgb [D28] Within (N=101,98,96,98,98,97)	89 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	CREA [D28] Above (N=101,98,96,98,98,97)	1 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	CREA [D21] Within (N=101,100,97,97,99,99)	92 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL D [D182] Above (N=99,91,88,91,93,97)	0 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hgb [D28] Unknown (N=101,98,96,98,98,97)	0 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL D [D63] Below (N=100,95,95,95,97,97)	0 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL D [D21] Below (N=101,100,97,97,99,99)	0 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	CREA [D7] Above (N=102,101,100,99,100,99)	0 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hgb [D42] Below (N=101,97,95,95,96,97)	6 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	EOS [D42] Within (N=101,97,95,95,96,97)	89 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hgb [D42] Above (N=101,97,95,95,96,97)	0 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL D [D7] Unknown(N=102,101,100,99,100,99)	0 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hgb [D42] Unknown (N=101,97,95,95,96,97)	0 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL D [D42] Below (N=101,97,95,95,96,97)	0 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	CREA [D21] Below (N=101,100,97,97,99,99)	5 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	EOS [D28] Below (N=101,98,96,98,98,97)	7 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hgb [D63] Within (N=100,95,95,95,97,97)	89 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL D [D0] Unknown (N=102,104,102,100,101,102)	1 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	CREA [D63] Unknown (N=100,95,95,95,97,97)	1 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL D [D0] Above (N=102,104,102,100,101,102)	0 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	CREA [D7] Unknown (N=102,101,100,99,100,99)	0 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL D [D182] Unknown (N=99,91,88,91,93,97)	0 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL D [D0] Below (N=102,104,102,100,101,102)	0 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	EOS [D21] Below (N=101,100,97,97,99,99)	9 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL D [D0] Within (N=102,104,102,100,101,102)	101 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	EOS [D63] Above (N=100,95,95,95,97,97)	2 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	CREA [D42] Within (N=101,97,95,95,96,97)	88 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	EOS [D63] Unknown (N=100,95,95,95,97,97)	0 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	CREA [D28] Within (N=101,98,96,98,98,97)	89 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	EOS [D182] Unknown (N=99,91,88,91,93,97)	0 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	EOS [D21] Within (N=101,100,97,97,99,99)	85 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	CREA [D63] Above (N=100,95,95,95,97,97)	0 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hct [D28] Below (N=101,98,96,98,98,97)	8 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL D [D42] Unknown (N=101,97,95,95,96,97)	1 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hct [D28] Within (N=101,98,96,98,98,97)	86 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	EOS [D0] Within (N=102,104,102,100,101,102)	93 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL D [D182] Below (N=99,91,88,91,93,97)	0 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hct [D28] Above (N=101,98,96,98,98,97)	2 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	CREA [D28] Below (N=101,98,96,98,98,97)	6 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hct [D28] Unknown (N=101,98,96,98,98,97)	0 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	EOS [D7] Unknown (N=102,101,100,99,100,99)	0 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	CREA [D63] Within (N=100,95,95,95,97,97)	87 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	CREA [D42] Below (N=101,97,95,95,96,97)	5 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	CREA [D63] Below (N=100,95,95,95,97,97)	7 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hct [D42] Above (N=101,97,95,95,96,97)	0 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	EOS [D28] Above (N=101,98,96,98,98,97)	0 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hct [D63] Below (N=100,95,95,95,97,97)	11 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	CREA [D42] Unknown (N=101,97,95,95,96,97)	1 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hct [D63] Above (N=100,95,95,95,97,97)	0 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	CREA [D42] Above (N=101,97,95,95,96,97)	1 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	CREA [D21] Unknown (N=101,100,97,97,99,99)	0 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hct [D63] Unknown (N=100,95,95,95,97,97)	0 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL D [D28] Unknown (N=101,98,96,98,98,97)	0 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hct [D7] Within (N=102,101,100,99,100,99)	95 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hct [D182] Above (N=99,91,88,91,93,97)	2 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	EOS [D0] Unknown (N=102,104,102,100,101,102)	0 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	CREA [D7] Below (N=102,101,100,99,100,99)	9 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL D [D182] Within (N=99,91,88,91,93,97)	88 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hgb [D0] Below (N=102,104,102,100,101,102)	5 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	CREA [D182] Within (N=99,91,88,91,93,97)	80 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	EOS [D28] Unknown (N=101,98,96,98,98,97)	0 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hgb [D0] Within (N=102,104,102,100,101,102)	95 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hgb [D7] Below (N=102,101,100,99,100,99)	5 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	EOS [D0] Above (N=102,104,102,100,101,102)	2 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL D [D21] Unknown (N=101,100,97,97,99,99)	0 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hgb [D7] Above (N=102,101,100,99,100,99)	1 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hgb [D7] Unknown (N=102,101,100,99,100,99)	0 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	CREA [D21] Above (N=101,100,97,97,99,99)	0 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL D [D21] Above (N=101,100,97,97,99,99)	0 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hgb [D21] Below (N=101,100,97,97,99,99)	3 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	EOS [D42] Below (N=101,97,95,95,96,97)	6 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	CREA [D0] Below (N=102,104,102,100,101,102)	6 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hgb [D21] Above (N=101,100,97,97,99,99)	1 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL D [D21] Within (N=101,100,97,97,99,99)	97 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	CREA [D28] Unknown (N=101,98,96,98,98,97)	0 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hgb [D63] Above (N=100,95,95,95,97,97)	0 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL D [D7] Above (N=102,101,100,99,100,99)	0 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL D [D63] Above (N=100,95,95,95,97,97)	0 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hct [D182] Unknown (N=99,91,88,91,93,97)	0 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	EOS [D7] Within (N=102,101,100,99,100,99)	91 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hct [D42] Below (N=101,97,95,95,96,97)	9 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hct [D0] Below (N=102,104,102,100,101,102)	4 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL D [D7] Below (N=102,101,100,99,100,99)	0 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	CREA [D0] Above (N=102,104,102,100,101,102)	1 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	EOS [D63] Below (N=100,95,95,95,97,97)	8 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	EOS [D7] Above (N=102,101,100,99,100,99)	2 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hgb [D0] Above (N=102,104,102,100,101,102)	2 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL D [D7] Within (N=102,101,100,99,100,99)	100 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hct [D0] Above (N=102,104,102,100,101,102)	3 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	EOS [D182] Above (N=99,91,88,91,93,97)	1 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	CREA [D0] Within (N=102,104,102,100,101,102)	94 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hct [D21] Within (N=101,100,97,97,99,99)	88 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hgb [D0] Unknown (N=102,104,102,100,101,102)	0 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hgb [D182] Above (N=99,91,88,91,93,97)	2 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	EOS [D42] Above (N=101,97,95,95,96,97)	0 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hct [D42] Unknown (N=101,97,95,95,96,97)	0 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	EOS [D21] Unknown (N=101,100,97,97,99,99)	3 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	EOS [D182] Within (N=99,91,88,91,93,97)	78 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	EOS [D7] Below (N=102,101,100,99,100,99)	7 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	CREA [D182] Unknown (N=99,91,88,91,93,97)	0 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hgb [D7] Within (N=102,101,100,99,100,99)	94 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hct [D7] Below (N=102,101,100,99,100,99)	4 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hct [D7] Unknown (N=102,101,100,99,100,99)	0 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hgb [D63] Unknown (N=100,95,95,95,97,97)	0 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hct [D0] Unknown (N=102,104,102,100,101,102)	0 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	EOS [D28] Within (N=101,98,96,98,98,97)	89 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hct [D0] Within (N=102,104,102,100,101,102)	95 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	EOS [D42] Unknown (N=101,97,95,95,96,97)	0 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hct [D63] Within (N=100,95,95,95,97,97)	84 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hct [D21] Below (N=101,100,97,97,99,99)	5 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL D [D63] Unknown (N=100,95,95,95,97,97)	1 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hgb [D21] Within (N=101,100,97,97,99,99)	90 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	EOS [D0] Below (N=102,104,102,100,101,102)	7 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hgb [D21] Unknown (N=101,100,97,97,99,99)	3 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	EOS [D63] Within (N=100,95,95,95,97,97)	85 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL D [D28] Below (N=101,98,96,98,98,97)	0 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	EOS [D182] Below (N=99,91,88,91,93,97)	9 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	EOS [D21] Above (N=101,100,97,97,99,99)	0 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hct [D21] Above (N=101,100,97,97,99,99)	1 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL D [D42] Within (N=101,97,95,95,96,97)	94 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hct [D182] Below (N=99,91,88,91,93,97)	4 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL D [D28] Within (N=101,98,96,98,98,97)	96 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hgb [D28] Above (N=101,98,96,98,98,97)	2 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hgb [D182] Below (N=99,91,88,91,93,97)	5 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL D [D42] Above (N=101,97,95,95,96,97)	0 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL D [D63] Within (N=100,95,95,95,97,97)	94 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hct [D7] Above (N=102,101,100,99,100,99)	1 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL D [D28] Above (N=101,98,96,98,98,97)	0 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hgb [D182] Unknown (N=99,91,88,91,93,97)	0 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hgb [D182] Within (N=99,91,88,91,93,97)	81 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hgb [D42] Within (N=101,97,95,95,96,97)	89 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	CREA [D0] Unknown (N=102,104,102,100,101,102)	1 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	CREA [D182] Above (N=99,91,88,91,93,97)	1 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hct [D182] Within (N=99,91,88,91,93,97)	82 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hgb [D63] Below (N=100,95,95,95,97,97)	6 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hct [D42] Within (N=101,97,95,95,96,97)	86 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hct [D21] Unknown (N=101,100,97,97,99,99)	3 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	EOS [D0] Unknown (N=102,104,102,100,101,102)	2 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hct [D21] Unknown (N=101,100,97,97,99,99)	1 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hgb [D63] Above (N=100,95,95,95,97,97)	0 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hct [D7] Below (N=102,101,100,99,100,99)	4 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	CREA [D0] Above (N=102,104,102,100,101,102)	2 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hgb [D63] Unknown (N=100,95,95,95,97,97)	0 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hct [D0] Above (N=102,104,102,100,101,102)	3 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL D [D28] Below (N=101,98,96,98,98,97)	0 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hgb [D182] Within (N=99,91,88,91,93,97)	84 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hct [D42] Below (N=101,97,95,95,96,97)	7 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hgb [D182] Above (N=99,91,88,91,93,97)	0 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL D [D63] Within (N=100,95,95,95,97,97)	95 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	EOS [D7] Below (N=102,101,100,99,100,99)	1 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	EOS [D7] Within (N=102,101,100,99,100,99)	95 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	CREA [D0] Within (N=102,104,102,100,101,102)	88 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hgb [D182] Unknown (N=99,91,88,91,93,97)	2 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL D [D7] Above (N=102,101,100,99,100,99)	0 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hct [D42] Within (N=101,97,95,95,96,97)	88 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL D [D7] Below (N=102,101,100,99,100,99)	0 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL D [D7] Within (N=102,101,100,99,100,99)	99 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	EOS [D42] Above (N=101,97,95,95,96,97)	1 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	CREA [D182] Above (N=99,91,88,91,93,97)	0 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hct [D42] Unknown (N=101,97,95,95,96,97)	0 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hct [D0] Within (N=102,104,102,100,101,102)	92 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	CREA [D182] Unknown (N=99,91,88,91,93,97)	0 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hct [D182] Below (N=99,91,88,91,93,97)	3 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hct [D21] Below (N=101,100,97,97,99,99)	8 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hct [D0] Below (N=102,104,102,100,101,102)	3 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	EOS [D63] Below (N=100,95,95,95,97,97)	4 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hct [D182] Within (N=99,91,88,91,93,97)	85 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hct [D7] Above (N=102,101,100,99,100,99)	2 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	EOS [D28] Below (N=101,98,96,98,98,97)	2 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hct [D182] Unknown (N=99,91,88,91,93,97)	2 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL D [D42] Above (N=101,97,95,95,96,97)	0 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	EOS [D63] Within (N=100,95,95,95,97,97)	90 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	EOS [D182] Above (N=99,91,88,91,93,97)	3 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	EOS [D42] Unknown (N=101,97,95,95,96,97)	0 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL D [D63] Above (N=100,95,95,95,97,97)	0 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hgb [D0] Above (N=102,104,102,100,101,102)	0 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hgb [D0] Below (N=102,104,102,100,101,102)	1 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	EOS [D21] Unknown (N=101,100,97,97,99,99)	1 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hgb [D0] Unknown (N=102,104,102,100,101,102)	2 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hct [D21] Within (N=101,100,97,97,99,99)	88 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	EOS [D182] Within (N=99,91,88,91,93,97)	83 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL D [D42] Within (N=101,97,95,95,96,97)	95 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hgb [D7] Within (N=102,101,100,99,100,99)	96 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	EOS [D63] Unknown (N=100,95,95,95,97,97)	0 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	CREA [D0] Unknown (N=102,104,102,100,101,102)	1 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hgb [D21] Below (N=101,100,97,97,99,99)	6 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	EOS [D182] Below (N=99,91,88,91,93,97)	3 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	EOS [D21] Above (N=101,100,97,97,99,99)	1 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL D [D63] Unknown (N=100,95,95,95,97,97)	0 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hgb [D21] Unknown (N=101,100,97,97,99,99)	1 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hct [D7] Unknown (N=102,101,100,99,100,99)	1 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hct [D21] Above (N=101,100,97,97,99,99)	0 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hgb [D28] Above (N=101,98,96,98,98,97)	0 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL D [D28] Above (N=101,98,96,98,98,97)	0 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	EOS [D7] Above (N=102,101,100,99,100,99)	2 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	CREA [D0] Below (N=102,104,102,100,101,102)	9 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hgb [D42] Within (N=101,97,95,95,96,97)	92 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL D [D28] Within (N=101,98,96,98,98,97)	97 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hgb [D63] Below (N=100,95,95,95,97,97)	4 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hct [D182] Above (N=99,91,88,91,93,97)	1 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hgb [D28] Below (N=101,98,96,98,98,97)	8 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hct [D28] Within (N=101,98,96,98,98,97)	88 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL D [D21] Below (N=101,100,97,97,99,99)	0 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	CREA [D21] Within (N=101,100,97,97,99,99)	81 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hct [D28] Above (N=101,98,96,98,98,97)	0 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	EOS [D28] Within (N=101,98,96,98,98,97)	93 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hgb [D28] Within (N=101,98,96,98,98,97)	89 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	CREA [D63] Within (N=100,95,95,95,97,97)	78 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	CREA [D21] Above (N=101,100,97,97,99,99)	0 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL D [D182] Below (N=99,91,88,91,93,97)	0 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	CREA [D28] Above (N=101,98,96,98,98,97)	1 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hgb [D28] Unknown (N=101,98,96,98,98,97)	1 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hct [D28] Unknown (N=101,98,96,98,98,97)	1 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	EOS [D42] Below (N=101,97,95,95,96,97)	5 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hgb [D7] Unknown (N=102,101,100,99,100,99)	1 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL D [D182] Above (N=99,91,88,91,93,97)	0 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	CREA [D63] Below (N=100,95,95,95,97,97)	14 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hgb [D42] Below (N=101,97,95,95,96,97)	3 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL D [D21] Unknown (N=101,100,97,97,99,99)	0 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	EOS [D42] Within (N=101,97,95,95,96,97)	89 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	CREA [D182] Below (N=99,91,88,91,93,97)	10 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hgb [D42] Above (N=101,97,95,95,96,97)	0 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL D [D42] Unknown (N=101,97,95,95,96,97)	0 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL D [D7] Unknown(N=102,101,100,99,100,99)	0 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	CREA [D21] Below (N=101,100,97,97,99,99)	16 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	EOS [D0] Below (N=102,104,102,100,101,102)	5 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	CREA [D42] Below (N=101,97,95,95,96,97)	10 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hgb [D42] Unknown (N=101,97,95,95,96,97)	0 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL D [D182] Within (N=99,91,88,91,93,97)	91 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL D [D0] Unknown (N=102,104,102,100,101,102)	1 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hct [D42] Above (N=101,97,95,95,96,97)	0 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL D [D21] Above (N=101,100,97,97,99,99)	0 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	EOS [D28] Above (N=101,98,96,98,98,97)	1 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hgb [D63] Within (N=100,95,95,95,97,97)	91 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	CREA [D63] Unknown (N=100,95,95,95,97,97)	0 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	CREA [D42] Unknown (N=101,97,95,95,96,97)	0 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	CREA [D7] Above (N=102,101,100,99,100,99)	1 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	CREA [D7] Within (N=102,101,100,99,100,99)	81 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL D [D0] Above (N=102,104,102,100,101,102)	0 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL D [D63] Below (N=100,95,95,95,97,97)	0 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hgb [D182] Below (N=99,91,88,91,93,97)	5 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hgb [D0] Within (N=102,104,102,100,101,102)	97 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hct [D63] Below (N=100,95,95,95,97,97)	6 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	CREA [D7] Unknown (N=102,101,100,99,100,99)	0 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	EOS [D7] Unknown (N=102,101,100,99,100,99)	1 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	EOS [D28] Unknown (N=101,98,96,98,98,97)	2 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	CREA [D21] Unknown (N=101,100,97,97,99,99)	0 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL D [D0] Below (N=102,104,102,100,101,102)	0 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL D [D28] Unknown (N=101,98,96,98,98,97)	1 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL D [D0] Within (N=102,104,102,100,101,102)	99 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hgb [D21] Above (N=101,100,97,97,99,99)	0 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL D [D182] Unknown (N=99,91,88,91,93,97)	0 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	EOS [D21] Below (N=101,100,97,97,99,99)	8 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hct [D63] Above (N=100,95,95,95,97,97)	0 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	EOS [D63] Above (N=100,95,95,95,97,97)	1 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	EOS [D0] Above (N=102,104,102,100,101,102)	1 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	CREA [D7] Below (N=102,101,100,99,100,99)	17 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	CREA [D28] Within (N=101,98,96,98,98,97)	81 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	CREA [D182] Within (N=99,91,88,91,93,97)	81 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hgb [D7] Below (N=102,101,100,99,100,99)	2 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	EOS [D0] Within (N=102,104,102,100,101,102)	92 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	CREA [D63] Above (N=100,95,95,95,97,97)	3 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hct [D63] Within (N=100,95,95,95,97,97)	89 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	CREA [D28] Unknown (N=101,98,96,98,98,97)	1 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hct [D0] Unknown (N=102,104,102,100,101,102)	2 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	EOS [D182] Unknown (N=99,91,88,91,93,97)	2 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL D [D21] Within (N=101,100,97,97,99,99)	97 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hct [D63] Unknown (N=100,95,95,95,97,97)	0 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hct [D28] Below (N=101,98,96,98,98,97)	9 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	EOS [D21] Within (N=101,100,97,97,99,99)	87 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	CREA [D42] Above (N=101,97,95,95,96,97)	1 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hgb [D21] Within (N=101,100,97,97,99,99)	90 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hct [D7] Within (N=102,101,100,99,100,99)	92 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hgb [D7] Above (N=102,101,100,99,100,99)	0 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL D [D42] Below (N=101,97,95,95,96,97)	0 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	CREA [D42] Within (N=101,97,95,95,96,97)	84 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	CREA [D28] Below (N=101,98,96,98,98,97)	15 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hct [D63] Within (N=100,95,95,95,97,97)	87 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	CREA [D28] Unknown (N=101,98,96,98,98,97)	0 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	CREA [D7] Below (N=102,101,100,99,100,99)	7 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	EOS [D7] Unknown (N=102,101,100,99,100,99)	0 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	EOS [D21] Below (N=101,100,97,97,99,99)	9 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL D [D42] Unknown (N=101,97,95,95,96,97)	2 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	EOS [D21] Within (N=101,100,97,97,99,99)	85 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	EOS [D28] Within (N=101,98,96,98,98,97)	90 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	EOS [D28] Above (N=101,98,96,98,98,97)	0 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	CREA [D28] Above (N=101,98,96,98,98,97)	0 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	EOS [D28] Unknown (N=101,98,96,98,98,97)	1 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	EOS [D42] Below (N=101,97,95,95,96,97)	8 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	EOS [D42] Within (N=101,97,95,95,96,97)	85 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	CREA [D28] Within (N=101,98,96,98,98,97)	91 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL D [D63] Below (N=100,95,95,95,97,97)	0 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	EOS [D63] Above (N=100,95,95,95,97,97)	1 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	EOS [D182] Above (N=99,91,88,91,93,97)	3 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hct [D0] Unknown (N=102,104,102,100,101,102)	0 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hct [D21] Above (N=101,100,97,97,99,99)	0 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hct [D28] Below (N=101,98,96,98,98,97)	5 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	CREA [D28] Below (N=101,98,96,98,98,97)	7 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hct [D28] Within (N=101,98,96,98,98,97)	92 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hct [D28] Above (N=101,98,96,98,98,97)	0 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hct [D28] Unknown (N=101,98,96,98,98,97)	1 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hct [D42] Below (N=101,97,95,95,96,97)	10 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	CREA [D21] Unknown (N=101,100,97,97,99,99)	0 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL D [D182] Below (N=99,91,88,91,93,97)	0 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hct [D42] Above (N=101,97,95,95,96,97)	0 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hct [D42] Unknown (N=101,97,95,95,96,97)	0 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hct [D63] Below (N=100,95,95,95,97,97)	10 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hct [D63] Above (N=100,95,95,95,97,97)	0 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hct [D182] Above (N=99,91,88,91,93,97)	0 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hgb [D0] Below (N=102,104,102,100,101,102)	4 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	CREA [D21] Above (N=101,100,97,97,99,99)	0 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hgb [D0] Within (N=102,104,102,100,101,102)	97 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hgb [D7] Below (N=102,101,100,99,100,99)	4 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hgb [D7] Above (N=102,101,100,99,100,99)	0 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL D [D182] Within (N=99,91,88,91,93,97)	92 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hgb [D7] Unknown (N=102,101,100,99,100,99)	0 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hgb [D21] Within (N=101,100,97,97,99,99)	92 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hgb [D21] Above (N=101,100,97,97,99,99)	0 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	CREA [D21] Within (N=101,100,97,97,99,99)	89 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hgb [D28] Below (N=101,98,96,98,98,97)	1 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hgb [D28] Within (N=101,98,96,98,98,97)	96 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hgb [D28] Unknown (N=101,98,96,98,98,97)	1 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	CREA [D21] Below (N=101,100,97,97,99,99)	10 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL D [D182] Above (N=99,91,88,91,93,97)	0 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hgb [D42] Above (N=101,97,95,95,96,97)	0 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hgb [D42] Unknown (N=101,97,95,95,96,97)	0 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hgb [D63] Within (N=100,95,95,95,97,97)	88 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	CREA [D7] Unknown (N=102,101,100,99,100,99)	0 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hgb [D182] Below (N=99,91,88,91,93,97)	6 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL D [D0] Below (N=102,104,102,100,101,102)	0 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL D [D0] Within (N=102,104,102,100,101,102)	100 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	CREA [D7] Above (N=102,101,100,99,100,99)	0 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL D [D182] Unknown (N=99,91,88,91,93,97)	1 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL D [D0] Above (N=102,104,102,100,101,102)	0 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL D [D0] Unknown (N=102,104,102,100,101,102)	1 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL D [D7] Unknown(N=102,101,100,99,100,99)	0 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	CREA [D63] Above (N=100,95,95,95,97,97)	0 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL D [D21] Below (N=101,100,97,97,99,99)	0 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	CREA [D7] Within (N=102,101,100,99,100,99)	93 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL D [D21] Within (N=101,100,97,97,99,99)	99 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL D [D21] Above (N=101,100,97,97,99,99)	0 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	CREA [D42] Above (N=101,97,95,95,96,97)	0 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	CREA [D42] Unknown (N=101,97,95,95,96,97)	2 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL D [D28] Unknown (N=101,98,96,98,98,97)	0 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	CREA [D63] Below (N=100,95,95,95,97,97)	7 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	CREA [D42] Within (N=101,97,95,95,96,97)	85 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	CREA [D63] Within (N=100,95,95,95,97,97)	89 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	CREA [D63] Unknown (N=100,95,95,95,97,97)	1 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	CREA [D182] Below (N=99,91,88,91,93,97)	6 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	CREA [D42] Below (N=101,97,95,95,96,97)	9 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	CREA [D182] Within (N=99,91,88,91,93,97)	86 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	EOS [D0] Below (N=102,104,102,100,101,102)	9 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL D [D42] Below (N=101,97,95,95,96,97)	0 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	EOS [D0] Within (N=102,104,102,100,101,102)	90 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	EOS [D0] Above (N=102,104,102,100,101,102)	2 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hct [D182] Within (N=99,91,88,91,93,97)	86 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hct [D7] Above (N=102,101,100,99,100,99)	0 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hct [D7] Unknown (N=102,101,100,99,100,99)	0 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	EOS [D42] Unknown (N=101,97,95,95,96,97)	0 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hct [D21] Below (N=101,100,97,97,99,99)	6 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hct [D21] Within (N=101,100,97,97,99,99)	91 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	CREA [D182] Unknown (N=99,91,88,91,93,97)	1 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	EOS [D42] Above (N=101,97,95,95,96,97)	3 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hct [D21] Unknown (N=101,100,97,97,99,99)	2 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hct [D42] Within (N=101,97,95,95,96,97)	86 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL D [D63] Within (N=100,95,95,95,97,97)	96 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hct [D63] Unknown (N=100,95,95,95,97,97)	0 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hct [D182] Below (N=99,91,88,91,93,97)	7 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	EOS [D28] Below (N=101,98,96,98,98,97)	7 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hct [D182] Unknown (N=99,91,88,91,93,97)	0 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	EOS [D21] Unknown (N=101,100,97,97,99,99)	2 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hgb [D0] Above (N=102,104,102,100,101,102)	0 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL D [D63] Above (N=100,95,95,95,97,97)	0 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hgb [D0] Unknown (N=102,104,102,100,101,102)	0 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hgb [D7] Within (N=102,101,100,99,100,99)	96 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	EOS [D21] Above (N=101,100,97,97,99,99)	3 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hgb [D21] Below (N=101,100,97,97,99,99)	5 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hgb [D21] Unknown (N=101,100,97,97,99,99)	2 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL D [D63] Unknown (N=100,95,95,95,97,97)	1 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	EOS [D7] Above (N=102,101,100,99,100,99)	3 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hgb [D28] Above (N=101,98,96,98,98,97)	0 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hgb [D42] Below (N=101,97,95,95,96,97)	6 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hgb [D42] Within (N=101,97,95,95,96,97)	90 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hgb [D63] Below (N=100,95,95,95,97,97)	9 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	CREA [D0] Below (N=102,104,102,100,101,102)	8 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hgb [D63] Above (N=100,95,95,95,97,97)	0 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hgb [D63] Unknown (N=100,95,95,95,97,97)	0 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	CREA [D0] Unknown (N=102,104,102,100,101,102)	1 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hgb [D182] Within (N=99,91,88,91,93,97)	87 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	EOS [D7] Within (N=102,101,100,99,100,99)	92 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hgb [D182] Above (N=99,91,88,91,93,97)	0 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hgb [D182] Unknown (N=99,91,88,91,93,97)	0 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	CREA [D0] Within (N=102,104,102,100,101,102)	92 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL D [D7] Below (N=102,101,100,99,100,99)	0 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL D [D7] Within (N=102,101,100,99,100,99)	100 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	CREA [D182] Above (N=99,91,88,91,93,97)	0 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL D [D7] Above (N=102,101,100,99,100,99)	0 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	EOS [D7] Below (N=102,101,100,99,100,99)	5 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL D [D21] Unknown (N=101,100,97,97,99,99)	0 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL D [D28] Below (N=101,98,96,98,98,97)	0 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL D [D28] Within (N=101,98,96,98,98,97)	98 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	CREA [D0] Above (N=102,104,102,100,101,102)	0 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL D [D28] Above (N=101,98,96,98,98,97)	0 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	EOS [D0] Unknown (N=102,104,102,100,101,102)	0 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	EOS [D63] Unknown (N=100,95,95,95,97,97)	0 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	EOS [D182] Below (N=99,91,88,91,93,97)	6 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	EOS [D182] Within (N=99,91,88,91,93,97)	84 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	EOS [D63] Within (N=100,95,95,95,97,97)	88 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL D [D42] Within (N=101,97,95,95,96,97)	94 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	EOS [D182] Unknown (N=99,91,88,91,93,97)	0 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hct [D0] Below (N=102,104,102,100,101,102)	3 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hct [D0] Within (N=102,104,102,100,101,102)	97 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hct [D0] Above (N=102,104,102,100,101,102)	1 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	EOS [D63] Below (N=100,95,95,95,97,97)	8 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hct [D7] Below (N=102,101,100,99,100,99)	3 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hct [D7] Within (N=102,101,100,99,100,99)	97 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL D [D42] Above (N=101,97,95,95,96,97)	0 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hgb [D42] Within (N=101,97,95,95,96,97)	86 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hct [D21] Unknown (N=101,100,97,97,99,99)	3 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL D [D28] Within (N=101,98,96,98,98,97)	96 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	EOS [D0] Unknown (N=102,104,102,100,101,102)	0 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hct [D7] Above (N=102,101,100,99,100,99)	1 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hgb [D42] Below (N=101,97,95,95,96,97)	11 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hgb [D28] Above (N=101,98,96,98,98,97)	0 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hct [D0] Above (N=102,104,102,100,101,102)	0 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL D [D28] Above (N=101,98,96,98,98,97)	0 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hct [D7] Within (N=102,101,100,99,100,99)	92 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL D [D63] Unknown (N=100,95,95,95,97,97)	2 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	CREA [D0] Above (N=102,104,102,100,101,102)	1 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	EOS [D63] Unknown (N=100,95,95,95,97,97)	0 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hct [D21] Above (N=101,100,97,97,99,99)	1 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hgb [D28] Within (N=101,98,96,98,98,97)	90 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hgb [D21] Unknown (N=101,100,97,97,99,99)	3 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hgb [D21] Below (N=101,100,97,97,99,99)	4 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hct [D21] Within (N=101,100,97,97,99,99)	91 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	EOS [D182] Below (N=99,91,88,91,93,97)	5 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hgb [D7] Within (N=102,101,100,99,100,99)	95 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	EOS [D21] Above (N=101,100,97,97,99,99)	0 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL D [D63] Above (N=100,95,95,95,97,97)	0 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hgb [D0] Unknown (N=102,104,102,100,101,102)	0 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hct [D21] Below (N=101,100,97,97,99,99)	4 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	EOS [D182] Within (N=99,91,88,91,93,97)	89 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	CREA [D182] Unknown (N=99,91,88,91,93,97)	0 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hct [D7] Unknown (N=102,101,100,99,100,99)	0 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hgb [D0] Above (N=102,104,102,100,101,102)	0 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hgb [D0] Within (N=102,104,102,100,101,102)	97 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	EOS [D42] Unknown (N=101,97,95,95,96,97)	0 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	EOS [D182] Unknown (N=99,91,88,91,93,97)	1 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	EOS [D21] Unknown (N=101,100,97,97,99,99)	4 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL D [D42] Within (N=101,97,95,95,96,97)	97 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hct [D182] Unknown (N=99,91,88,91,93,97)	0 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hct [D182] Below (N=99,91,88,91,93,97)	10 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hct [D7] Below (N=102,101,100,99,100,99)	6 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hct [D0] Below (N=102,104,102,100,101,102)	5 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	EOS [D28] Below (N=101,98,96,98,98,97)	5 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hct [D63] Unknown (N=100,95,95,95,97,97)	0 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL D [D63] Within (N=100,95,95,95,97,97)	95 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	CREA [D0] Within (N=102,104,102,100,101,102)	92 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	EOS [D7] Below (N=102,101,100,99,100,99)	8 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL D [D7] Below (N=102,101,100,99,100,99)	0 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hct [D63] Below (N=100,95,95,95,97,97)	10 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL D [D7] Within (N=102,101,100,99,100,99)	99 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL D [D42] Above (N=101,97,95,95,96,97)	0 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL D [D0] Unknown (N=102,104,102,100,101,102)	0 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hgb [D182] Unknown (N=99,91,88,91,93,97)	0 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hct [D0] Within (N=102,104,102,100,101,102)	97 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL D [D7] Above (N=102,101,100,99,100,99)	0 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	EOS [D63] Below (N=100,95,95,95,97,97)	10 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	CREA [D0] Unknown (N=102,104,102,100,101,102)	0 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hct [D42] Above (N=101,97,95,95,96,97)	0 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL D [D21] Unknown (N=101,100,97,97,99,99)	1 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hgb [D182] Above (N=99,91,88,91,93,97)	1 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hgb [D182] Within (N=99,91,88,91,93,97)	87 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	CREA [D182] Above (N=99,91,88,91,93,97)	0 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	EOS [D7] Within (N=102,101,100,99,100,99)	89 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hct [D42] Within (N=101,97,95,95,96,97)	83 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL D [D28] Below (N=101,98,96,98,98,97)	0 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hgb [D63] Unknown (N=100,95,95,95,97,97)	0 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	CREA [D0] Below (N=102,104,102,100,101,102)	9 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hgb [D63] Below (N=100,95,95,95,97,97)	10 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	EOS [D0] Above (N=102,104,102,100,101,102)	0 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	CREA [D28] Unknown (N=101,98,96,98,98,97)	1 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hgb [D21] Above (N=101,100,97,97,99,99)	1 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	EOS [D42] Above (N=101,97,95,95,96,97)	0 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	CREA [D182] Within (N=99,91,88,91,93,97)	83 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL D [D21] Within (N=101,100,97,97,99,99)	98 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	CREA [D21] Within (N=101,100,97,97,99,99)	87 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hgb [D21] Within (N=101,100,97,97,99,99)	91 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL D [D182] Within (N=99,91,88,91,93,97)	96 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hgb [D7] Unknown (N=102,101,100,99,100,99)	0 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL D [D42] Unknown (N=101,97,95,95,96,97)	0 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL D [D21] Above (N=101,100,97,97,99,99)	0 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hgb [D7] Above (N=102,101,100,99,100,99)	1 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	CREA [D7] Within (N=102,101,100,99,100,99)	90 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hgb [D7] Below (N=102,101,100,99,100,99)	3 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hgb [D0] Below (N=102,104,102,100,101,102)	5 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hct [D182] Above (N=99,91,88,91,93,97)	1 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	CREA [D21] Above (N=101,100,97,97,99,99)	2 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hct [D182] Within (N=99,91,88,91,93,97)	86 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	CREA [D28] Above (N=101,98,96,98,98,97)	0 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	CREA [D42] Above (N=101,97,95,95,96,97)	0 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hct [D63] Above (N=100,95,95,95,97,97)	0 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL D [D182] Below (N=99,91,88,91,93,97)	0 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hct [D63] Within (N=100,95,95,95,97,97)	87 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hct [D42] Unknown (N=101,97,95,95,96,97)	0 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL D [D42] Below (N=101,97,95,95,96,97)	0 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	CREA [D42] Unknown (N=101,97,95,95,96,97)	0 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	CREA [D42] Within (N=101,97,95,95,96,97)	86 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	EOS [D0] Below (N=102,104,102,100,101,102)	5 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hct [D42] Below (N=101,97,95,95,96,97)	14 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	CREA [D21] Unknown (N=101,100,97,97,99,99)	1 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	EOS [D28] Within (N=101,98,96,98,98,97)	87 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	CREA [D63] Below (N=100,95,95,95,97,97)	9 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	EOS [D7] Unknown (N=102,101,100,99,100,99)	0 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL D [D28] Unknown (N=101,98,96,98,98,97)	1 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hct [D28] Unknown (N=101,98,96,98,98,97)	3 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hct [D28] Above (N=101,98,96,98,98,97)	1 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	EOS [D21] Within (N=101,100,97,97,99,99)	92 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	CREA [D63] Within (N=100,95,95,95,97,97)	85 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hct [D28] Within (N=101,98,96,98,98,97)	84 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hct [D28] Below (N=101,98,96,98,98,97)	9 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	CREA [D28] Below (N=101,98,96,98,98,97)	7 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	EOS [D182] Above (N=99,91,88,91,93,97)	2 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	CREA [D63] Above (N=100,95,95,95,97,97)	1 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL D [D63] Below (N=100,95,95,95,97,97)	0 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	EOS [D63] Above (N=100,95,95,95,97,97)	1 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	EOS [D63] Within (N=100,95,95,95,97,97)	86 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	CREA [D28] Within (N=101,98,96,98,98,97)	89 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	EOS [D21] Below (N=101,100,97,97,99,99)	3 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	CREA [D63] Unknown (N=100,95,95,95,97,97)	2 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	CREA [D42] Below (N=101,97,95,95,96,97)	11 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	EOS [D42] Within (N=101,97,95,95,96,97)	88 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	CREA [D7] Above (N=102,101,100,99,100,99)	1 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL D [D0] Below (N=102,104,102,100,101,102)	0 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	EOS [D42] Below (N=101,97,95,95,96,97)	9 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL D [D0] Within (N=102,104,102,100,101,102)	102 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	CREA [D7] Below (N=102,101,100,99,100,99)	8 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	EOS [D7] Above (N=102,101,100,99,100,99)	2 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hgb [D182] Below (N=99,91,88,91,93,97)	9 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hgb [D63] Above (N=100,95,95,95,97,97)	0 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	CREA [D182] Below (N=99,91,88,91,93,97)	14 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL D [D0] Above (N=102,104,102,100,101,102)	0 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	CREA [D7] Unknown (N=102,101,100,99,100,99)	0 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL D [D182] Unknown (N=99,91,88,91,93,97)	0 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hgb [D63] Within (N=100,95,95,95,97,97)	87 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hgb [D42] Unknown (N=101,97,95,95,96,97)	0 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	EOS [D0] Within (N=102,104,102,100,101,102)	97 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL D [D182] Above (N=99,91,88,91,93,97)	1 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hgb [D42] Above (N=101,97,95,95,96,97)	0 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	EOS [D28] Unknown (N=101,98,96,98,98,97)	3 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL D [D7] Unknown(N=102,101,100,99,100,99)	0 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	CREA [D21] Below (N=101,100,97,97,99,99)	9 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hct [D0] Unknown (N=102,104,102,100,101,102)	0 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hgb [D28] Unknown (N=101,98,96,98,98,97)	3 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	Hgb [D28] Below (N=101,98,96,98,98,97)	4 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	EOS [D28] Above (N=101,98,96,98,98,97)	2 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL D [D21] Below (N=101,100,97,97,99,99)	0 Subjects

Secondary

Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed

Laboratory parameters assessed were serum urea nitrogen (SUN), white blood cells (WBC), red blood cells (RBC). For each parameter and for each range it was assessed whether the values of the subjects were unknown, above, below or within the range.

Time frame: On Days 0, 7, 21, 28, 42, 63 and 182

Population: The Total Vaccinated cohort included all vaccinated subjects

Arm	Measure	Group	Value (NUMBER)
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	SUN [D0] Above (N=102,104,102,100101,102)	1 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	SUN [D0] Below (N=102,104,102,100101,102)	1 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	RBC [D7] Above (N=102,101,100,99,100,99)	0 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	WBC [D63] Above (N=100,95,95,95,97,97)	1 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	SUN [D7] Unknown (N=102,101,100,99,100,99)	0 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	RBC [D42] Within (N=101,97,95,95,96,97)	99 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	SUN [D28] Unknown (N=101,98,96,98,98,97)	1 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	WBC [D63] Unknown (N=100,95,95,95,97,97)	0 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	SUN [D182] Above (N=99,91,88,91,93,97)	0 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	RBC [D7] Within (N=102,101,100,99,100,99)	99 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	WBC [D182] Below (N=99,91,88,91,93,97)	2 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	RBC [D63] Unknown (N=100,95,95,95,97,97)	0 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	SUN [D0] Within (N=102,104,102,100101,102)	100 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	WBC [D182] Within (N=99,91,88,91,93,97)	93 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	SUN [D28] Above (N=101,98,96,98,98,97)	0 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	WBC [D182] Above (N=99,91,88,91,93,97)	4 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	RBC [D7] Below (N=102,101,100,99,100,99)	3 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	SUN [D182] Unknown (N=99,91,88,91,93,97)	0 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	WBC [D182] Unknown (N=99,91,88,91,93,97)	0 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	WBC [D0] Above (N=102,104,102,100,101,102)	4 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	RBC [D0] Below (N=102,104,102,100101,102)	4 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	RBC [D0] Unknown (N=102,104,102,100101,102)	2 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	RBC [D0] Within (N=102,104,102,100101,102)	96 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	WBC [D42] Above (N=101,97,95,95,96,97)	1 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	SUN [D28] Within (N=101,98,96,98,98,97)	98 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	RBC [D0] Above (N=102,104,102,100101,102)	0 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	RBC [D42] Below (N=101,97,95,95,96,97)	2 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	SUN [D7] Within (N=102,101,100,99,100,99)	100 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	SUN [D0] Unknown (N=102,104,102,100101,102)	0 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	WBC [D0] Within (N=102,104,102,100,101,102)	95 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	RBC [D28] Unknown (N=101,98,96,98,98,97)	1 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	SUN [D7] Below (N=102,101,100,99,100,99)	2 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	RBC [D63] Below (N=100,95,95,95,97,97)	6 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	SUN [D63] Below (N=100,95,95,95,97,97)	1 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	WBC [D7] Below (N=102,101,100,99,100,99)	3 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	RBC [D182] Below (N=99,91,88,91,93,97)	6 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	SUN [D21] Within (N=101,100,97,97,99,99)	100 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	WBC [D7] Within (N=102,101,100,99,100,99)	99 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	RBC [D28] Above (N=101,98,96,98,98,97)	0 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	SUN [D63] Unknown (N=100,95,95,95,97,97)	1 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	RBC [D63] Above (N=100,95,95,95,97,97)	0 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	WBC [D7] Above (N=102,101,100,99,100,99)	0 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	WBC [D7] Unknown (N=102,101,100,99,100,99)	0 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	RBC [D42] Unknown (N=101,97,95,95,96,97)	0 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	SUN [D42] Unknown (N=101,97,95,95,96,97)	0 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	WBC [D21] Below (N=101,100,97,97,99,99)	1 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	RBC [D182] Within (N=99,91,88,91,93,97)	92 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	RBC [D28] Within (N=101,98,96,98,98,97)	95 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	RBC [D28] Below (N=101,98,96,98,98,97)	5 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	WBC [D21] Within (N=101,100,97,97,99,99)	98 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	RBC [D21] Unknown (N=101,100,97,97,99,99)	0 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	WBC [D21] Above (N=101,100,97,97,99,99)	2 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	SUN [D21] Below (N=101,100,97,97,99,99)	1 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	SUN [D21] Above (N=101,100,97,97,99,99)	0 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	SUN [D63] Above (N=100,95,95,95,97,97)	0 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	WBC [D21] Unknown (N=101,100,97,97,99,99)	0 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	SUN [D182] Below (N=99,91,88,91,93,97)	0 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	SUN [D42] Above (N=101,97,95,95,96,97)	0 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	WBC [D28] Below (N=101,98,96,98,98,97)	0 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	RBC [D21] Above (N=101,100,97,97,99,99)	0 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	WBC [D28] Within (N=101,98,96,98,98,97)	98 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	RBC [D182] Above (N=99,91,88,91,93,97)	1 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	RBC [D63] Within (N=100,95,95,95,97,97)	94 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	WBC [D28] Above (N=101,98,96,98,98,97)	1 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	RBC [D42] Above (N=101,97,95,95,96,97)	0 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	WBC [D0] Below (N=102,104,102,100,101,102)	1 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	WBC [D28] Unknown (N=101,98,96,98,98,97)	2 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	RBC [D21] Within (N=101,100,97,97,99,99)	96 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	SUN [D28] Below (N=101,98,96,98,98,97)	2 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	SUN [D42] Within (N=101,97,95,95,96,97)	100 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	WBC [D42] Below (N=101,97,95,95,96,97)	0 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	SUN [D7] Above (N=102,101,100,99,100,99)	0 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	SUN [D63] Within (N=100,95,95,95,97,97)	98 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	RBC [D21] Below (N=101,100,97,97,99,99)	5 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	WBC [D42] Within (N=101,97,95,95,96,97)	100 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	RBC [D182] Unknown (N=99,91,88,91,93,97)	0 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	SUN [D182] Within (N=99,91,88,91,93,97)	99 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	WBC [D42] Unknown (N=101,97,95,95,96,97)	0 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	RBC [D7] Unknown (N=102,101,100,99,100,99)	0 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	WBC [D0] Unknown (N=102,104,102,100,101,102)	2 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	SUN [D42] Below (N=101,97,95,95,96,97)	1 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	WBC [D63] Below (N=100,95,95,95,97,97)	1 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	SUN [D21] Unknown (N=101,100,97,97,99,99)	0 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	WBC [D63] Within (N=100,95,95,95,97,97)	98 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	SUN [D63] Unknown (N=100,95,95,95,97,97)	1 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	SUN [D42] Unknown (N=101,97,95,95,96,97)	0 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	RBC [D182] Above (N=99,91,88,91,93,97)	0 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	SUN [D0] Below (N=102,104,102,100101,102)	0 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	SUN [D28] Unknown (N=101,98,96,98,98,97)	0 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	WBC [D7] Unknown (N=102,101,100,99,100,99)	1 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	WBC [D63] Above (N=100,95,95,95,97,97)	1 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	SUN [D21] Below (N=101,100,97,97,99,99)	1 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	SUN [D21] Unknown (N=101,100,97,97,99,99)	0 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	RBC [D28] Within (N=101,98,96,98,98,97)	87 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	RBC [D63] Above (N=100,95,95,95,97,97)	1 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	WBC [D42] Within (N=101,97,95,95,96,97)	91 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	WBC [D63] Unknown (N=100,95,95,95,97,97)	0 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	WBC [D0] Unknown (N=102,104,102,100,101,102)	0 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	RBC [D7] Within (N=102,101,100,99,100,99)	94 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	WBC [D28] Above (N=101,98,96,98,98,97)	3 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	WBC [D21] Below (N=101,100,97,97,99,99)	4 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	RBC [D7] Above (N=102,101,100,99,100,99)	1 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	WBC [D182] Below (N=99,91,88,91,93,97)	2 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	WBC [D42] Above (N=101,97,95,95,96,97)	2 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	SUN [D182] Unknown (N=99,91,88,91,93,97)	1 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	RBC [D28] Below (N=101,98,96,98,98,97)	8 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	SUN [D28] Above (N=101,98,96,98,98,97)	0 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	RBC [D21] Within (N=101,100,97,97,99,99)	92 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	WBC [D182] Within (N=99,91,88,91,93,97)	87 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	SUN [D0] Within (N=102,104,102,100101,102)	104 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	RBC [D7] Below (N=102,101,100,99,100,99)	5 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	SUN [D182] Above (N=99,91,88,91,93,97)	0 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	SUN [D42] Within (N=101,97,95,95,96,97)	96 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	WBC [D21] Within (N=101,100,97,97,99,99)	94 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	WBC [D182] Above (N=99,91,88,91,93,97)	2 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	RBC [D63] Unknown (N=100,95,95,95,97,97)	0 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	RBC [D182] Within (N=99,91,88,91,93,97)	85 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	WBC [D0] Within (N=102,104,102,100,101,102)	100 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	RBC [D21] Unknown (N=101,100,97,97,99,99)	1 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	WBC [D63] Below (N=100,95,95,95,97,97)	2 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	WBC [D182] Unknown (N=99,91,88,91,93,97)	0 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	RBC [D63] Within (N=100,95,95,95,97,97)	86 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	RBC [D0] Unknown (N=102,104,102,100101,102)	0 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	SUN [D7] Within (N=102,101,100,99,100,99)	99 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	WBC [D28] Unknown (N=101,98,96,98,98,97)	2 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	RBC [D0] Below (N=102,104,102,100101,102)	2 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	WBC [D63] Within (N=100,95,95,95,97,97)	92 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	WBC [D21] Above (N=101,100,97,97,99,99)	1 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	SUN [D28] Below (N=101,98,96,98,98,97)	1 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	SUN [D28] Within (N=101,98,96,98,98,97)	97 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	SUN [D63] Below (N=100,95,95,95,97,97)	0 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	RBC [D0] Within (N=102,104,102,100101,102)	100 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	SUN [D0] Above (N=102,104,102,100101,102)	0 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	SUN [D63] Within (N=100,95,95,95,97,97)	94 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	RBC [D182] Unknown (N=99,91,88,91,93,97)	0 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	WBC [D0] Above (N=102,104,102,100,101,102)	2 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	SUN [D42] Above (N=101,97,95,95,96,97)	0 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	RBC [D0] Above (N=102,104,102,100101,102)	2 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	RBC [D63] Below (N=100,95,95,95,97,97)	8 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	RBC [D42] Below (N=101,97,95,95,96,97)	9 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	RBC [D7] Unknown (N=102,101,100,99,100,99)	1 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	WBC [D21] Unknown (N=101,100,97,97,99,99)	1 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	RBC [D42] Above (N=101,97,95,95,96,97)	1 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	SUN [D0] Unknown (N=102,104,102,100101,102)	0 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	SUN [D7] Unknown (N=102,101,100,99,100,99)	0 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	WBC [D0] Below (N=102,104,102,100,101,102)	2 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	RBC [D28] Unknown (N=101,98,96,98,98,97)	2 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	SUN [D182] Within (N=99,91,88,91,93,97)	88 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	WBC [D42] Below (N=101,97,95,95,96,97)	4 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	SUN [D7] Below (N=102,101,100,99,100,99)	1 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	SUN [D42] Below (N=101,97,95,95,96,97)	1 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	WBC [D28] Below (N=101,98,96,98,98,97)	1 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	SUN [D7] Above (N=102,101,100,99,100,99)	1 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	WBC [D7] Below (N=102,101,100,99,100,99)	0 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	RBC [D21] Above (N=101,100,97,97,99,99)	0 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	SUN [D182] Below (N=99,91,88,91,93,97)	2 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	SUN [D63] Above (N=100,95,95,95,97,97)	0 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	RBC [D28] Above (N=101,98,96,98,98,97)	1 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	RBC [D42] Within (N=101,97,95,95,96,97)	87 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	WBC [D7] Within (N=102,101,100,99,100,99)	97 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	RBC [D182] Below (N=99,91,88,91,93,97)	6 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	RBC [D21] Below (N=101,100,97,97,99,99)	7 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	WBC [D28] Within (N=101,98,96,98,98,97)	92 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	WBC [D42] Unknown (N=101,97,95,95,96,97)	0 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	SUN [D21] Above (N=101,100,97,97,99,99)	0 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	WBC [D7] Above (N=102,101,100,99,100,99)	3 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	RBC [D42] Unknown (N=101,97,95,95,96,97)	0 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	SUN [D21] Within (N=101,100,97,97,99,99)	99 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	RBC [D0] Below (N=102,104,102,100101,102)	7 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	RBC [D63] Above (N=100,95,95,95,97,97)	0 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	RBC [D63] Unknown (N=100,95,95,95,97,97)	0 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	WBC [D0] Above (N=102,104,102,100,101,102)	3 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	RBC [D182] Below (N=99,91,88,91,93,97)	9 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	SUN [D7] Above (N=102,101,100,99,100,99)	0 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	RBC [D182] Within (N=99,91,88,91,93,97)	77 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	RBC [D182] Above (N=99,91,88,91,93,97)	2 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	RBC [D182] Unknown (N=99,91,88,91,93,97)	0 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	SUN [D0] Below (N=102,104,102,100101,102)	1 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	SUN [D7] Within (N=102,101,100,99,100,99)	96 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	SUN [D0] Within (N=102,104,102,100101,102)	100 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	WBC [D0] Unknown (N=102,104,102,100,101,102)	0 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	SUN [D0] Above (N=102,104,102,100101,102)	0 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	SUN [D0] Unknown (N=102,104,102,100101,102)	1 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	SUN [D7] Below (N=102,101,100,99,100,99)	4 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	WBC [D7] Below (N=102,101,100,99,100,99)	2 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	WBC [D7] Within (N=102,101,100,99,100,99)	98 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	SUN [D42] Unknown (N=101,97,95,95,96,97)	1 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	WBC [D7] Above (N=102,101,100,99,100,99)	0 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	WBC [D7] Unknown (N=102,101,100,99,100,99)	0 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	SUN [D63] Unknown (N=100,95,95,95,97,97)	1 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	WBC [D21] Below (N=101,100,97,97,99,99)	2 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	WBC [D21] Within (N=101,100,97,97,99,99)	90 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	SUN [D42] Above (N=101,97,95,95,96,97)	1 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	WBC [D21] Above (N=101,100,97,97,99,99)	2 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	WBC [D21] Unknown (N=101,100,97,97,99,99)	3 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	WBC [D28] Below (N=101,98,96,98,98,97)	3 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	WBC [D28] Within (N=101,98,96,98,98,97)	92 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	SUN [D182] Below (N=99,91,88,91,93,97)	1 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	SUN [D42] Within (N=101,97,95,95,96,97)	91 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	WBC [D28] Above (N=101,98,96,98,98,97)	1 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	WBC [D28] Unknown (N=101,98,96,98,98,97)	0 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	WBC [D42] Below (N=101,97,95,95,96,97)	2 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	WBC [D42] Within (N=101,97,95,95,96,97)	92 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	SUN [D42] Below (N=101,97,95,95,96,97)	2 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	WBC [D42] Above (N=101,97,95,95,96,97)	1 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	WBC [D42] Unknown (N=101,97,95,95,96,97)	0 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	SUN [D182] Within (N=99,91,88,91,93,97)	87 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	SUN [D28] Unknown (N=101,98,96,98,98,97)	0 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	WBC [D63] Within (N=100,95,95,95,97,97)	93 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	SUN [D63] Above (N=100,95,95,95,97,97)	0 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	WBC [D63] Above (N=100,95,95,95,97,97)	1 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	SUN [D63] Within (N=100,95,95,95,97,97)	93 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	WBC [D63] Unknown (N=100,95,95,95,97,97)	0 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	WBC [D182] Below (N=99,91,88,91,93,97)	4 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	SUN [D28] Above (N=101,98,96,98,98,97)	0 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	WBC [D182] Within (N=99,91,88,91,93,97)	82 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	WBC [D182] Above (N=99,91,88,91,93,97)	2 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	SUN [D182] Above (N=99,91,88,91,93,97)	0 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	WBC [D182] Unknown (N=99,91,88,91,93,97)	0 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	SUN [D28] Within (N=101,98,96,98,98,97)	96 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	RBC [D63] Within (N=100,95,95,95,97,97)	90 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	RBC [D0] Within (N=102,104,102,100101,102)	95 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	RBC [D0] Above (N=102,104,102,100101,102)	0 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	RBC [D0] Unknown (N=102,104,102,100101,102)	0 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	RBC [D7] Below (N=102,101,100,99,100,99)	5 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	SUN [D21] Unknown (N=101,100,97,97,99,99)	0 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	RBC [D7] Within (N=102,101,100,99,100,99)	95 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	SUN [D182] Unknown (N=99,91,88,91,93,97)	0 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	RBC [D7] Above (N=102,101,100,99,100,99)	0 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	RBC [D7] Unknown (N=102,101,100,99,100,99)	0 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	RBC [D21] Below (N=101,100,97,97,99,99)	5 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	SUN [D21] Above (N=101,100,97,97,99,99)	1 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	RBC [D21] Within (N=101,100,97,97,99,99)	89 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	RBC [D21] Above (N=101,100,97,97,99,99)	0 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	RBC [D21] Unknown (N=101,100,97,97,99,99)	3 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	WBC [D0] Below (N=102,104,102,100,101,102)	5 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	RBC [D28] Below (N=101,98,96,98,98,97)	8 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	SUN [D21] Within (N=101,100,97,97,99,99)	96 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	RBC [D28] Within (N=101,98,96,98,98,97)	88 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	WBC [D63] Below (N=100,95,95,95,97,97)	1 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	RBC [D28] Above (N=101,98,96,98,98,97)	0 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	RBC [D28] Unknown (N=101,98,96,98,98,97)	0 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	RBC [D42] Below (N=101,97,95,95,96,97)	9 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	SUN [D21] Below (N=101,100,97,97,99,99)	0 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	RBC [D42] Within (N=101,97,95,95,96,97)	86 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	WBC [D0] Within (N=102,104,102,100,101,102)	94 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	RBC [D42] Above (N=101,97,95,95,96,97)	0 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	RBC [D42] Unknown (N=101,97,95,95,96,97)	0 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	SUN [D28] Below (N=101,98,96,98,98,97)	0 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	RBC [D63] Below (N=100,95,95,95,97,97)	5 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	SUN [D63] Below (N=100,95,95,95,97,97)	1 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	SUN [D7] Unknown (N=102,101,100,99,100,99)	0 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	RBC [D42] Within (N=101,97,95,95,96,97)	89 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	RBC [D7] Unknown (N=102,101,100,99,100,99)	1 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	WBC [D42] Within (N=101,97,95,95,96,97)	90 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	SUN [D21] Above (N=101,100,97,97,99,99)	0 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	SUN [D42] Below (N=101,97,95,95,96,97)	1 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	SUN [D63] Within (N=100,95,95,95,97,97)	93 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	RBC [D63] Unknown (N=100,95,95,95,97,97)	0 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	RBC [D21] Below (N=101,100,97,97,99,99)	6 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	WBC [D42] Below (N=101,97,95,95,96,97)	3 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	RBC [D182] Unknown (N=99,91,88,91,93,97)	2 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	WBC [D28] Unknown (N=101,98,96,98,98,97)	2 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	SUN [D182] Below (N=99,91,88,91,93,97)	1 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	RBC [D182] Above (N=99,91,88,91,93,97)	1 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	RBC [D21] Within (N=101,100,97,97,99,99)	90 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	WBC [D28] Above (N=101,98,96,98,98,97)	1 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	WBC [D28] Within (N=101,98,96,98,98,97)	92 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	SUN [D42] Within (N=101,97,95,95,96,97)	94 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	WBC [D28] Below (N=101,98,96,98,98,97)	3 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	SUN [D63] Above (N=100,95,95,95,97,97)	0 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	RBC [D21] Above (N=101,100,97,97,99,99)	0 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	WBC [D21] Unknown (N=101,100,97,97,99,99)	1 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	WBC [D21] Above (N=101,100,97,97,99,99)	1 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	SUN [D28] Unknown (N=101,98,96,98,98,97)	1 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	WBC [D21] Within (N=101,100,97,97,99,99)	93 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	RBC [D63] Within (N=100,95,95,95,97,97)	89 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	RBC [D21] Unknown (N=101,100,97,97,99,99)	1 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	RBC [D42] Above (N=101,97,95,95,96,97)	0 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	SUN [D21] Within (N=101,100,97,97,99,99)	95 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	SUN [D42] Above (N=101,97,95,95,96,97)	0 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	SUN [D63] Unknown (N=100,95,95,95,97,97)	0 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	WBC [D0] Within (N=102,104,102,100,101,102)	93 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	RBC [D28] Below (N=101,98,96,98,98,97)	7 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	WBC [D0] Below (N=102,104,102,100,101,102)	3 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	RBC [D182] Within (N=99,91,88,91,93,97)	84 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	WBC [D21] Below (N=101,100,97,97,99,99)	2 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	WBC [D7] Unknown (N=102,101,100,99,100,99)	1 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	WBC [D0] Above (N=102,104,102,100,101,102)	2 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	RBC [D28] Within (N=101,98,96,98,98,97)	89 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	RBC [D182] Below (N=99,91,88,91,93,97)	4 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	WBC [D7] Above (N=102,101,100,99,100,99)	5 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	WBC [D7] Within (N=102,101,100,99,100,99)	92 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	SUN [D42] Unknown (N=101,97,95,95,96,97)	0 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	RBC [D63] Below (N=100,95,95,95,97,97)	5 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	RBC [D28] Above (N=101,98,96,98,98,97)	1 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	SUN [D63] Below (N=100,95,95,95,97,97)	2 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	WBC [D7] Below (N=102,101,100,99,100,99)	1 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	SUN [D7] Below (N=102,101,100,99,100,99)	1 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	SUN [D28] Below (N=101,98,96,98,98,97)	0 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	RBC [D42] Unknown (N=101,97,95,95,96,97)	0 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	RBC [D28] Unknown (N=101,98,96,98,98,97)	1 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	SUN [D0] Unknown (N=102,104,102,100101,102)	1 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	SUN [D21] Below (N=101,100,97,97,99,99)	2 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	WBC [D0] Unknown (N=102,104,102,100,101,102)	2 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	SUN [D0] Above (N=102,104,102,100101,102)	0 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	RBC [D63] Above (N=100,95,95,95,97,97)	1 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	RBC [D0] Above (N=102,104,102,100101,102)	2 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	RBC [D0] Within (N=102,104,102,100101,102)	93 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	SUN [D182] Above (N=99,91,88,91,93,97)	0 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	RBC [D0] Below (N=102,104,102,100101,102)	3 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	WBC [D182] Unknown (N=99,91,88,91,93,97)	2 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	RBC [D42] Below (N=101,97,95,95,96,97)	6 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	RBC [D0] Unknown (N=102,104,102,100101,102)	2 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	SUN [D28] Within (N=101,98,96,98,98,97)	97 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	SUN [D21] Unknown (N=101,100,97,97,99,99)	0 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	WBC [D182] Above (N=99,91,88,91,93,97)	2 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	WBC [D182] Within (N=99,91,88,91,93,97)	84 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	SUN [D0] Within (N=102,104,102,100101,102)	98 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	RBC [D7] Below (N=102,101,100,99,100,99)	4 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	WBC [D182] Below (N=99,91,88,91,93,97)	3 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	SUN [D7] Unknown (N=102,101,100,99,100,99)	0 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	SUN [D28] Above (N=101,98,96,98,98,97)	0 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	WBC [D63] Unknown (N=100,95,95,95,97,97)	0 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	SUN [D0] Below (N=102,104,102,100101,102)	1 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	RBC [D7] Within (N=102,101,100,99,100,99)	93 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	SUN [D7] Within (N=102,101,100,99,100,99)	98 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	WBC [D63] Above (N=100,95,95,95,97,97)	4 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	WBC [D63] Within (N=100,95,95,95,97,97)	89 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	SUN [D182] Within (N=99,91,88,91,93,97)	90 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	SUN [D7] Above (N=102,101,100,99,100,99)	0 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	RBC [D7] Above (N=102,101,100,99,100,99)	1 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	SUN [D182] Unknown (N=99,91,88,91,93,97)	0 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	WBC [D63] Below (N=100,95,95,95,97,97)	2 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	WBC [D42] Unknown (N=101,97,95,95,96,97)	0 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	WBC [D42] Above (N=101,97,95,95,96,97)	2 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	WBC [D182] Below (N=99,91,88,91,93,97)	2 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	SUN [D28] Unknown (N=101,98,96,98,98,97)	0 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	WBC [D182] Unknown (N=99,91,88,91,93,97)	0 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	SUN [D63] Above (N=100,95,95,95,97,97)	0 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	SUN [D63] Unknown (N=100,95,95,95,97,97)	1 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	SUN [D182] Below (N=99,91,88,91,93,97)	1 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	SUN [D182] Within (N=99,91,88,91,93,97)	91 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	SUN [D182] Above (N=99,91,88,91,93,97)	0 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	SUN [D182] Unknown (N=99,91,88,91,93,97)	1 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	WBC [D0] Below (N=102,104,102,100,101,102)	2 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	WBC [D0] Within (N=102,104,102,100,101,102)	95 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	WBC [D0] Above (N=102,104,102,100,101,102)	4 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	WBC [D0] Unknown (N=102,104,102,100,101,102)	0 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	WBC [D7] Below (N=102,101,100,99,100,99)	3 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	WBC [D7] Within (N=102,101,100,99,100,99)	94 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	WBC [D7] Above (N=102,101,100,99,100,99)	3 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	WBC [D7] Unknown (N=102,101,100,99,100,99)	0 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	WBC [D21] Below (N=101,100,97,97,99,99)	3 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	WBC [D21] Within (N=101,100,97,97,99,99)	91 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	WBC [D21] Above (N=101,100,97,97,99,99)	3 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	WBC [D21] Unknown (N=101,100,97,97,99,99)	2 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	WBC [D28] Below (N=101,98,96,98,98,97)	2 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	WBC [D28] Within (N=101,98,96,98,98,97)	93 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	WBC [D28] Above (N=101,98,96,98,98,97)	2 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	WBC [D28] Unknown (N=101,98,96,98,98,97)	1 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	WBC [D42] Below (N=101,97,95,95,96,97)	3 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	WBC [D42] Within (N=101,97,95,95,96,97)	92 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	WBC [D42] Above (N=101,97,95,95,96,97)	1 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	WBC [D42] Unknown (N=101,97,95,95,96,97)	0 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	WBC [D63] Below (N=100,95,95,95,97,97)	3 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	WBC [D63] Within (N=100,95,95,95,97,97)	91 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	WBC [D63] Above (N=100,95,95,95,97,97)	3 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	WBC [D63] Unknown (N=100,95,95,95,97,97)	0 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	WBC [D182] Within (N=99,91,88,91,93,97)	88 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	WBC [D182] Above (N=99,91,88,91,93,97)	3 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	RBC [D0] Below (N=102,104,102,100101,102)	2 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	RBC [D0] Within (N=102,104,102,100101,102)	99 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	RBC [D0] Above (N=102,104,102,100101,102)	0 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	RBC [D0] Unknown (N=102,104,102,100101,102)	0 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	RBC [D7] Below (N=102,101,100,99,100,99)	5 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	RBC [D7] Within (N=102,101,100,99,100,99)	95 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	RBC [D7] Above (N=102,101,100,99,100,99)	0 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	RBC [D7] Unknown (N=102,101,100,99,100,99)	0 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	RBC [D21] Below (N=101,100,97,97,99,99)	3 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	RBC [D21] Within (N=101,100,97,97,99,99)	94 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	RBC [D21] Above (N=101,100,97,97,99,99)	0 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	RBC [D21] Unknown (N=101,100,97,97,99,99)	2 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	RBC [D28] Below (N=101,98,96,98,98,97)	2 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	RBC [D28] Within (N=101,98,96,98,98,97)	95 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	RBC [D28] Above (N=101,98,96,98,98,97)	0 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	RBC [D28] Unknown (N=101,98,96,98,98,97)	1 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	RBC [D42] Below (N=101,97,95,95,96,97)	7 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	RBC [D42] Within (N=101,97,95,95,96,97)	89 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	RBC [D42] Above (N=101,97,95,95,96,97)	0 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	RBC [D42] Unknown (N=101,97,95,95,96,97)	0 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	RBC [D63] Below (N=100,95,95,95,97,97)	6 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	RBC [D63] Within (N=100,95,95,95,97,97)	91 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	RBC [D63] Above (N=100,95,95,95,97,97)	0 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	RBC [D63] Unknown (N=100,95,95,95,97,97)	0 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	RBC [D182] Below (N=99,91,88,91,93,97)	5 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	RBC [D182] Within (N=99,91,88,91,93,97)	88 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	RBC [D182] Above (N=99,91,88,91,93,97)	0 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	RBC [D182] Unknown (N=99,91,88,91,93,97)	0 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	SUN [D0] Below (N=102,104,102,100101,102)	1 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	SUN [D0] Within (N=102,104,102,100101,102)	98 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	SUN [D0] Above (N=102,104,102,100101,102)	1 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	SUN [D0] Unknown (N=102,104,102,100101,102)	1 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	SUN [D7] Below (N=102,101,100,99,100,99)	0 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	SUN [D7] Within (N=102,101,100,99,100,99)	99 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	SUN [D7] Above (N=102,101,100,99,100,99)	1 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	SUN [D7] Unknown (N=102,101,100,99,100,99)	0 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	SUN [D21] Below (N=101,100,97,97,99,99)	1 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	SUN [D21] Within (N=101,100,97,97,99,99)	98 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	SUN [D21] Above (N=101,100,97,97,99,99)	0 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	SUN [D21] Unknown (N=101,100,97,97,99,99)	0 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	SUN [D28] Below (N=101,98,96,98,98,97)	0 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	SUN [D28] Within (N=101,98,96,98,98,97)	98 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	SUN [D28] Above (N=101,98,96,98,98,97)	0 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	SUN [D42] Below (N=101,97,95,95,96,97)	2 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	SUN [D42] Within (N=101,97,95,95,96,97)	92 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	SUN [D42] Above (N=101,97,95,95,96,97)	0 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	SUN [D42] Unknown (N=101,97,95,95,96,97)	2 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	SUN [D63] Below (N=100,95,95,95,97,97)	0 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	SUN [D63] Within (N=100,95,95,95,97,97)	96 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	RBC [D63] Below (N=100,95,95,95,97,97)	12 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	RBC [D42] Unknown (N=101,97,95,95,96,97)	0 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	WBC [D0] Above (N=102,104,102,100,101,102)	5 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	SUN [D7] Unknown (N=102,101,100,99,100,99)	0 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	RBC [D42] Above (N=101,97,95,95,96,97)	0 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	RBC [D42] Within (N=101,97,95,95,96,97)	85 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	RBC [D42] Below (N=101,97,95,95,96,97)	12 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	RBC [D28] Unknown (N=101,98,96,98,98,97)	3 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	WBC [D0] Within (N=102,104,102,100,101,102)	95 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	SUN [D21] Below (N=101,100,97,97,99,99)	3 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	RBC [D28] Above (N=101,98,96,98,98,97)	0 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	RBC [D28] Within (N=101,98,96,98,98,97)	86 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	RBC [D28] Below (N=101,98,96,98,98,97)	8 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	RBC [D21] Unknown (N=101,100,97,97,99,99)	3 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	WBC [D0] Below (N=102,104,102,100,101,102)	2 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	SUN [D21] Within (N=101,100,97,97,99,99)	95 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	RBC [D21] Above (N=101,100,97,97,99,99)	0 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	RBC [D21] Within (N=101,100,97,97,99,99)	90 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	RBC [D21] Below (N=101,100,97,97,99,99)	6 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	RBC [D7] Unknown (N=102,101,100,99,100,99)	0 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	SUN [D63] Above (N=100,95,95,95,97,97)	0 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	SUN [D21] Above (N=101,100,97,97,99,99)	0 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	RBC [D7] Above (N=102,101,100,99,100,99)	0 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	RBC [D7] Within (N=102,101,100,99,100,99)	96 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	RBC [D7] Below (N=102,101,100,99,100,99)	3 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	RBC [D0] Unknown (N=102,104,102,100101,102)	0 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	SUN [D63] Below (N=100,95,95,95,97,97)	1 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	RBC [D0] Above (N=102,104,102,100101,102)	0 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	SUN [D182] Unknown (N=99,91,88,91,93,97)	0 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	SUN [D28] Below (N=101,98,96,98,98,97)	4 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	RBC [D0] Within (N=102,104,102,100101,102)	98 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	RBC [D0] Below (N=102,104,102,100101,102)	4 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	WBC [D182] Unknown (N=99,91,88,91,93,97)	1 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	WBC [D182] Above (N=99,91,88,91,93,97)	1 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	SUN [D182] Above (N=99,91,88,91,93,97)	0 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	SUN [D28] Within (N=101,98,96,98,98,97)	91 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	WBC [D182] Within (N=99,91,88,91,93,97)	91 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	WBC [D182] Below (N=99,91,88,91,93,97)	4 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	SUN [D21] Unknown (N=101,100,97,97,99,99)	1 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	WBC [D63] Unknown (N=100,95,95,95,97,97)	0 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	SUN [D182] Within (N=99,91,88,91,93,97)	94 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	SUN [D28] Above (N=101,98,96,98,98,97)	1 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	WBC [D63] Above (N=100,95,95,95,97,97)	3 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	WBC [D63] Within (N=100,95,95,95,97,97)	91 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	WBC [D63] Below (N=100,95,95,95,97,97)	3 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	SUN [D28] Unknown (N=101,98,96,98,98,97)	1 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	WBC [D42] Unknown (N=101,97,95,95,96,97)	0 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	WBC [D42] Above (N=101,97,95,95,96,97)	3 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	WBC [D42] Within (N=101,97,95,95,96,97)	91 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	WBC [D42] Below (N=101,97,95,95,96,97)	3 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	SUN [D182] Below (N=99,91,88,91,93,97)	3 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	WBC [D28] Unknown (N=101,98,96,98,98,97)	3 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	WBC [D28] Above (N=101,98,96,98,98,97)	3 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	WBC [D28] Within (N=101,98,96,98,98,97)	91 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	WBC [D28] Below (N=101,98,96,98,98,97)	0 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	SUN [D42] Below (N=101,97,95,95,96,97)	2 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	SUN [D42] Within (N=101,97,95,95,96,97)	95 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	WBC [D21] Unknown (N=101,100,97,97,99,99)	4 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	WBC [D21] Above (N=101,100,97,97,99,99)	3 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	WBC [D21] Within (N=101,100,97,97,99,99)	90 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	WBC [D21] Below (N=101,100,97,97,99,99)	2 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	SUN [D63] Within (N=100,95,95,95,97,97)	94 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	SUN [D42] Above (N=101,97,95,95,96,97)	0 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	WBC [D7] Unknown (N=102,101,100,99,100,99)	0 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	WBC [D7] Above (N=102,101,100,99,100,99)	3 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	WBC [D7] Within (N=102,101,100,99,100,99)	94 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	WBC [D7] Below (N=102,101,100,99,100,99)	2 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	SUN [D0] Unknown (N=102,104,102,100101,102)	0 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	SUN [D63] Unknown (N=100,95,95,95,97,97)	2 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	SUN [D7] Below (N=102,101,100,99,100,99)	0 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	SUN [D0] Above (N=102,104,102,100101,102)	1 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	SUN [D0] Within (N=102,104,102,100101,102)	99 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	SUN [D0] Below (N=102,104,102,100101,102)	2 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	RBC [D182] Unknown (N=99,91,88,91,93,97)	0 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	SUN [D42] Unknown (N=101,97,95,95,96,97)	0 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	SUN [D7] Within (N=102,101,100,99,100,99)	99 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	RBC [D182] Above (N=99,91,88,91,93,97)	0 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	RBC [D182] Within (N=99,91,88,91,93,97)	87 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	RBC [D182] Below (N=99,91,88,91,93,97)	10 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	RBC [D63] Unknown (N=100,95,95,95,97,97)	0 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	WBC [D0] Unknown (N=102,104,102,100,101,102)	0 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	SUN [D7] Above (N=102,101,100,99,100,99)	0 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	RBC [D63] Above (N=100,95,95,95,97,97)	0 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	RBC [D63] Within (N=100,95,95,95,97,97)	85 Subjects

Secondary

Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed

Laboratory parameters assessed were neutrophils (NEU), lymphocytes (LYM), monocytes (MON) and platelets (PLA). For each parameter and for each range it was assessed whether the values of the subjects were unknown, in above, below or within the range.

Time frame: On Days 0, 7, 21, 28, 42, 63 and 182

Population: The Total Vaccinated cohort included all vaccinated subjects

Arm	Measure	Group	Value (NUMBER)
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	PLA [D7] Unknown (N=102,101,100,99,100,99)	0 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	LYM [D42] Below (N=101,97,95,95,96,97)	0 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	NEU [D182] Below (N=99,91,88,91,93,97)	3 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	MON [D182] Within (N=99,91,88,91,93,97)	82 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	PLA [D28] Unknown (N=101,98,96,98,98,97)	1 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	LYM [D63] Within (N=100,95,95,95,97,97)	100 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	MON [D28] Above (N=101,98,96,98,98,97)	0 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	MON [D0] Above (N=102,104,102,100,101,102)	0 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	MON [D42] Above (N=101,97,95,95,96,97)	0 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	NEU [D42] Above (N=101,97,95,95,96,97)	0 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	PLA [D42] Below (N=101,97,95,95,96,97)	1 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	LYM [D28] Below (N=101,98,96,98,98,97)	0 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	NEU [D28] Below (N=101,98,96,98,98,97)	1 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	NEU [D7] Above (N=101,100,98,97,97,97)	3 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	NEU [D182] Unknown (N=99,91,88,91,93,97)	0 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	PLA [D7] Above (N=102,101,100,99,100,99)	0 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	PLA [D42] Within (N=101,97,95,95,96,97)	100 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	LYM [D7] Unknown (N=102,101,100,99,100,99)	0 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	PLA [D0] Above (N=102,104,102,100,101,102)	0 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	PLA [D7] Below (N=102,101,100,99,100,99)	1 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	NEU [D21] Above (N=101,100,97,97,99,99)	1 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	LYM [D28] Within (N=101,98,96,98,98,97)	99 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	PLA [D42] Above (N=101,97,95,95,96,97)	0 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	MON [D63] Unknown (N=100,95,95,95,97,97)	0 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	NEU [D63] Below (N=100,95,95,95,97,97)	1 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	MON [D0] Within (N=102,104,102,100,101,102)	89 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	NEU [D0] Unknown (N=102,104,102,100,101,102)	2 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	LYM [D42] Unknown (N=101,97,95,95,96,97)	0 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	PLA [D42] Unknown (N=101,97,95,95,96,97)	0 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	NEU [D63] Unknown (N=100,95,95,95,97,97)	0 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	MON [D42] Unknown (N=101,97,95,95,96,97)	0 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	LYM [D28] Unknown (N=101,98,96,98,98,97)	2 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	LYM [D28] Above (N=101,98,96,98,98,97)	0 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	NEU [D42] Within (N=101,97,95,95,96,97)	98 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	PLA [D63] Below (N=100,95,95,95,97,97)	0 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	LYM [D7] Within (N=102,101,100,99,100,99)	100 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	LYM [D42] Above (N=101,97,95,95,96,97)	0 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	MON [D0] Below (N=102,104,102,100,101,102)	11 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	LYM [D21] Below (N=101,100,97,97,99,99)	0 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	PLA [D21] Above (N=101,100,97,97,99,99)	0 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	PLA [D63] Within (N=100,95,95,95,97,97)	100 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	MON [D42] Below (N=101,97,95,95,96,97)	16 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	MON [D21] Above (N=101,100,97,97,99,99)	0 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	MON [D182] Above (N=99,91,88,91,93,97)	0 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	NEU [D28] Within (N=101,98,96,98,98,97)	98 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	PLA [D21] Within (N=101,100,97,97,99,99)	100 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	PLA [D63] Above (N=100,95,95,95,97,97)	0 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	NEU [D0] Within (N=102,104,102,100,101,102)	98 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	NEU [D0] Above (N=102,104,102,100,101,102)	1 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	LYM [D182] Unknown (N=99,91,88,91,93,97)	0 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	PLA [D0] Below (N=102,104,102,100,101,102)	0 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	MON [D7] Above (N=102,101,100,99,100,99)	0 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	PLA [D63] Unknown (N=100,95,95,95,97,97)	0 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	LYM [D0] Unknown (N=102,104,102,100,101,102)	2 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	MON [D63] Below (N=100,95,95,95,97,97)	17 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	MON [D182] Unknown (N=99,91,88,91,93,97)	0 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	LYM [D42] Within (N=101,97,95,95,96,97)	101 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	NEU [D42] Below (N=101,97,95,95,96,97)	3 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	PLA [D182] Below (N=99,91,88,91,93,97)	2 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	MON [D182] Below (N=99,91,88,91,93,97)	17 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	MON [D28] Within (N=101,98,96,98,98,97)	82 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	LYM [D182] Above (N=99,91,88,91,93,97)	1 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	NEU [D7] Within (N=101,100,98,97,97,97)	96 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	NEU [D7] Unknown (N=101,100,98,97,97,97)	0 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	PLA [D182] Within (N=99,91,88,91,93,97)	97 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	LYM [D21] Within (N=101,100,97,97,99,99)	101 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	MON [D21] Below (N=101,100,97,97,99,99)	25 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	NEU [D0] Below (N=102,104,102,100,101,102)	1 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	LYM [D0] Above (N=102,104,102,100,101,102)	0 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	NEU [D182] Above (N=99,91,88,91,93,97)	3 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	PLA [D182] Above (N=99,91,88,91,93,97)	0 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	NEU [D21] Within (N=101,100,97,97,99,99)	97 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	MON [D63] Within (N=100,95,95,95,97,97)	82 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	LYM [D182] Within (N=99,91,88,91,93,97)	98 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	PLA [D21] Unknown (N=101,100,97,97,99,99)	0 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	PLA [D21] Below (N=101,100,97,97,99,99)	1 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	PLA [D182] Unknown (N=99,91,88,91,93,97)	0 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	MON [D21] Unknown (N=101,100,97,97,99,99)	0 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	MON [D7] Within (N=102,101,100,99,100,99)	82 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	NEU [D21] Below (N=101,100,97,97,99,99)	3 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	MON [D28] Below (N=101,98,96,98,98,97)	17 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	NEU [D28] Unknown (N=101,98,96,98,98,97)	2 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	MON [D21] Within (N=101,100,97,97,99,99)	76 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	LYM [D21] Above (N=101,100,97,97,99,99)	0 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	LYM [D182] Below (N=99,91,88,91,93,97)	0 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	NEU [D63] Above (N=100,95,95,95,97,97)	1 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	PLA [D28] Below (N=101,98,96,98,98,97)	2 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	PLA [D0] Within (N=102,104,102,100,101,102)	100 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	PLA [D7] Within (N=102,101,100,99,100,99)	101 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	LYM [D7] Above (N=102,101,100,99,100,99)	1 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	MON [D42] Within (N=101,97,95,95,96,97)	85 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	MON [D7] Unknown (N=102,101,100,99,100,99)	0 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	NEU [D182] Within (N=99,91,88,91,93,97)	93 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	MON [D7] Below (N=102,101,100,99,100,99)	20 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	NEU [D28] Above (N=101,98,96,98,98,97)	0 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	LYM [D63] Unknown (N=100,95,95,95,97,97)	0 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	NEU [D21] Unknown (N=101,100,97,97,99,99)	0 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	PLA [D28] Within (N=101,98,96,98,98,97)	98 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	NEU [D42] Unknown (N=101,97,95,95,96,97)	0 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	PLA [D0] Unknown (N=102,104,102,100,101,102)	2 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	LYM [D63] Below (N=100,95,95,95,97,97)	0 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	LYM [D0] Below (N=102,104,102,100,101,102)	0 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	LYM [D21] Unknown (N=101,100,97,97,99,99)	0 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	MON [D63] Above (N=100,95,95,95,97,97)	1 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	MON [D0] Unknown (N=102,104,102,100,101,102)	2 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	NEU [D7] Below (N=101,100,98,97,97,97)	2 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	MON [D28] Unknown (N=101,98,96,98,98,97)	2 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	LYM [D0] Within (N=102,104,102,100,101,102)	100 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	PLA [D28] Above (N=101,98,96,98,98,97)	0 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	LYM [D7] Below (N=102,101,100,99,100,99)	1 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	LYM [D63] Above (N=100,95,95,95,97,97)	0 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	NEU [D63] Within (N=100,95,95,95,97,97)	98 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	LYM [D182] Below (N=99,91,88,91,93,97)	1 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	LYM [D0] Above (N=102,104,102,100,101,102)	1 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	LYM [D63] Within (N=100,95,95,95,97,97)	95 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	LYM [D0] Unknown (N=102,104,102,100,101,102)	0 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	NEU [D0] Within (N=102,104,102,100,101,102)	98 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	LYM [D7] Below (N=102,101,100,99,100,99)	0 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	LYM [D7] Within (N=102,101,100,99,100,99)	100 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	MON [D63] Unknown (N=100,95,95,95,97,97)	0 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	NEU [D21] Below (N=101,100,97,97,99,99)	5 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	PLA [D0] Above (N=102,104,102,100,101,102)	0 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	NEU [D28] Below (N=101,98,96,98,98,97)	5 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	LYM [D7] Above (N=102,101,100,99,100,99)	0 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	MON [D28] Unknown (N=101,98,96,98,98,97)	2 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	LYM [D42] Unknown (N=101,97,95,95,96,97)	0 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	PLA [D7] Unknown (N=102,101,100,99,100,99)	1 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	LYM [D7] Unknown (N=102,101,100,99,100,99)	1 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	MON [D7] Unknown (N=102,101,100,99,100,99)	1 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	LYM [D42] Above (N=101,97,95,95,96,97)	0 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	LYM [D21] Below (N=101,100,97,97,99,99)	1 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	LYM [D42] Within (N=101,97,95,95,96,97)	95 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	LYM [D21] Within (N=101,100,97,97,99,99)	98 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	MON [D182] Below (N=99,91,88,91,93,97)	20 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	PLA [D7] Below (N=102,101,100,99,100,99)	0 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	LYM [D21] Above (N=101,100,97,97,99,99)	0 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	LYM [D42] Below (N=101,97,95,95,96,97)	2 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	NEU [D7] Within (N=101,100,98,97,97,97)	94 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	LYM [D21] Unknown (N=101,100,97,97,99,99)	1 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	NEU [D21] Above (N=101,100,97,97,99,99)	2 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	LYM [D28] Below (N=101,98,96,98,98,97)	0 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	MON [D182] Within (N=99,91,88,91,93,97)	71 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	NEU [D21] Within (N=101,100,97,97,99,99)	92 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	LYM [D28] Within (N=101,98,96,98,98,97)	96 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	LYM [D28] Unknown (N=101,98,96,98,98,97)	2 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	LYM [D28] Above (N=101,98,96,98,98,97)	0 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	MON [D7] Above (N=102,101,100,99,100,99)	0 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	NEU [D63] Within (N=100,95,95,95,97,97)	93 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	MON [D182] Above (N=99,91,88,91,93,97)	0 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	MON [D42] Below (N=101,97,95,95,96,97)	19 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	PLA [D21] Above (N=101,100,97,97,99,99)	0 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	MON [D182] Unknown (N=99,91,88,91,93,97)	0 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	MON [D28] Below (N=101,98,96,98,98,97)	19 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	NEU [D63] Below (N=100,95,95,95,97,97)	1 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	NEU [D0] Below (N=102,104,102,100,101,102)	4 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	MON [D7] Within (N=102,101,100,99,100,99)	86 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	MON [D21] Unknown (N=101,100,97,97,99,99)	1 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	PLA [D21] Unknown (N=101,100,97,97,99,99)	1 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	NEU [D182] Above (N=99,91,88,91,93,97)	2 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	NEU [D42] Unknown (N=101,97,95,95,96,97)	0 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	PLA [D28] Below (N=101,98,96,98,98,97)	0 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	MON [D7] Below (N=102,101,100,99,100,99)	14 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	MON [D42] Within (N=101,97,95,95,96,97)	78 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	PLA [D28] Within (N=101,98,96,98,98,97)	96 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	PLA [D21] Below (N=101,100,97,97,99,99)	0 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	MON [D0] Unknown (N=102,104,102,100,101,102)	0 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	PLA [D28] Above (N=101,98,96,98,98,97)	0 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	NEU [D63] Unknown (N=100,95,95,95,97,97)	0 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	MON [D0] Above (N=102,104,102,100,101,102)	0 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	NEU [D42] Above (N=101,97,95,95,96,97)	2 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	PLA [D28] Unknown (N=101,98,96,98,98,97)	2 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	PLA [D42] Below (N=101,97,95,95,96,97)	1 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	MON [D42] Above (N=101,97,95,95,96,97)	0 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	PLA [D42] Within (N=101,97,95,95,96,97)	96 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	MON [D28] Above (N=101,98,96,98,98,97)	0 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	MON [D0] Within (N=102,104,102,100,101,102)	86 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	NEU [D182] Unknown (N=99,91,88,91,93,97)	0 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	MON [D21] Above (N=101,100,97,97,99,99)	0 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	PLA [D42] Above (N=101,97,95,95,96,97)	0 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	NEU [D0] Above (N=102,104,102,100,101,102)	2 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	NEU [D42] Within (N=101,97,95,95,96,97)	91 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	PLA [D42] Unknown (N=101,97,95,95,96,97)	0 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	NEU [D7] Above (N=101,100,98,97,97,97)	3 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	MON [D0] Below (N=102,104,102,100,101,102)	18 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	PLA [D63] Below (N=100,95,95,95,97,97)	1 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	MON [D42] Unknown (N=101,97,95,95,96,97)	0 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	NEU [D182] Below (N=99,91,88,91,93,97)	3 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	NEU [D182] Within (N=99,91,88,91,93,97)	86 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	PLA [D63] Within (N=100,95,95,95,97,97)	94 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	LYM [D182] Unknown (N=99,91,88,91,93,97)	0 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	NEU [D63] Above (N=100,95,95,95,97,97)	1 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	PLA [D63] Above (N=100,95,95,95,97,97)	0 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	NEU [D42] Below (N=101,97,95,95,96,97)	4 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	PLA [D63] Unknown (N=100,95,95,95,97,97)	0 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	LYM [D182] Above (N=99,91,88,91,93,97)	0 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	MON [D63] Below (N=100,95,95,95,97,97)	20 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	PLA [D182] Below (N=99,91,88,91,93,97)	1 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	PLA [D0] Below (N=102,104,102,100,101,102)	0 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	PLA [D182] Within (N=99,91,88,91,93,97)	90 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	NEU [D7] Below (N=101,100,98,97,97,97)	2 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	LYM [D182] Within (N=99,91,88,91,93,97)	90 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	PLA [D21] Within (N=101,100,97,97,99,99)	99 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	MON [D21] Within (N=101,100,97,97,99,99)	79 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	PLA [D182] Above (N=99,91,88,91,93,97)	0 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	NEU [D7] Unknown (N=101,100,98,97,97,97)	1 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	NEU [D28] Unknown (N=101,98,96,98,98,97)	2 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	PLA [D182] Unknown (N=99,91,88,91,93,97)	0 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	MON [D63] Within (N=100,95,95,95,97,97)	75 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	PLA [D7] Within (N=102,101,100,99,100,99)	100 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	NEU [D28] Within (N=101,98,96,98,98,97)	89 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	LYM [D63] Below (N=100,95,95,95,97,97)	0 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	MON [D28] Within (N=101,98,96,98,98,97)	77 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	NEU [D28] Above (N=101,98,96,98,98,97)	2 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	LYM [D63] Unknown (N=100,95,95,95,97,97)	0 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	PLA [D0] Within (N=102,104,102,100,101,102)	104 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	NEU [D0] Unknown (N=102,104,102,100,101,102)	0 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	NEU [D21] Unknown (N=101,100,97,97,99,99)	1 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	PLA [D0] Unknown (N=102,104,102,100,101,102)	0 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	PLA [D7] Above (N=102,101,100,99,100,99)	0 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	LYM [D0] Below (N=102,104,102,100,101,102)	2 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	LYM [D63] Above (N=100,95,95,95,97,97)	0 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	MON [D63] Above (N=100,95,95,95,97,97)	0 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	LYM [D0] Within (N=102,104,102,100,101,102)	101 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	MON [D21] Below (N=101,100,97,97,99,99)	20 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	MON [D28] Below (N=101,98,96,98,98,97)	26 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	NEU [D0] Unknown (N=102,104,102,100,101,102)	0 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	MON [D28] Within (N=101,98,96,98,98,97)	70 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	MON [D28] Above (N=101,98,96,98,98,97)	0 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	PLA [D21] Below (N=101,100,97,97,99,99)	1 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	MON [D28] Unknown (N=101,98,96,98,98,97)	0 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	MON [D42] Below (N=101,97,95,95,96,97)	20 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	MON [D42] Within (N=101,97,95,95,96,97)	75 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	NEU [D0] Above (N=102,104,102,100,101,102)	1 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	MON [D42] Above (N=101,97,95,95,96,97)	0 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	MON [D63] Below (N=100,95,95,95,97,97)	21 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	MON [D63] Within (N=100,95,95,95,97,97)	73 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	PLA [D21] Within (N=101,100,97,97,99,99)	93 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	NEU [D0] Within (N=102,104,102,100,101,102)	97 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	MON [D63] Above (N=100,95,95,95,97,97)	1 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	MON [D63] Unknown (N=100,95,95,95,97,97)	0 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	MON [D182] Below (N=99,91,88,91,93,97)	20 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	MON [D182] Within (N=99,91,88,91,93,97)	68 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	NEU [D0] Below (N=102,104,102,100,101,102)	4 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	MON [D182] Above (N=99,91,88,91,93,97)	0 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	MON [D182] Unknown (N=99,91,88,91,93,97)	0 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	PLA [D21] Above (N=101,100,97,97,99,99)	0 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	NEU [D42] Unknown (N=101,97,95,95,96,97)	0 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	PLA [D21] Unknown (N=101,100,97,97,99,99)	3 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	PLA [D28] Below (N=101,98,96,98,98,97)	0 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	NEU [D182] Above (N=99,91,88,91,93,97)	1 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	PLA [D28] Within (N=101,98,96,98,98,97)	96 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	NEU [D42] Above (N=101,97,95,95,96,97)	0 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	PLA [D28] Above (N=101,98,96,98,98,97)	0 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	PLA [D28] Unknown (N=101,98,96,98,98,97)	0 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	NEU [D63] Above (N=100,95,95,95,97,97)	0 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	PLA [D42] Below (N=101,97,95,95,96,97)	0 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	PLA [D42] Within (N=101,97,95,95,96,97)	93 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	NEU [D42] Within (N=101,97,95,95,96,97)	94 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	PLA [D42] Above (N=101,97,95,95,96,97)	1 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	NEU [D182] Unknown (N=99,91,88,91,93,97)	0 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	PLA [D42] Unknown (N=101,97,95,95,96,97)	1 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	PLA [D63] Below (N=100,95,95,95,97,97)	1 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	PLA [D63] Within (N=100,95,95,95,97,97)	94 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	NEU [D42] Below (N=101,97,95,95,96,97)	1 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	PLA [D63] Above (N=100,95,95,95,97,97)	0 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	PLA [D63] Unknown (N=100,95,95,95,97,97)	0 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	NEU [D63] Unknown (N=100,95,95,95,97,97)	0 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	PLA [D182] Below (N=99,91,88,91,93,97)	1 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	PLA [D182] Within (N=99,91,88,91,93,97)	87 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	PLA [D0] Below (N=102,104,102,100,101,102)	0 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	NEU [D28] Unknown (N=101,98,96,98,98,97)	0 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	PLA [D182] Above (N=99,91,88,91,93,97)	0 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	PLA [D182] Unknown (N=99,91,88,91,93,97)	0 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	NEU [D182] Below (N=99,91,88,91,93,97)	4 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	LYM [D7] Below (N=102,101,100,99,100,99)	1 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	NEU [D28] Above (N=101,98,96,98,98,97)	1 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	MON [D42] Unknown (N=101,97,95,95,96,97)	0 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	LYM [D0] Below (N=102,104,102,100,101,102)	0 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	PLA [D0] Within (N=102,104,102,100,101,102)	102 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	NEU [D28] Within (N=101,98,96,98,98,97)	92 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	LYM [D0] Within (N=102,104,102,100,101,102)	102 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	LYM [D0] Above (N=102,104,102,100,101,102)	0 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	LYM [D0] Unknown (N=102,104,102,100,101,102)	0 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	NEU [D28] Below (N=101,98,96,98,98,97)	3 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	LYM [D7] Within (N=102,101,100,99,100,99)	99 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	LYM [D7] Above (N=102,101,100,99,100,99)	0 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	PLA [D0] Above (N=102,104,102,100,101,102)	0 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	LYM [D7] Unknown (N=102,101,100,99,100,99)	0 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	LYM [D21] Below (N=101,100,97,97,99,99)	0 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	NEU [D21] Unknown (N=101,100,97,97,99,99)	3 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	LYM [D21] Within (N=101,100,97,97,99,99)	94 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	NEU [D63] Within (N=100,95,95,95,97,97)	94 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	LYM [D21] Above (N=101,100,97,97,99,99)	0 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	NEU [D21] Above (N=101,100,97,97,99,99)	1 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	LYM [D21] Unknown (N=101,100,97,97,99,99)	3 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	PLA [D0] Unknown (N=102,104,102,100,101,102)	0 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	LYM [D28] Below (N=101,98,96,98,98,97)	0 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	LYM [D28] Within (N=101,98,96,98,98,97)	95 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	LYM [D28] Above (N=101,98,96,98,98,97)	1 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	NEU [D21] Within (N=101,100,97,97,99,99)	91 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	LYM [D28] Unknown (N=101,98,96,98,98,97)	0 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	LYM [D42] Below (N=101,97,95,95,96,97)	0 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	LYM [D42] Within (N=101,97,95,95,96,97)	95 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	PLA [D7] Below (N=102,101,100,99,100,99)	0 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	LYM [D42] Above (N=101,97,95,95,96,97)	0 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	NEU [D21] Below (N=101,100,97,97,99,99)	2 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	LYM [D42] Unknown (N=101,97,95,95,96,97)	0 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	LYM [D63] Below (N=100,95,95,95,97,97)	0 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	LYM [D63] Within (N=100,95,95,95,97,97)	95 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	LYM [D63] Above (N=100,95,95,95,97,97)	0 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	LYM [D63] Unknown (N=100,95,95,95,97,97)	0 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	NEU [D7] Unknown (N=101,100,98,97,97,97)	0 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	LYM [D182] Below (N=99,91,88,91,93,97)	0 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	LYM [D182] Within (N=99,91,88,91,93,97)	88 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	PLA [D7] Within (N=102,101,100,99,100,99)	100 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	LYM [D182] Above (N=99,91,88,91,93,97)	0 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	LYM [D182] Unknown (N=99,91,88,91,93,97)	0 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	NEU [D7] Above (N=101,100,98,97,97,97)	2 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	MON [D0] Below (N=102,104,102,100,101,102)	26 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	MON [D0] Within (N=102,104,102,100,101,102)	75 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	MON [D0] Above (N=102,104,102,100,101,102)	1 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	PLA [D7] Above (N=102,101,100,99,100,99)	0 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	MON [D0] Unknown (N=102,104,102,100,101,102)	0 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	NEU [D7] Within (N=101,100,98,97,97,97)	94 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	MON [D7] Below (N=102,101,100,99,100,99)	22 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	NEU [D182] Within (N=99,91,88,91,93,97)	83 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	MON [D7] Within (N=102,101,100,99,100,99)	78 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	NEU [D63] Below (N=100,95,95,95,97,97)	1 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	MON [D7] Above (N=102,101,100,99,100,99)	0 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	MON [D7] Unknown (N=102,101,100,99,100,99)	0 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	MON [D21] Below (N=101,100,97,97,99,99)	20 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	PLA [D7] Unknown (N=102,101,100,99,100,99)	0 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	NEU [D7] Below (N=101,100,98,97,97,97)	2 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	MON [D21] Within (N=101,100,97,97,99,99)	74 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	MON [D21] Above (N=101,100,97,97,99,99)	0 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	MON [D21] Unknown (N=101,100,97,97,99,99)	3 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	NEU [D7] Below (N=101,100,98,97,97,97)	2 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	LYM [D63] Within (N=100,95,95,95,97,97)	95 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	PLA [D0] Within (N=102,104,102,100,101,102)	97 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	NEU [D7] Unknown (N=101,100,98,97,97,97)	1 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	LYM [D0] Within (N=102,104,102,100,101,102)	98 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	LYM [D0] Below (N=102,104,102,100,101,102)	0 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	PLA [D21] Within (N=101,100,97,97,99,99)	96 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	LYM [D63] Above (N=100,95,95,95,97,97)	0 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	NEU [D28] Within (N=101,98,96,98,98,97)	93 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	MON [D28] Unknown (N=101,98,96,98,98,97)	2 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	MON [D63] Above (N=100,95,95,95,97,97)	0 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	LYM [D63] Unknown (N=100,95,95,95,97,97)	0 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	NEU [D28] Above (N=101,98,96,98,98,97)	1 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	MON [D21] Unknown (N=101,100,97,97,99,99)	1 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	LYM [D42] Above (N=101,97,95,95,96,97)	1 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	LYM [D7] Below (N=102,101,100,99,100,99)	0 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	MON [D21] Below (N=101,100,97,97,99,99)	12 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	LYM [D182] Below (N=99,91,88,91,93,97)	0 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	PLA [D182] Unknown (N=99,91,88,91,93,97)	3 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	PLA [D0] Below (N=102,104,102,100,101,102)	1 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	PLA [D182] Above (N=99,91,88,91,93,97)	1 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	PLA [D182] Within (N=99,91,88,91,93,97)	87 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	MON [D42] Below (N=101,97,95,95,96,97)	25 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	LYM [D182] Within (N=99,91,88,91,93,97)	89 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	NEU [D0] Unknown (N=102,104,102,100,101,102)	2 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	NEU [D28] Unknown (N=101,98,96,98,98,97)	2 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	PLA [D182] Below (N=99,91,88,91,93,97)	0 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	PLA [D63] Unknown (N=100,95,95,95,97,97)	0 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	MON [D63] Within (N=100,95,95,95,97,97)	76 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	LYM [D182] Above (N=99,91,88,91,93,97)	0 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	PLA [D7] Within (N=102,101,100,99,100,99)	97 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	NEU [D7] Above (N=101,100,98,97,97,97)	4 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	PLA [D63] Above (N=100,95,95,95,97,97)	1 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	PLA [D63] Within (N=100,95,95,95,97,97)	93 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	NEU [D0] Within (N=102,104,102,100,101,102)	92 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	LYM [D182] Unknown (N=99,91,88,91,93,97)	2 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	NEU [D42] Below (N=101,97,95,95,96,97)	1 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	MON [D28] Above (N=101,98,96,98,98,97)	0 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	PLA [D63] Below (N=100,95,95,95,97,97)	1 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	NEU [D182] Unknown (N=99,91,88,91,93,97)	2 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	MON [D21] Within (N=101,100,97,97,99,99)	84 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	MON [D0] Below (N=102,104,102,100,101,102)	18 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	NEU [D63] Below (N=100,95,95,95,97,97)	1 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	PLA [D42] Unknown (N=101,97,95,95,96,97)	0 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	PLA [D42] Above (N=101,97,95,95,96,97)	0 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	PLA [D42] Within (N=101,97,95,95,96,97)	95 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	PLA [D7] Unknown (N=102,101,100,99,100,99)	2 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	MON [D0] Within (N=102,104,102,100,101,102)	79 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	NEU [D42] Within (N=101,97,95,95,96,97)	92 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	PLA [D42] Below (N=101,97,95,95,96,97)	0 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	PLA [D28] Unknown (N=101,98,96,98,98,97)	1 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	PLA [D28] Above (N=101,98,96,98,98,97)	0 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	MON [D63] Below (N=100,95,95,95,97,97)	19 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	MON [D0] Above (N=102,104,102,100,101,102)	1 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	MON [D42] Unknown (N=101,97,95,95,96,97)	0 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	NEU [D7] Within (N=101,100,98,97,97,97)	90 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	NEU [D182] Above (N=99,91,88,91,93,97)	1 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	PLA [D28] Within (N=101,98,96,98,98,97)	96 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	MON [D42] Above (N=101,97,95,95,96,97)	0 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	MON [D0] Unknown (N=102,104,102,100,101,102)	2 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	PLA [D7] Above (N=102,101,100,99,100,99)	0 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	MON [D28] Within (N=101,98,96,98,98,97)	70 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	NEU [D42] Above (N=101,97,95,95,96,97)	2 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	PLA [D28] Below (N=101,98,96,98,98,97)	1 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	MON [D21] Above (N=101,100,97,97,99,99)	0 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	MON [D7] Below (N=102,101,100,99,100,99)	12 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	NEU [D182] Within (N=99,91,88,91,93,97)	86 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	PLA [D21] Unknown (N=101,100,97,97,99,99)	1 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	PLA [D21] Above (N=101,100,97,97,99,99)	0 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	MON [D42] Within (N=101,97,95,95,96,97)	70 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	MON [D7] Within (N=102,101,100,99,100,99)	86 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	NEU [D0] Above (N=102,104,102,100,101,102)	2 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	MON [D182] Unknown (N=99,91,88,91,93,97)	2 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	MON [D182] Above (N=99,91,88,91,93,97)	0 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	MON [D182] Within (N=99,91,88,91,93,97)	68 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	LYM [D28] Above (N=101,98,96,98,98,97)	0 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	PLA [D21] Below (N=101,100,97,97,99,99)	0 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	NEU [D21] Within (N=101,100,97,97,99,99)	93 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	LYM [D28] Within (N=101,98,96,98,98,97)	96 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	MON [D7] Above (N=102,101,100,99,100,99)	0 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	LYM [D28] Unknown (N=101,98,96,98,98,97)	2 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	PLA [D0] Unknown (N=102,104,102,100,101,102)	2 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	LYM [D28] Below (N=101,98,96,98,98,97)	0 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	LYM [D21] Unknown (N=101,100,97,97,99,99)	1 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	LYM [D21] Above (N=101,100,97,97,99,99)	1 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	NEU [D0] Below (N=102,104,102,100,101,102)	4 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	LYM [D42] Below (N=101,97,95,95,96,97)	0 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	NEU [D21] Above (N=101,100,97,97,99,99)	1 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	LYM [D21] Within (N=101,100,97,97,99,99)	95 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	NEU [D63] Unknown (N=100,95,95,95,97,97)	0 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	LYM [D21] Below (N=101,100,97,97,99,99)	0 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	NEU [D42] Unknown (N=101,97,95,95,96,97)	0 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	LYM [D42] Within (N=101,97,95,95,96,97)	94 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	MON [D182] Below (N=99,91,88,91,93,97)	21 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	NEU [D21] Below (N=101,100,97,97,99,99)	2 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	NEU [D21] Unknown (N=101,100,97,97,99,99)	1 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	PLA [D0] Above (N=102,104,102,100,101,102)	0 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	NEU [D63] Above (N=100,95,95,95,97,97)	2 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	MON [D28] Below (N=101,98,96,98,98,97)	26 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	LYM [D7] Unknown (N=102,101,100,99,100,99)	1 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	LYM [D7] Above (N=102,101,100,99,100,99)	0 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	MON [D7] Unknown (N=102,101,100,99,100,99)	1 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	LYM [D42] Unknown (N=101,97,95,95,96,97)	0 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	PLA [D7] Below (N=102,101,100,99,100,99)	0 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	LYM [D7] Within (N=102,101,100,99,100,99)	98 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	NEU [D28] Below (N=101,98,96,98,98,97)	2 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	MON [D63] Unknown (N=100,95,95,95,97,97)	0 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	LYM [D63] Below (N=100,95,95,95,97,97)	0 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	NEU [D63] Within (N=100,95,95,95,97,97)	92 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	LYM [D0] Unknown (N=102,104,102,100,101,102)	2 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	NEU [D182] Below (N=99,91,88,91,93,97)	2 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	LYM [D0] Above (N=102,104,102,100,101,102)	0 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	PLA [D63] Unknown (N=100,95,95,95,97,97)	0 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	NEU [D63] Unknown (N=100,95,95,95,97,97)	0 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	NEU [D182] Below (N=99,91,88,91,93,97)	1 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	NEU [D182] Within (N=99,91,88,91,93,97)	89 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	NEU [D182] Above (N=99,91,88,91,93,97)	3 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	NEU [D182] Unknown (N=99,91,88,91,93,97)	0 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	PLA [D0] Below (N=102,104,102,100,101,102)	1 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	PLA [D0] Within (N=102,104,102,100,101,102)	98 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	PLA [D0] Above (N=102,104,102,100,101,102)	2 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	PLA [D0] Unknown (N=102,104,102,100,101,102)	0 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	PLA [D7] Below (N=102,101,100,99,100,99)	0 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	PLA [D7] Within (N=102,101,100,99,100,99)	99 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	PLA [D7] Above (N=102,101,100,99,100,99)	1 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	PLA [D7] Unknown (N=102,101,100,99,100,99)	0 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	PLA [D21] Below (N=101,100,97,97,99,99)	0 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	PLA [D21] Within (N=101,100,97,97,99,99)	97 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	PLA [D21] Above (N=101,100,97,97,99,99)	0 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	PLA [D21] Unknown (N=101,100,97,97,99,99)	2 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	PLA [D28] Below (N=101,98,96,98,98,97)	0 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	PLA [D28] Within (N=101,98,96,98,98,97)	95 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	PLA [D28] Above (N=101,98,96,98,98,97)	1 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	PLA [D28] Unknown (N=101,98,96,98,98,97)	2 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	PLA [D42] Below (N=101,97,95,95,96,97)	1 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	PLA [D42] Within (N=101,97,95,95,96,97)	93 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	PLA [D42] Above (N=101,97,95,95,96,97)	0 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	PLA [D42] Unknown (N=101,97,95,95,96,97)	2 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	PLA [D63] Below (N=100,95,95,95,97,97)	0 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	PLA [D63] Within (N=100,95,95,95,97,97)	96 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	PLA [D63] Above (N=100,95,95,95,97,97)	1 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	PLA [D182] Below (N=99,91,88,91,93,97)	1 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	PLA [D182] Within (N=99,91,88,91,93,97)	91 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	PLA [D182] Above (N=99,91,88,91,93,97)	1 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	PLA [D182] Unknown (N=99,91,88,91,93,97)	0 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	LYM [D42] Above (N=101,97,95,95,96,97)	0 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	LYM [D63] Above (N=100,95,95,95,97,97)	0 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	MON [D28] Unknown (N=101,98,96,98,98,97)	1 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	LYM [D0] Below (N=102,104,102,100,101,102)	0 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	LYM [D0] Within (N=102,104,102,100,101,102)	101 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	LYM [D0] Above (N=102,104,102,100,101,102)	0 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	LYM [D0] Unknown (N=102,104,102,100,101,102)	0 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	LYM [D7] Below (N=102,101,100,99,100,99)	0 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	LYM [D7] Within (N=102,101,100,99,100,99)	100 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	LYM [D7] Above (N=102,101,100,99,100,99)	0 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	LYM [D7] Unknown (N=102,101,100,99,100,99)	0 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	LYM [D21] Below (N=101,100,97,97,99,99)	0 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	LYM [D21] Within (N=101,100,97,97,99,99)	97 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	LYM [D21] Above (N=101,100,97,97,99,99)	0 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	LYM [D21] Unknown (N=101,100,97,97,99,99)	2 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	LYM [D28] Below (N=101,98,96,98,98,97)	0 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	LYM [D28] Within (N=101,98,96,98,98,97)	97 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	LYM [D28] Above (N=101,98,96,98,98,97)	0 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	LYM [D28] Unknown (N=101,98,96,98,98,97)	1 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	LYM [D42] Below (N=101,97,95,95,96,97)	3 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	LYM [D42] Within (N=101,97,95,95,96,97)	93 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	LYM [D42] Unknown (N=101,97,95,95,96,97)	0 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	LYM [D63] Below (N=100,95,95,95,97,97)	1 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	LYM [D63] Within (N=100,95,95,95,97,97)	96 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	LYM [D63] Unknown (N=100,95,95,95,97,97)	0 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	LYM [D182] Below (N=99,91,88,91,93,97)	1 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	LYM [D182] Within (N=99,91,88,91,93,97)	91 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	LYM [D182] Above (N=99,91,88,91,93,97)	1 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	LYM [D182] Unknown (N=99,91,88,91,93,97)	0 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	MON [D0] Below (N=102,104,102,100,101,102)	13 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	MON [D0] Within (N=102,104,102,100,101,102)	88 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	MON [D0] Above (N=102,104,102,100,101,102)	0 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	MON [D0] Unknown (N=102,104,102,100,101,102)	0 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	MON [D7] Below (N=102,101,100,99,100,99)	13 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	MON [D7] Within (N=102,101,100,99,100,99)	87 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	MON [D7] Above (N=102,101,100,99,100,99)	0 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	MON [D7] Unknown (N=102,101,100,99,100,99)	0 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	MON [D21] Below (N=101,100,97,97,99,99)	18 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	MON [D21] Within (N=101,100,97,97,99,99)	79 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	MON [D21] Above (N=101,100,97,97,99,99)	0 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	MON [D21] Unknown (N=101,100,97,97,99,99)	2 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	MON [D28] Below (N=101,98,96,98,98,97)	17 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	MON [D28] Within (N=101,98,96,98,98,97)	80 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	MON [D28] Above (N=101,98,96,98,98,97)	0 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	MON [D42] Below (N=101,97,95,95,96,97)	20 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	MON [D42] Within (N=101,97,95,95,96,97)	76 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	MON [D42] Above (N=101,97,95,95,96,97)	0 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	MON [D42] Unknown (N=101,97,95,95,96,97)	0 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	MON [D63] Below (N=100,95,95,95,97,97)	15 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	MON [D63] Within (N=100,95,95,95,97,97)	82 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	MON [D63] Above (N=100,95,95,95,97,97)	0 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	MON [D63] Unknown (N=100,95,95,95,97,97)	0 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	MON [D182] Below (N=99,91,88,91,93,97)	20 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	MON [D182] Within (N=99,91,88,91,93,97)	73 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	MON [D182] Above (N=99,91,88,91,93,97)	0 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	MON [D182] Unknown (N=99,91,88,91,93,97)	0 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	NEU [D0] Below (N=102,104,102,100,101,102)	0 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	NEU [D0] Within (N=102,104,102,100,101,102)	98 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	NEU [D0] Above (N=102,104,102,100,101,102)	3 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	NEU [D0] Unknown (N=102,104,102,100,101,102)	0 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	NEU [D7] Below (N=101,100,98,97,97,97)	1 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	NEU [D7] Within (N=101,100,98,97,97,97)	93 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	NEU [D7] Above (N=101,100,98,97,97,97)	3 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	NEU [D7] Unknown (N=101,100,98,97,97,97)	0 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	NEU [D21] Below (N=101,100,97,97,99,99)	2 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	NEU [D21] Within (N=101,100,97,97,99,99)	92 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	NEU [D21] Above (N=101,100,97,97,99,99)	3 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	NEU [D21] Unknown (N=101,100,97,97,99,99)	2 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	NEU [D28] Below (N=101,98,96,98,98,97)	3 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	NEU [D28] Within (N=101,98,96,98,98,97)	93 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	NEU [D28] Above (N=101,98,96,98,98,97)	1 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	NEU [D28] Unknown (N=101,98,96,98,98,97)	1 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	NEU [D42] Below (N=101,97,95,95,96,97)	1 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	NEU [D42] Within (N=101,97,95,95,96,97)	93 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	NEU [D42] Above (N=101,97,95,95,96,97)	2 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	NEU [D42] Unknown (N=101,97,95,95,96,97)	0 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	NEU [D63] Below (N=100,95,95,95,97,97)	3 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	NEU [D63] Within (N=100,95,95,95,97,97)	92 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	NEU [D63] Above (N=100,95,95,95,97,97)	2 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	MON [D21] Above (N=101,100,97,97,99,99)	0 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	MON [D21] Within (N=101,100,97,97,99,99)	75 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	MON [D21] Below (N=101,100,97,97,99,99)	20 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	MON [D7] Unknown (N=102,101,100,99,100,99)	0 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	PLA [D7] Unknown (N=102,101,100,99,100,99)	0 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	MON [D7] Above (N=102,101,100,99,100,99)	0 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	NEU [D7] Below (N=101,100,98,97,97,97)	3 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	MON [D7] Within (N=102,101,100,99,100,99)	77 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	MON [D0] Unknown (N=102,104,102,100,101,102)	0 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	MON [D0] Above (N=102,104,102,100,101,102)	0 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	PLA [D7] Above (N=102,101,100,99,100,99)	0 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	NEU [D7] Within (N=101,100,98,97,97,97)	91 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	MON [D0] Within (N=102,104,102,100,101,102)	79 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	MON [D0] Below (N=102,104,102,100,101,102)	23 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	LYM [D182] Unknown (N=99,91,88,91,93,97)	1 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	LYM [D182] Above (N=99,91,88,91,93,97)	1 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	PLA [D7] Within (N=102,101,100,99,100,99)	99 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	NEU [D7] Above (N=101,100,98,97,97,97)	3 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	LYM [D182] Within (N=99,91,88,91,93,97)	95 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	LYM [D182] Below (N=99,91,88,91,93,97)	0 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	LYM [D63] Unknown (N=100,95,95,95,97,97)	0 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	LYM [D63] Within (N=100,95,95,95,97,97)	96 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	NEU [D63] Above (N=100,95,95,95,97,97)	4 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	NEU [D7] Unknown (N=101,100,98,97,97,97)	0 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	LYM [D63] Below (N=100,95,95,95,97,97)	0 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	LYM [D42] Unknown (N=101,97,95,95,96,97)	0 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	LYM [D42] Above (N=101,97,95,95,96,97)	0 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	LYM [D42] Within (N=101,97,95,95,96,97)	97 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	NEU [D63] Below (N=100,95,95,95,97,97)	5 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	NEU [D21] Below (N=101,100,97,97,99,99)	4 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	LYM [D42] Below (N=101,97,95,95,96,97)	0 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	LYM [D28] Unknown (N=101,98,96,98,98,97)	3 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	LYM [D28] Above (N=101,98,96,98,98,97)	1 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	LYM [D28] Within (N=101,98,96,98,98,97)	93 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	PLA [D7] Below (N=102,101,100,99,100,99)	0 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	NEU [D21] Within (N=101,100,97,97,99,99)	88 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	LYM [D28] Below (N=101,98,96,98,98,97)	0 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	LYM [D21] Unknown (N=101,100,97,97,99,99)	4 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	LYM [D21] Above (N=101,100,97,97,99,99)	1 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	LYM [D21] Within (N=101,100,97,97,99,99)	94 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	PLA [D0] Unknown (N=102,104,102,100,101,102)	0 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	LYM [D21] Below (N=101,100,97,97,99,99)	0 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	LYM [D7] Unknown (N=102,101,100,99,100,99)	0 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	PLA [D0] Above (N=102,104,102,100,101,102)	0 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	NEU [D21] Unknown (N=101,100,97,97,99,99)	4 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	LYM [D7] Above (N=102,101,100,99,100,99)	0 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	LYM [D7] Within (N=102,101,100,99,100,99)	98 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	LYM [D7] Below (N=102,101,100,99,100,99)	1 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	LYM [D0] Unknown (N=102,104,102,100,101,102)	0 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	PLA [D0] Within (N=102,104,102,100,101,102)	101 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	NEU [D28] Below (N=101,98,96,98,98,97)	2 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	LYM [D0] Above (N=102,104,102,100,101,102)	1 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	LYM [D0] Within (N=102,104,102,100,101,102)	101 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	LYM [D0] Below (N=102,104,102,100,101,102)	0 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	NEU [D21] Above (N=101,100,97,97,99,99)	3 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	NEU [D182] Below (N=99,91,88,91,93,97)	6 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	NEU [D28] Within (N=101,98,96,98,98,97)	91 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	MON [D182] Above (N=99,91,88,91,93,97)	0 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	MON [D28] Within (N=101,98,96,98,98,97)	75 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	MON [D7] Below (N=102,101,100,99,100,99)	22 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	LYM [D63] Above (N=100,95,95,95,97,97)	1 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	NEU [D63] Within (N=100,95,95,95,97,97)	88 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	NEU [D28] Above (N=101,98,96,98,98,97)	1 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	PLA [D182] Unknown (N=99,91,88,91,93,97)	0 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	PLA [D182] Above (N=99,91,88,91,93,97)	1 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	PLA [D182] Within (N=99,91,88,91,93,97)	95 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	PLA [D182] Below (N=99,91,88,91,93,97)	1 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	PLA [D0] Below (N=102,104,102,100,101,102)	1 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	NEU [D28] Unknown (N=101,98,96,98,98,97)	3 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	PLA [D63] Unknown (N=100,95,95,95,97,97)	0 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	PLA [D63] Above (N=100,95,95,95,97,97)	0 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	PLA [D63] Within (N=100,95,95,95,97,97)	96 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	PLA [D63] Below (N=100,95,95,95,97,97)	1 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	NEU [D182] Unknown (N=99,91,88,91,93,97)	1 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	NEU [D42] Below (N=101,97,95,95,96,97)	2 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	PLA [D42] Unknown (N=101,97,95,95,96,97)	0 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	PLA [D42] Above (N=101,97,95,95,96,97)	0 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	PLA [D42] Within (N=101,97,95,95,96,97)	97 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	PLA [D42] Below (N=101,97,95,95,96,97)	0 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	NEU [D182] Above (N=99,91,88,91,93,97)	1 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	NEU [D42] Within (N=101,97,95,95,96,97)	93 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	PLA [D28] Unknown (N=101,98,96,98,98,97)	3 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	PLA [D28] Above (N=101,98,96,98,98,97)	0 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	PLA [D28] Within (N=101,98,96,98,98,97)	94 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	PLA [D28] Below (N=101,98,96,98,98,97)	0 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	NEU [D182] Within (N=99,91,88,91,93,97)	89 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	NEU [D42] Above (N=101,97,95,95,96,97)	2 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	PLA [D21] Unknown (N=101,100,97,97,99,99)	3 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	PLA [D21] Above (N=101,100,97,97,99,99)	0 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	MON [D182] Unknown (N=99,91,88,91,93,97)	1 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	MON [D182] Within (N=99,91,88,91,93,97)	73 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	MON [D182] Below (N=99,91,88,91,93,97)	23 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	PLA [D21] Within (N=101,100,97,97,99,99)	96 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	NEU [D0] Below (N=102,104,102,100,101,102)	4 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	MON [D63] Unknown (N=100,95,95,95,97,97)	0 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	MON [D63] Above (N=100,95,95,95,97,97)	0 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	MON [D63] Within (N=100,95,95,95,97,97)	79 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	MON [D63] Below (N=100,95,95,95,97,97)	18 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	NEU [D63] Unknown (N=100,95,95,95,97,97)	0 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	NEU [D0] Within (N=102,104,102,100,101,102)	93 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	MON [D42] Unknown (N=101,97,95,95,96,97)	0 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	MON [D42] Above (N=101,97,95,95,96,97)	0 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	MON [D42] Within (N=101,97,95,95,96,97)	77 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	MON [D42] Below (N=101,97,95,95,96,97)	20 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	NEU [D42] Unknown (N=101,97,95,95,96,97)	0 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	NEU [D0] Above (N=102,104,102,100,101,102)	5 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	MON [D28] Unknown (N=101,98,96,98,98,97)	3 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	MON [D28] Above (N=101,98,96,98,98,97)	0 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	MON [D28] Below (N=101,98,96,98,98,97)	19 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	MON [D21] Unknown (N=101,100,97,97,99,99)	4 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	PLA [D21] Below (N=101,100,97,97,99,99)	0 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	NEU [D0] Unknown (N=102,104,102,100,101,102)	0 Subjects

Secondary

Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed

Laboratory parameters assessed were alanine aminotransferase (ALAT), aspartate aminotransferase (ASAT), alkaline phosphatase (AP), bilirubin (BIL) (total (T)), basophils (BAS). For each parameter and for each range it was assessed whether the values of the subjects were in unkown, above, below or within the range.

Time frame: On Days 0, 7, 21, 28, 42, 63 and 182

Population: The Total Vaccinated Cohort included all vaccinated subjects.

Arm	Measure	Group	Value (NUMBER)
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL T [D28] Above (N=101,98,96,98,98,97)	1 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL T [D28] Within (N=101,98,96,98,98,97)	99 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ALAT [D182] Below (N=99,91,88,91,93,97)	0 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BAS [D42] Below (N=101,97,95,95,96,97)	0 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BAS [D28] Within (N=101,98,96,98,98,97)	99 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BAS [D21] Above (N=101,100,97,97,99,99)	0 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ALAT [D182] Above (N=99,91,88,91,93,97)	2 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BAS [D7] Above (N=102,101,100,99,100,99)	0 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BAS [D7] Within (N=102,101,100,99,100,99)	102 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ASAT [D63] Within (N=100,95,95,95,97,97)	98 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ASAT [D0] Within (N=102,104,102,100,101,102)	101 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	AP [D28] Below (N=101,98,96,98,98,97)	0 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	AP [D7] Below (N=102,101,100,99,100,99)	0 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BAS [D21] Unknown (N=101,100,97,97,99,99)	0 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	AP [D21] Below (N=101,100,97,97,99,99)	0 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL T [D0] Below (N=102,104,102,100,101,102)	0 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ASAT [D182] Below (N=99,91,88,91,93,97)	0 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ASAT [D63] Above (N=100,95,95,95,97,97)	1 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ASAT [D42] Below (N=101,97,95,95,96,97)	0 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ASAT [D28] Above (N=101,98,96,98,98,97)	4 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BAS [D28] Unknown (N=101,98,96,98,98,97)	2 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BAS [D182] Within (N=99,91,88,91,93,97)	99 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ASAT [D28] Within (N=101,98,96,98,98,97)	96 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ASAT [D28] Below (N=101,98,96,98,98,97)	0 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ASAT [D21] Above (N=101,100,97,97,99,99)	2 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ASAT [D21] Below (N=101,100,97,97,99,99)	0 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BAS [D63] Unknown (N=100,95,95,95,97,97)	0 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BAS [D182] Below (N=99,91,88,91,93,97)	0 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ASAT [D7] Above (N=102,101,100,99,100,99)	3 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ASAT [D7] Within (N=102,101,100,99,100,99)	99 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ALAT [D0] Below (N=102,101,102,100,101,102)	0 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BAS [D63] Within (N=100,95,95,95,97,97)	100 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	AP [D182] Below (N=99,91,88,91,93,97)	0 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	AP [D63] Above (N=100,95,95,95,97,97)	0 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	AP [D63] Within (N=100,95,95,95,97,97)	99 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ASAT [D63] Unknown (N=100,95,95,95,97,97)	1 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	AP [D63] Below (N=100,95,95,95,97,97)	0 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	AP [D42] Above (N=101,97, 95,95,96,97)	2 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	AP [D42] Within (N=101,97, 95,95,96,97)	99 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	AP [D7] Above (N=102,101,100,99,100,99)	1 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL T [D7] Unknown (N=102,101,100,99,100,99)	0 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	AP [D7] Within (N=102,101,100,99,100,99)	101 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	AP [D0] Above (N=102,104, 102,100,101,102)	0 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	AP [D0] Within (N=102,104, 102,100,101,102)	102 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	AP [D0] Below (N=102,104, 102,100,101,102)	0 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ALAT [D28] Below (N=101,98,96,98,98,97)	0 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ALAT [D21] Below (N=101,100,97,97,99,99)	0 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ALAT [D7] Within (N=102,101,100,99,100,99)	100 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ALAT [D7] Below (N=102,101,100,99,100,99)	0 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ALAT [D0] Above (N=102,101,102,100,101,102)	2 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ALAT [D28] Within (N=101,98,96,98,98,97)	96 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BAS [D63] Below (N=100,95,95,95,97,97)	0 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ALAT [D0] Within (N=102,101,102,100,101,102)	100 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL T [D42] Unknown (N=101,97,95,95,96,97)	0 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ALAT [D28] Above (N=101,98,96,98,98,97)	4 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BAS [D42] Above (N=101,97,95,95,96,97)	0 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BAS [D7] Unknown (N=102,101,100,99,100,99)	0 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ASAT [D42] Unknown (N=101,97,95,95,96,97)	0 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ASAT [D7] Unknown (N=102,101,100,99,100,99)	0 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	AP [D63] Unknown (N=100,95,95,95,97,97)	1 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ALAT [D42] Within (N=101,97,95,95,96,97)	97 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BAS [D28] Below (N=101,98,96,98,98,97)	0 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	AP [D42] Unknown (N=101,97, 95,95,96,97)	0 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	AP [D7] Unknown (N=102,101,100,99,100,99)	0 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BAS [D21] Within (N=101,100,97,97,99,99)	101 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	AP [D0] Unknown (N=102,104, 102,100,101,102)	0 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ALAT [D182] Unknown (N=99,91,88,91,93,97)	0 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ALAT [D28] Unknown (N=101,98,96,98,98,97)	1 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ALAT [D21] Unknown (N=101,100,97,97,99,99)	0 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ALAT [D63] Below (N=100,95,95,95,97,97)	0 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ASAT [D182] Unknown (N=99,91,88,91,93,97)	1 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL T [D182] Above (N=99,91,88,91,93,97)	0 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL T [D63] Above (N=100,95,95,95,97,97)	1 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL T [D42] Above (N=101,97,95,95,96,97)	3 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ALAT [D63] Above (N=100,95,95,95,97,97)	6 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ASAT [D182] Within (N=99,91,88,91,93,97)	96 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL T [D42] Within (N=101,97,95,95,96,97)	98 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL T [D42] Below (N=101,97,95,95,96,97)	0 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ALAT [D21] Within (N=101,100,97,97,99,99)	96 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ALAT [D21] Above (N=101,100,97,97,99,99)	5 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BAS [D0] Above (N=102,104,102,100,101,102)	0 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ALAT [D63] Unknown (N=100,95,95,95,97,97)	1 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ASAT [D182] Above (N=99,91,88,91,93,97)	2 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL T [D21] Above (N=101,100,97,97,99,99)	2 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL T [D0] Unknown (N=102,104,102,100,101,102)	0 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BAS [D63] Above (N=100,95,95,95,97,97)	0 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL T [D63] Unknown (N=100,95,95,95,97,97)	1 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	AP [D28] Above (N=101,98,96,98,98,97)	1 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BAS [D28] Above (N=101,98,96,98,98,97)	0 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL T [D28] Below (N=101,98,96,98,98,97)	0 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ASAT [D7] Below (N=102,101,100,99,100,99)	0 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ALAT [D42] Unknown (N=101,97,95,95,96,97)	0 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ALAT [D182] Within (N=99,91,88,91,93,97)	97 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ALAT [D7] Unknown (N=102,101,100,99,100,99)	0 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	AP [D182] Within (N=99,91,88,91,93,97)	98 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL T [D63] Below (N=100,95,95,95,97,97)	0 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL T [D182] Unknown (N=99,91,88,91,93,97)	0 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BAS [D21] Below (N=101,100,97,97,99,99)	0 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL T [D28] Unknown (N=101,98,96,98,98,97)	1 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ALAT [D0] Unknown (N=102,101,102,100,101,102)	0 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ALAT [D42] Below (N=101,97,95,95,96,97)	0 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL T [D63] Within (N=100,95,95,95,97,97)	98 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BAS [D42] Unknown (N=101,97,95,95,96,97)	0 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BAS [D0] Within (N=102,104,102,100,101,102)	100 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL T [D182] Within (N=99,91,88,91,93,97)	99 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL T [D182] Below (N=99,91,88,91,93,97)	0 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL T [D0] Within (N=102,104,102,100,101,102)	101 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BAS [D0] Below (N=102,104,102,100,101,102)	0 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	AP [D28] Within (N=101,98,96,98,98,97)	99 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	AP [D21] Within (N=101,100,97,97,99,99)	101 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ASAT [D21] Within (N=101,100,97,97,99,99)	99 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	AP [D21] Above (N=101,100,97,97,99,99)	0 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ASAT [D0] Below (N=102,104,102,100,101,102)	0 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ALAT [D42] Above (N=101,97,95,95,96,97)	4 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL T [D0] Above (N=102,104,102,100,101,102)	1 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	AP [D42] Below (N=101,97, 95,95,96,97)	0 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BAS [D0] Unknown (N=102,104,102,100,101,102)	2 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ASAT [D28] Unknown (N=101,98,96,98,98,97)	1 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BAS [D182] Unknown (N=99,91,88,91,93,97)	0 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ASAT [D21] Unknown (N=101,100,97,97,99,99)	0 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ALAT [D63] Within (N=100,95,95,95,97,97)	93 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ASAT [D42] Within (N=101,97,95,95,96,97)	95 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BAS [D182] Above (N=99,91,88,91,93,97)	0 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ASAT [D0] Unknown (N=102,104,102,100,101,102)	0 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	AP [D182] Above (N=99,91,88,91,93,97)	1 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	AP [D182] Unknown (N=99,91,88,91,93,97)	0 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BAS [D7] Below (N=102,101,100,99,100,99)	0 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL T [D7] Above (N=102,101,100,99,100,99)	1 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ASAT [D0] Above (N=102,104,102,100,101,102)	1 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ASAT [D42] Above (N=101,97,95,95,96,97)	6 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL T [D21] Unknown (N=101,100,97,97,99,99)	0 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL T [D7] Within (N=102,101,100,99,100,99)	101 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL T [D7] Below (N=102,101,100,99,100,99)	0 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL T [D21] Below (N=101,100,97,97,99,99)	0 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ALAT [D7] Above (N=102,101,100,99,100,99)	2 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	AP [D28] Unknown (N=101,98,96,98,98,97)	1 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	AP [D21] Unknown (N=101,100,97,97,99,99)	0 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ASAT [D63] Below (N=100,95,95,95,97,97)	0 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BAS [D42] Within (N=101,97,95,95,96,97)	101 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL T [D21] Within (N=101,100,97,97,99,99)	99 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	AP [D7] Unknown (N=102,101,100,99,100,99)	0 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ALAT [D21] Above (N=101,100,97,97,99,99)	3 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	AP [D182] Within (N=99,91,88,91,93,97)	90 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	AP [D42] Below (N=101,97, 95,95,96,97)	0 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ALAT [D63] Within (N=100,95,95,95,97,97)	89 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	AP [D28] Above (N=101,98,96,98,98,97)	1 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ALAT [D182] Below (N=99,91,88,91,93,97)	0 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ALAT [D182] Within (N=99,91,88,91,93,97)	89 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ALAT [D182] Above (N=99,91,88,91,93,97)	1 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	AP [D28] Within (N=101,98,96,98,98,97)	97 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	AP [D21] Above (N=101,100,97,97,99,99)	0 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BAS [D182] Unknown (N=99,91,88,91,93,97)	0 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL T [D0] Above (N=102,104,102,100,101,102)	2 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL T [D7] Below (N=102,101,100,99,100,99)	0 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL T [D63] Unknown (N=100,95,95,95,97,97)	1 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL T [D7] Within (N=102,101,100,99,100,99)	100 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL T [D7] Above (N=102,101,100,99,100,99)	1 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BAS [D63] Below (N=100,95,95,95,97,97)	0 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL T [D21] Below (N=101,100,97,97,99,99)	0 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL T [D21] Within (N=101,100,97,97,99,99)	97 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL T [D182] Unknown (N=99,91,88,91,93,97)	1 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL T [D21] Above (N=101,100,97,97,99,99)	3 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BAS [D28] Above (N=101,98,96,98,98,97)	0 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL T [D28] Below (N=101,98,96,98,98,97)	0 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BAS [D63] Within (N=100,95,95,95,97,97)	95 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BAS [D28] Below (N=101,98,96,98,98,97)	0 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL T [D63] Below (N=100,95,95,95,97,97)	0 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BAS [D0] Within (N=102,104,102,100,101,102)	104 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BAS [D42] Within (N=101,97,95,95,96,97)	97 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL T [D182] Below (N=99,91,88,91,93,97)	0 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL T [D28] Unknown (N=101,98,96,98,98,97)	0 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BAS [D0] Below (N=102,104,102,100,101,102)	0 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ALAT [D0] Unknown (N=102,101,102,100,101,102)	0 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BAS [D21] Below (N=101,100,97,97,99,99)	0 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ASAT [D182] Above (N=99,91,88,91,93,97)	4 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ALAT [D42] Unknown (N=101,97,95,95,96,97)	0 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ALAT [D63] Unknown (N=100,95,95,95,97,97)	1 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BAS [D63] Above (N=100,95,95,95,97,97)	0 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ASAT [D63] Below (N=100,95,95,95,97,97)	0 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ASAT [D42] Above (N=101,97,95,95,96,97)	2 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	AP [D28] Unknown (N=101,98,96,98,98,97)	0 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	AP [D182] Unknown (N=99,91,88,91,93,97)	1 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ASAT [D0] Unknown (N=102,104,102,100,101,102)	0 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ASAT [D42] Within (N=101,97,95,95,96,97)	95 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ASAT [D21] Unknown (N=101,100,97,97,99,99)	0 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BAS [D182] Above (N=99,91,88,91,93,97)	0 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ASAT [D28] Unknown (N=101,98,96,98,98,97)	0 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BAS [D0] Unknown (N=102,104,102,100,101,102)	0 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ASAT [D21] Within (N=101,100,97,97,99,99)	99 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL T [D21] Unknown (N=101,100,97,97,99,99)	0 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ASAT [D7] Below (N=102,101,100,99,100,99)	0 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BAS [D0] Above (N=102,104,102,100,101,102)	0 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ASAT [D0] Above (N=102,104,102,100,101,102)	2 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ASAT [D0] Below (N=102,104,102,100,101,102)	0 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ALAT [D7] Above (N=102,101,100,99,100,99)	5 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ALAT [D21] Below (N=101,100,97,97,99,99)	0 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL T [D0] Within (N=102,104,102,100,101,102)	102 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ALAT [D21] Within (N=101,100,97,97,99,99)	97 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	AP [D182] Above (N=99,91,88,91,93,97)	0 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	AP [D21] Unknown (N=101,100,97,97,99,99)	0 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ASAT [D63] Unknown (N=100,95,95,95,97,97)	1 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BAS [D21] Unknown (N=101,100,97,97,99,99)	1 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BAS [D28] Unknown (N=101,98,96,98,98,97)	2 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BAS [D63] Unknown (N=100,95,95,95,97,97)	0 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ALAT [D0] Below (N=102,101,102,100,101,102)	0 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ALAT [D0] Within (N=102,101,102,100,101,102)	101 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ALAT [D7] Within (N=102,101,100,99,100,99)	96 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ALAT [D28] Within (N=101,98,96,98,98,97)	96 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ALAT [D42] Below (N=101,97,95,95,96,97)	0 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ALAT [D42] Within (N=101,97,95,95,96,97)	94 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ALAT [D42] Above (N=101,97,95,95,96,97)	3 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ALAT [D63] Below (N=100,95,95,95,97,97)	0 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ALAT [D63] Above (N=100,95,95,95,97,97)	5 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	AP [D7] Below (N=102,101,100,99,100,99)	0 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	AP [D21] Below (N=101,100,97,97,99,99)	0 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	AP [D21] Within (N=101,100,97,97,99,99)	100 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	AP [D28] Below (N=101,98,96,98,98,97)	0 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	AP [D42] Above (N=101,97, 95,95,96,97)	0 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ASAT [D0] Within (N=102,104,102,100,101,102)	102 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ASAT [D63] Within (N=100,95,95,95,97,97)	94 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BAS [D7] Below (N=102,101,100,99,100,99)	0 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BAS [D21] Above (N=101,100,97,97,99,99)	0 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BAS [D28] Within (N=101,98,96,98,98,97)	96 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BAS [D42] Below (N=101,97,95,95,96,97)	0 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL T [D28] Within (N=101,98,96,98,98,97)	96 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL T [D28] Above (N=101,98,96,98,98,97)	2 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL T [D42] Below (N=101,97,95,95,96,97)	0 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL T [D42] Within (N=101,97,95,95,96,97)	93 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL T [D42] Above (N=101,97,95,95,96,97)	4 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL T [D63] Within (N=100,95,95,95,97,97)	92 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL T [D63] Above (N=100,95,95,95,97,97)	2 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL T [D182] Within (N=99,91,88,91,93,97)	87 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL T [D182] Above (N=99,91,88,91,93,97)	3 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ALAT [D7] Unknown (N=102,101,100,99,100,99)	0 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ALAT [D21] Unknown (N=101,100,97,97,99,99)	0 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ALAT [D28] Unknown (N=101,98,96,98,98,97)	0 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ALAT [D182] Unknown (N=99,91,88,91,93,97)	1 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	AP [D0] Unknown (N=102,104, 102,100,101,102)	0 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	AP [D42] Unknown (N=101,97, 95,95,96,97)	0 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	AP [D63] Unknown (N=100,95,95,95,97,97)	1 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ASAT [D7] Unknown (N=102,101,100,99,100,99)	0 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ASAT [D42] Unknown (N=101,97,95,95,96,97)	0 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ASAT [D182] Unknown (N=99,91,88,91,93,97)	1 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BAS [D7] Unknown (N=102,101,100,99,100,99)	1 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BAS [D42] Unknown (N=101,97,95,95,96,97)	0 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BAS [D7] Within (N=102,101,100,99,100,99)	100 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BAS [D7] Above (N=102,101,100,99,100,99)	0 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ALAT [D0] Above (N=102,101,102,100,101,102)	3 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ALAT [D7] Below (N=102,101,100,99,100,99)	0 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ALAT [D28] Below (N=101,98,96,98,98,97)	0 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ALAT [D28] Above (N=101,98,96,98,98,97)	2 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	AP [D0] Below (N=102,104, 102,100,101,102)	0 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	AP [D0] Within (N=102,104, 102,100,101,102)	104 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	AP [D0] Above (N=102,104, 102,100,101,102)	0 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	AP [D7] Within (N=102,101,100,99,100,99)	101 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	AP [D7] Above (N=102,101,100,99,100,99)	0 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	AP [D42] Within (N=101,97, 95,95,96,97)	97 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	AP [D63] Below (N=100,95,95,95,97,97)	0 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	AP [D63] Within (N=100,95,95,95,97,97)	94 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	AP [D63] Above (N=100,95,95,95,97,97)	0 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	AP [D182] Below (N=99,91,88,91,93,97)	0 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ASAT [D7] Within (N=102,101,100,99,100,99)	99 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ASAT [D7] Above (N=102,101,100,99,100,99)	2 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ASAT [D21] Below (N=101,100,97,97,99,99)	0 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ASAT [D21] Above (N=101,100,97,97,99,99)	1 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ASAT [D28] Below (N=101,98,96,98,98,97)	0 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ASAT [D28] Within (N=101,98,96,98,98,97)	97 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ASAT [D28] Above (N=101,98,96,98,98,97)	1 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ASAT [D42] Below (N=101,97,95,95,96,97)	0 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ASAT [D63] Above (N=100,95,95,95,97,97)	0 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ASAT [D182] Below (N=99,91,88,91,93,97)	0 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ASAT [D182] Within (N=99,91,88,91,93,97)	86 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BAS [D21] Within (N=101,100,97,97,99,99)	99 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BAS [D42] Above (N=101,97,95,95,96,97)	0 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BAS [D182] Below (N=99,91,88,91,93,97)	0 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BAS [D182] Within (N=99,91,88,91,93,97)	91 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL T [D0] Below (N=102,104,102,100,101,102)	0 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL T [D0] Unknown (N=102,104,102,100,101,102)	0 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL T [D7] Unknown (N=102,101,100,99,100,99)	0 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL T [D42] Unknown (N=101,97,95,95,96,97)	0 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ALAT [D42] Within (N=101,97,95,95,96,97)	93 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL T [D28] Above (N=101,98,96,98,98,97)	2 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ASAT [D182] Within (N=99,91,88,91,93,97)	87 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL T [D42] Below (N=101,97,95,95,96,97)	0 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ALAT [D63] Above (N=100,95,95,95,97,97)	1 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL T [D42] Within (N=101,97,95,95,96,97)	92 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL T [D63] Within (N=100,95,95,95,97,97)	92 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL T [D63] Above (N=100,95,95,95,97,97)	2 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BAS [D21] Within (N=101,100,97,97,99,99)	94 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL T [D182] Within (N=99,91,88,91,93,97)	86 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ALAT [D63] Below (N=100,95,95,95,97,97)	0 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL T [D182] Above (N=99,91,88,91,93,97)	2 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ALAT [D7] Unknown (N=102,101,100,99,100,99)	0 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ALAT [D21] Unknown (N=101,100,97,97,99,99)	0 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ALAT [D28] Unknown (N=101,98,96,98,98,97)	0 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ALAT [D182] Unknown (N=99,91,88,91,93,97)	0 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ALAT [D42] Above (N=101,97,95,95,96,97)	1 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	AP [D0] Unknown (N=102,104, 102,100,101,102)	1 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	AP [D42] Unknown (N=101,97, 95,95,96,97)	1 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ASAT [D63] Unknown (N=100,95,95,95,97,97)	2 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	AP [D63] Unknown (N=100,95,95,95,97,97)	1 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ASAT [D7] Unknown (N=102,101,100,99,100,99)	1 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ASAT [D42] Unknown (N=101,97,95,95,96,97)	1 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ASAT [D182] Unknown (N=99,91,88,91,93,97)	1 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ALAT [D42] Below (N=101,97,95,95,96,97)	0 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BAS [D7] Unknown (N=102,101,100,99,100,99)	0 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BAS [D42] Unknown (N=101,97,95,95,96,97)	0 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL T [D42] Unknown (N=101,97,95,95,96,97)	1 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BAS [D7] Within (N=102,101,100,99,100,99)	100 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BAS [D182] Below (N=99,91,88,91,93,97)	0 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BAS [D7] Above (N=102,101,100,99,100,99)	0 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ALAT [D28] Within (N=101,98,96,98,98,97)	94 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ALAT [D0] Above (N=102,101,102,100,101,102)	2 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ALAT [D7] Below (N=102,101,100,99,100,99)	0 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ALAT [D28] Below (N=101,98,96,98,98,97)	0 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ALAT [D28] Above (N=101,98,96,98,98,97)	2 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	AP [D0] Below (N=102,104, 102,100,101,102)	0 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BAS [D182] Within (N=99,91,88,91,93,97)	88 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	AP [D0] Within (N=102,104, 102,100,101,102)	100 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	AP [D0] Above (N=102,104, 102,100,101,102)	1 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ALAT [D7] Within (N=102,101,100,99,100,99)	99 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	AP [D7] Within (N=102,101,100,99,100,99)	100 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	AP [D7] Above (N=102,101,100,99,100,99)	0 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	AP [D42] Within (N=101,97, 95,95,96,97)	94 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ALAT [D0] Within (N=102,101,102,100,101,102)	99 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	AP [D63] Below (N=100,95,95,95,97,97)	0 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	AP [D63] Within (N=100,95,95,95,97,97)	93 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	AP [D63] Above (N=100,95,95,95,97,97)	1 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ALAT [D0] Below (N=102,101,102,100,101,102)	0 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL T [D0] Unknown (N=102,104,102,100,101,102)	1 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	AP [D182] Below (N=99,91,88,91,93,97)	0 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ASAT [D7] Within (N=102,101,100,99,100,99)	97 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BAS [D63] Unknown (N=100,95,95,95,97,97)	0 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ASAT [D7] Above (N=102,101,100,99,100,99)	2 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ASAT [D21] Below (N=101,100,97,97,99,99)	0 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ASAT [D21] Above (N=101,100,97,97,99,99)	0 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BAS [D28] Unknown (N=101,98,96,98,98,97)	0 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL T [D7] Unknown (N=102,101,100,99,100,99)	0 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ASAT [D28] Within (N=101,98,96,98,98,97)	93 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ASAT [D28] Above (N=101,98,96,98,98,97)	3 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	AP [D7] Below (N=102,101,100,99,100,99)	0 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ASAT [D63] Above (N=100,95,95,95,97,97)	1 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	AP [D21] Below (N=101,100,97,97,99,99)	0 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	AP [D21] Within (N=101,100,97,97,99,99)	96 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	AP [D28] Below (N=101,98,96,98,98,97)	0 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	AP [D42] Above (N=101,97, 95,95,96,97)	0 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BAS [D21] Unknown (N=101,100,97,97,99,99)	3 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ASAT [D0] Within (N=102,104,102,100,101,102)	100 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ASAT [D7] Below (N=102,101,100,99,100,99)	0 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ASAT [D28] Below (N=101,98,96,98,98,97)	0 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ASAT [D63] Below (N=100,95,95,95,97,97)	0 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL T [D28] Unknown (N=101,98,96,98,98,97)	0 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ASAT [D182] Below (N=99,91,88,91,93,97)	0 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BAS [D7] Below (N=102,101,100,99,100,99)	0 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BAS [D21] Below (N=101,100,97,97,99,99)	0 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BAS [D21] Above (N=101,100,97,97,99,99)	0 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BAS [D28] Within (N=101,98,96,98,98,97)	96 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	AP [D21] Unknown (N=101,100,97,97,99,99)	0 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BAS [D42] Within (N=101,97,95,95,96,97)	95 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ASAT [D42] Above (N=101,97,95,95,96,97)	1 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BAS [D0] Above (N=102,104,102,100,101,102)	0 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL T [D21] Below (N=101,100,97,97,99,99)	0 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	AP [D28] Above (N=101,98,96,98,98,97)	1 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	AP [D28] Unknown (N=101,98,96,98,98,97)	0 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL T [D21] Unknown (N=101,100,97,97,99,99)	0 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL T [D7] Above (N=102,101,100,99,100,99)	3 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ASAT [D42] Within (N=101,97,95,95,96,97)	93 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL T [D7] Within (N=102,101,100,99,100,99)	97 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ALAT [D21] Within (N=101,100,97,97,99,99)	96 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	AP [D182] Unknown (N=99,91,88,91,93,97)	0 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL T [D28] Within (N=101,98,96,98,98,97)	94 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BAS [D42] Above (N=101,97,95,95,96,97)	0 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ASAT [D0] Unknown (N=102,104,102,100,101,102)	1 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL T [D63] Unknown (N=100,95,95,95,97,97)	1 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ALAT [D63] Within (N=100,95,95,95,97,97)	93 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL T [D7] Below (N=102,101,100,99,100,99)	0 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL T [D42] Above (N=101,97,95,95,96,97)	2 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	AP [D42] Below (N=101,97, 95,95,96,97)	0 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ASAT [D21] Unknown (N=101,100,97,97,99,99)	0 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ASAT [D0] Below (N=102,104,102,100,101,102)	0 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL T [D182] Unknown (N=99,91,88,91,93,97)	0 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL T [D0] Within (N=102,104,102,100,101,102)	100 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ASAT [D28] Unknown (N=101,98,96,98,98,97)	0 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BAS [D182] Above (N=99,91,88,91,93,97)	0 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ASAT [D42] Below (N=101,97,95,95,96,97)	0 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ASAT [D21] Within (N=101,100,97,97,99,99)	97 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL T [D0] Above (N=102,104,102,100,101,102)	1 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	AP [D182] Within (N=99,91,88,91,93,97)	88 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BAS [D0] Unknown (N=102,104,102,100,101,102)	0 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	AP [D182] Above (N=99,91,88,91,93,97)	0 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	AP [D21] Above (N=101,100,97,97,99,99)	1 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ALAT [D182] Above (N=99,91,88,91,93,97)	0 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BAS [D182] Unknown (N=99,91,88,91,93,97)	0 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL T [D182] Below (N=99,91,88,91,93,97)	0 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BAS [D0] Below (N=102,104,102,100,101,102)	0 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ASAT [D182] Above (N=99,91,88,91,93,97)	0 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BAS [D0] Within (N=102,104,102,100,101,102)	102 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ALAT [D182] Within (N=99,91,88,91,93,97)	88 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ALAT [D0] Unknown (N=102,101,102,100,101,102)	1 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BAS [D63] Within (N=100,95,95,95,97,97)	95 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ALAT [D7] Above (N=102,101,100,99,100,99)	1 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL T [D63] Below (N=100,95,95,95,97,97)	0 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BAS [D28] Below (N=101,98,96,98,98,97)	0 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ALAT [D21] Above (N=101,100,97,97,99,99)	1 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL T [D28] Below (N=101,98,96,98,98,97)	0 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	AP [D28] Within (N=101,98,96,98,98,97)	95 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ALAT [D42] Unknown (N=101,97,95,95,96,97)	1 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL T [D21] Above (N=101,100,97,97,99,99)	2 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BAS [D28] Above (N=101,98,96,98,98,97)	0 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ASAT [D63] Within (N=100,95,95,95,97,97)	92 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BAS [D42] Below (N=101,97,95,95,96,97)	0 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ASAT [D0] Above (N=102,104,102,100,101,102)	1 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ALAT [D63] Unknown (N=100,95,95,95,97,97)	1 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ALAT [D182] Below (N=99,91,88,91,93,97)	0 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL T [D21] Within (N=101,100,97,97,99,99)	95 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	AP [D7] Unknown (N=102,101,100,99,100,99)	0 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BAS [D63] Above (N=100,95,95,95,97,97)	0 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ALAT [D21] Below (N=101,100,97,97,99,99)	0 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL T [D0] Below (N=102,104,102,100,101,102)	0 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BAS [D63] Below (N=100,95,95,95,97,97)	0 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL T [D182] Unknown (N=99,91,88,91,93,97)	0 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BAS [D42] Above (N=101,97,95,95,96,97)	0 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BAS [D63] Below (N=100,95,95,95,97,97)	0 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BAS [D63] Within (N=100,95,95,95,97,97)	95 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BAS [D63] Above (N=100,95,95,95,97,97)	0 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BAS [D182] Above (N=99,91,88,91,93,97)	0 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL T [D0] Within (N=102,104,102,100,101,102)	98 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL T [D0] Above (N=102,104,102,100,101,102)	1 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL T [D7] Below (N=102,101,100,99,100,99)	0 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL T [D7] Within (N=102,101,100,99,100,99)	98 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL T [D7] Above (N=102,101,100,99,100,99)	1 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL T [D21] Below (N=101,100,97,97,99,99)	0 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL T [D21] Within (N=101,100,97,97,99,99)	96 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL T [D21] Above (N=101,100,97,97,99,99)	1 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL T [D42] Above (N=101,97,95,95,96,97)	4 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL T [D63] Below (N=100,95,95,95,97,97)	0 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL T [D63] Above (N=100,95,95,95,97,97)	1 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL T [D182] Below (N=99,91,88,91,93,97)	0 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ALAT [D0] Unknown (N=102,101,102,100,101,102)	1 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ALAT [D42] Unknown (N=101,97,95,95,96,97)	0 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ALAT [D63] Unknown (N=100,95,95,95,97,97)	0 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	AP [D7] Unknown (N=102,101,100,99,100,99)	0 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	AP [D21] Unknown (N=101,100,97,97,99,99)	0 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	AP [D28] Unknown (N=101,98,96,98,98,97)	1 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ASAT [D0] Unknown (N=102,104,102,100,101,102)	1 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ASAT [D21] Unknown (N=101,100,97,97,99,99)	0 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ASAT [D28] Unknown (N=101,98,96,98,98,97)	1 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BAS [D182] Unknown (N=99,91,88,91,93,97)	2 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL T [D63] Unknown (N=100,95,95,95,97,97)	0 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BAS [D0] Above (N=102,104,102,100,101,102)	0 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BAS [D7] Below (N=102,101,100,99,100,99)	0 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ALAT [D21] Below (N=101,100,97,97,99,99)	0 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ALAT [D21] Above (N=101,100,97,97,99,99)	1 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ALAT [D63] Within (N=100,95,95,95,97,97)	95 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ALAT [D182] Below (N=99,91,88,91,93,97)	0 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	AP [D21] Above (N=101,100,97,97,99,99)	1 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	AP [D28] Above (N=101,98,96,98,98,97)	2 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	AP [D182] Within (N=99,91,88,91,93,97)	90 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ASAT [D0] Within (N=102,104,102,100,101,102)	98 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ASAT [D0] Above (N=102,104,102,100,101,102)	1 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ASAT [D7] Below (N=102,101,100,99,100,99)	0 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ASAT [D21] Within (N=101,100,97,97,99,99)	97 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ASAT [D42] Below (N=101,97,95,95,96,97)	0 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ASAT [D42] Within (N=101,97,95,95,96,97)	95 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ASAT [D42] Above (N=101,97,95,95,96,97)	0 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ASAT [D182] Above (N=99,91,88,91,93,97)	3 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BAS [D0] Below (N=102,104,102,100,101,102)	0 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BAS [D28] Below (N=101,98,96,98,98,97)	0 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BAS [D28] Within (N=101,98,96,98,98,97)	96 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BAS [D28] Above (N=101,98,96,98,98,97)	0 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BAS [D42] Within (N=101,97,95,95,96,97)	95 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL T [D0] Below (N=102,104,102,100,101,102)	0 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL T [D21] Unknown (N=101,100,97,97,99,99)	0 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BAS [D42] Below (N=101,97,95,95,96,97)	0 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	AP [D0] Within (N=102,104, 102,100,101,102)	98 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ALAT [D182] Unknown (N=99,91,88,91,93,97)	0 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ALAT [D182] Above (N=99,91,88,91,93,97)	1 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ALAT [D7] Within (N=102,101,100,99,100,99)	97 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BAS [D182] Within (N=99,91,88,91,93,97)	89 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ASAT [D182] Unknown (N=99,91,88,91,93,97)	0 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	AP [D0] Above (N=102,104, 102,100,101,102)	1 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL T [D7] Unknown (N=102,101,100,99,100,99)	0 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BAS [D7] Within (N=102,101,100,99,100,99)	98 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	AP [D21] Within (N=101,100,97,97,99,99)	96 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ASAT [D182] Below (N=99,91,88,91,93,97)	0 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	AP [D7] Within (N=102,101,100,99,100,99)	98 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ASAT [D63] Above (N=100,95,95,95,97,97)	1 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ASAT [D28] Below (N=101,98,96,98,98,97)	0 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BAS [D42] Unknown (N=101,97,95,95,96,97)	0 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ASAT [D21] Above (N=101,100,97,97,99,99)	0 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL T [D182] Within (N=99,91,88,91,93,97)	89 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	AP [D7] Above (N=102,101,100,99,100,99)	1 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	AP [D28] Below (N=101,98,96,98,98,97)	0 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	AP [D21] Below (N=101,100,97,97,99,99)	0 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BAS [D7] Unknown (N=102,101,100,99,100,99)	1 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ASAT [D21] Below (N=101,100,97,97,99,99)	0 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	AP [D63] Unknown (N=100,95,95,95,97,97)	0 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ASAT [D7] Above (N=102,101,100,99,100,99)	0 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BAS [D21] Above (N=101,100,97,97,99,99)	0 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	AP [D42] Within (N=101,97, 95,95,96,97)	92 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BAS [D21] Unknown (N=101,100,97,97,99,99)	1 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ASAT [D7] Within (N=102,101,100,99,100,99)	99 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ALAT [D0] Within (N=102,101,102,100,101,102)	95 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL T [D0] Unknown (N=102,104,102,100,101,102)	1 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ASAT [D28] Within (N=101,98,96,98,98,97)	95 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BAS [D28] Unknown (N=101,98,96,98,98,97)	2 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	AP [D182] Unknown (N=99,91,88,91,93,97)	0 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	AP [D63] Below (N=100,95,95,95,97,97)	0 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ALAT [D63] Below (N=100,95,95,95,97,97)	0 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BAS [D63] Unknown (N=100,95,95,95,97,97)	0 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ALAT [D42] Within (N=101,97,95,95,96,97)	94 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	AP [D28] Within (N=101,98,96,98,98,97)	95 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL T [D63] Within (N=100,95,95,95,97,97)	94 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	AP [D63] Within (N=100,95,95,95,97,97)	92 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ASAT [D63] Within (N=100,95,95,95,97,97)	94 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	AP [D182] Below (N=99,91,88,91,93,97)	0 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ALAT [D0] Below (N=102,101,102,100,101,102)	0 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	AP [D63] Above (N=100,95,95,95,97,97)	3 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ASAT [D63] Below (N=100,95,95,95,97,97)	0 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL T [D42] Within (N=101,97,95,95,96,97)	91 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BAS [D0] Within (N=102,104,102,100,101,102)	98 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ALAT [D42] Above (N=101,97,95,95,96,97)	1 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ASAT [D63] Unknown (N=100,95,95,95,97,97)	0 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	AP [D42] Below (N=101,97, 95,95,96,97)	0 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ASAT [D182] Within (N=99,91,88,91,93,97)	88 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL T [D42] Below (N=101,97,95,95,96,97)	0 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BAS [D7] Above (N=102,101,100,99,100,99)	0 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ALAT [D63] Above (N=100,95,95,95,97,97)	0 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	AP [D42] Above (N=101,97, 95,95,96,97)	3 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL T [D28] Above (N=101,98,96,98,98,97)	2 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BAS [D182] Below (N=99,91,88,91,93,97)	0 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BAS [D21] Below (N=101,100,97,97,99,99)	0 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ALAT [D0] Above (N=102,101,102,100,101,102)	4 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ALAT [D28] Unknown (N=101,98,96,98,98,97)	1 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ASAT [D28] Above (N=101,98,96,98,98,97)	2 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ALAT [D21] Unknown (N=101,100,97,97,99,99)	0 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ASAT [D7] Unknown (N=102,101,100,99,100,99)	0 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	AP [D182] Above (N=99,91,88,91,93,97)	1 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ALAT [D7] Below (N=102,101,100,99,100,99)	0 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	AP [D42] Unknown (N=101,97, 95,95,96,97)	0 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL T [D28] Unknown (N=101,98,96,98,98,97)	1 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ALAT [D21] Within (N=101,100,97,97,99,99)	96 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL T [D28] Within (N=101,98,96,98,98,97)	95 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BAS [D0] Unknown (N=102,104,102,100,101,102)	2 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ALAT [D7] Unknown (N=102,101,100,99,100,99)	0 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ALAT [D28] Below (N=101,98,96,98,98,97)	0 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL T [D182] Above (N=99,91,88,91,93,97)	2 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ALAT [D28] Within (N=101,98,96,98,98,97)	93 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ALAT [D42] Below (N=101,97,95,95,96,97)	0 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ASAT [D42] Unknown (N=101,97,95,95,96,97)	0 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL T [D28] Below (N=101,98,96,98,98,97)	0 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ALAT [D28] Above (N=101,98,96,98,98,97)	4 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	AP [D7] Below (N=102,101,100,99,100,99)	0 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL T [D42] Unknown (N=101,97,95,95,96,97)	0 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ASAT [D0] Below (N=102,104,102,100,101,102)	0 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	AP [D0] Below (N=102,104, 102,100,101,102)	0 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BAS [D21] Within (N=101,100,97,97,99,99)	96 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ALAT [D7] Above (N=102,101,100,99,100,99)	2 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	AP [D0] Unknown (N=102,104, 102,100,101,102)	1 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ALAT [D182] Within (N=99,91,88,91,93,97)	90 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BAS [D182] Below (N=99,91,88,91,93,97)	0 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	AP [D28] Unknown (N=101,98,96,98,98,97)	0 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BAS [D28] Above (N=101,98,96,98,98,97)	0 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	AP [D42] Unknown (N=101,97, 95,95,96,97)	2 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	AP [D21] Within (N=101,100,97,97,99,99)	97 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	AP [D182] Unknown (N=99,91,88,91,93,97)	1 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ASAT [D0] Unknown (N=102,104,102,100,101,102)	1 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ALAT [D42] Below (N=101,97,95,95,96,97)	0 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ASAT [D21] Unknown (N=101,100,97,97,99,99)	0 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BAS [D63] Above (N=100,95,95,95,97,97)	0 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ASAT [D63] Above (N=100,95,95,95,97,97)	0 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ASAT [D182] Unknown (N=99,91,88,91,93,97)	1 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BAS [D21] Below (N=101,100,97,97,99,99)	0 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BAS [D7] Unknown (N=102,101,100,99,100,99)	0 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BAS [D28] Unknown (N=101,98,96,98,98,97)	1 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ASAT [D42] Unknown (N=101,97,95,95,96,97)	2 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BAS [D7] Below (N=102,101,100,99,100,99)	0 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	AP [D28] Within (N=101,98,96,98,98,97)	98 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	AP [D42] Above (N=101,97, 95,95,96,97)	1 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ALAT [D0] Above (N=102,101,102,100,101,102)	0 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ALAT [D21] Within (N=101,100,97,97,99,99)	96 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	AP [D0] Unknown (N=102,104, 102,100,101,102)	1 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ALAT [D7] Below (N=102,101,100,99,100,99)	0 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	AP [D182] Above (N=99,91,88,91,93,97)	3 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ALAT [D28] Below (N=101,98,96,98,98,97)	0 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ALAT [D28] Within (N=101,98,96,98,98,97)	96 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ALAT [D7] Above (N=102,101,100,99,100,99)	0 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	AP [D0] Below (N=102,104, 102,100,101,102)	0 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ASAT [D0] Below (N=102,104,102,100,101,102)	0 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	AP [D0] Within (N=102,104, 102,100,101,102)	99 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	AP [D0] Above (N=102,104, 102,100,101,102)	1 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BAS [D182] Within (N=99,91,88,91,93,97)	93 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	AP [D7] Within (N=102,101,100,99,100,99)	99 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ASAT [D182] Below (N=99,91,88,91,93,97)	0 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	AP [D7] Above (N=102,101,100,99,100,99)	1 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	AP [D21] Below (N=101,100,97,97,99,99)	0 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ALAT [D0] Within (N=102,101,102,100,101,102)	100 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	AP [D42] Within (N=101,97, 95,95,96,97)	93 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL T [D42] Unknown (N=101,97,95,95,96,97)	2 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ASAT [D28] Within (N=101,98,96,98,98,97)	98 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	AP [D63] Below (N=100,95,95,95,97,97)	0 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ALAT [D0] Below (N=102,101,102,100,101,102)	0 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BAS [D63] Unknown (N=100,95,95,95,97,97)	0 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BAS [D21] Above (N=101,100,97,97,99,99)	0 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	AP [D63] Within (N=100,95,95,95,97,97)	95 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	AP [D63] Above (N=100,95,95,95,97,97)	1 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ASAT [D63] Below (N=100,95,95,95,97,97)	0 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ASAT [D7] Below (N=102,101,100,99,100,99)	0 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BAS [D0] Below (N=102,104,102,100,101,102)	0 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ASAT [D7] Within (N=102,101,100,99,100,99)	99 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BAS [D28] Below (N=101,98,96,98,98,97)	0 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL T [D0] Unknown (N=102,104,102,100,101,102)	1 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ASAT [D7] Above (N=102,101,100,99,100,99)	1 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BAS [D42] Unknown (N=101,97,95,95,96,97)	0 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ALAT [D182] Above (N=99,91,88,91,93,97)	1 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ASAT [D21] Above (N=101,100,97,97,99,99)	1 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL T [D182] Unknown (N=99,91,88,91,93,97)	1 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ASAT [D28] Below (N=101,98,96,98,98,97)	0 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BAS [D7] Within (N=102,101,100,99,100,99)	100 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL T [D28] Below (N=101,98,96,98,98,97)	0 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL T [D28] Within (N=101,98,96,98,98,97)	97 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ALAT [D63] Above (N=100,95,95,95,97,97)	3 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL T [D28] Above (N=101,98,96,98,98,97)	1 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ASAT [D28] Above (N=101,98,96,98,98,97)	0 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL T [D42] Below (N=101,97,95,95,96,97)	0 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BAS [D21] Unknown (N=101,100,97,97,99,99)	2 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL T [D7] Unknown (N=102,101,100,99,100,99)	0 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL T [D42] Within (N=101,97,95,95,96,97)	93 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ALAT [D63] Below (N=100,95,95,95,97,97)	0 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ASAT [D182] Within (N=99,91,88,91,93,97)	91 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL T [D63] Within (N=100,95,95,95,97,97)	93 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL T [D28] Unknown (N=101,98,96,98,98,97)	0 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ASAT [D63] Within (N=100,95,95,95,97,97)	95 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL T [D182] Within (N=99,91,88,91,93,97)	90 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BAS [D21] Within (N=101,100,97,97,99,99)	97 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	AP [D7] Below (N=102,101,100,99,100,99)	0 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ALAT [D7] Unknown (N=102,101,100,99,100,99)	0 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ALAT [D21] Unknown (N=101,100,97,97,99,99)	0 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ALAT [D42] Above (N=101,97,95,95,96,97)	2 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ASAT [D63] Unknown (N=100,95,95,95,97,97)	2 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BAS [D7] Above (N=102,101,100,99,100,99)	0 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ALAT [D28] Unknown (N=101,98,96,98,98,97)	0 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ALAT [D63] Unknown (N=100,95,95,95,97,97)	1 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BAS [D42] Within (N=101,97,95,95,96,97)	96 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ALAT [D182] Unknown (N=99,91,88,91,93,97)	1 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ALAT [D182] Within (N=99,91,88,91,93,97)	91 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	AP [D182] Below (N=99,91,88,91,93,97)	0 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ALAT [D28] Above (N=101,98,96,98,98,97)	2 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	AP [D182] Within (N=99,91,88,91,93,97)	89 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ALAT [D21] Above (N=101,100,97,97,99,99)	3 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ALAT [D21] Below (N=101,100,97,97,99,99)	0 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ALAT [D7] Within (N=102,101,100,99,100,99)	100 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL T [D0] Within (N=102,104,102,100,101,102)	99 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ASAT [D0] Within (N=102,104,102,100,101,102)	99 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BAS [D0] Above (N=102,104,102,100,101,102)	0 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ASAT [D0] Above (N=102,104,102,100,101,102)	1 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BAS [D0] Within (N=102,104,102,100,101,102)	101 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL T [D63] Unknown (N=100,95,95,95,97,97)	1 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BAS [D182] Above (N=99,91,88,91,93,97)	0 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ASAT [D21] Below (N=101,100,97,97,99,99)	0 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BAS [D0] Unknown (N=102,104,102,100,101,102)	0 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ASAT [D21] Within (N=101,100,97,97,99,99)	98 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ASAT [D28] Unknown (N=101,98,96,98,98,97)	0 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BAS [D42] Below (N=101,97,95,95,96,97)	0 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ASAT [D42] Below (N=101,97,95,95,96,97)	0 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ASAT [D7] Unknown (N=102,101,100,99,100,99)	0 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL T [D21] Unknown (N=101,100,97,97,99,99)	0 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ASAT [D42] Within (N=101,97,95,95,96,97)	94 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	AP [D63] Unknown (N=100,95,95,95,97,97)	1 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	AP [D21] Unknown (N=101,100,97,97,99,99)	0 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ASAT [D42] Above (N=101,97,95,95,96,97)	0 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	AP [D7] Unknown (N=102,101,100,99,100,99)	0 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ALAT [D42] Unknown (N=101,97,95,95,96,97)	2 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ALAT [D0] Unknown (N=102,101,102,100,101,102)	1 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ASAT [D182] Above (N=99,91,88,91,93,97)	1 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL T [D182] Below (N=99,91,88,91,93,97)	0 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BAS [D63] Within (N=100,95,95,95,97,97)	97 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL T [D63] Above (N=100,95,95,95,97,97)	3 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL T [D63] Below (N=100,95,95,95,97,97)	0 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL T [D42] Above (N=101,97,95,95,96,97)	1 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BAS [D63] Below (N=100,95,95,95,97,97)	0 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BAS [D28] Within (N=101,98,96,98,98,97)	97 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL T [D21] Above (N=101,100,97,97,99,99)	2 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BAS [D42] Above (N=101,97,95,95,96,97)	0 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL T [D21] Within (N=101,100,97,97,99,99)	97 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL T [D21] Below (N=101,100,97,97,99,99)	0 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL T [D0] Below (N=102,104,102,100,101,102)	0 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL T [D7] Above (N=102,101,100,99,100,99)	1 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL T [D7] Within (N=102,101,100,99,100,99)	99 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL T [D7] Below (N=102,101,100,99,100,99)	0 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL T [D182] Above (N=99,91,88,91,93,97)	2 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL T [D0] Above (N=102,104,102,100,101,102)	1 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	AP [D21] Above (N=101,100,97,97,99,99)	2 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	AP [D28] Below (N=101,98,96,98,98,97)	0 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ALAT [D182] Below (N=99,91,88,91,93,97)	0 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ALAT [D63] Within (N=100,95,95,95,97,97)	93 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BAS [D182] Unknown (N=99,91,88,91,93,97)	0 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	AP [D28] Above (N=101,98,96,98,98,97)	0 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ALAT [D42] Within (N=101,97,95,95,96,97)	92 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	AP [D42] Below (N=101,97, 95,95,96,97)	0 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL T [D7] Below (N=102,101,100,99,100,99)	0 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ALAT [D28] Unknown (N=101,98,96,98,98,97)	1 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ALAT [D0] Unknown (N=102,101,102,100,101,102)	0 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ALAT [D182] Above (N=99,91,88,91,93,97)	2 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL T [D182] Above (N=99,91,88,91,93,97)	1 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BAS [D63] Within (N=100,95,95,95,97,97)	97 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL T [D7] Within (N=102,101,100,99,100,99)	97 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ASAT [D182] Above (N=99,91,88,91,93,97)	0 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	AP [D182] Below (N=99,91,88,91,93,97)	0 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ALAT [D28] Above (N=101,98,96,98,98,97)	4 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL T [D182] Below (N=99,91,88,91,93,97)	0 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ALAT [D21] Above (N=101,100,97,97,99,99)	1 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BAS [D182] Unknown (N=99,91,88,91,93,97)	1 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ALAT [D182] Below (N=99,91,88,91,93,97)	0 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	AP [D182] Within (N=99,91,88,91,93,97)	97 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL T [D63] Above (N=100,95,95,95,97,97)	1 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ALAT [D21] Within (N=101,100,97,97,99,99)	97 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ALAT [D21] Below (N=101,100,97,97,99,99)	0 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	AP [D28] Within (N=101,98,96,98,98,97)	96 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ALAT [D7] Within (N=102,101,100,99,100,99)	98 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BAS [D0] Below (N=102,104,102,100,101,102)	0 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL T [D0] Above (N=102,104,102,100,101,102)	1 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL T [D63] Below (N=100,95,95,95,97,97)	0 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ASAT [D0] Within (N=102,104,102,100,101,102)	101 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BAS [D0] Above (N=102,104,102,100,101,102)	0 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ALAT [D42] Within (N=101,97,95,95,96,97)	95 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BAS [D0] Within (N=102,104,102,100,101,102)	102 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL T [D0] Below (N=102,104,102,100,101,102)	0 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL T [D42] Above (N=101,97,95,95,96,97)	2 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ASAT [D0] Above (N=102,104,102,100,101,102)	1 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BAS [D63] Unknown (N=100,95,95,95,97,97)	0 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ALAT [D63] Within (N=100,95,95,95,97,97)	92 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BAS [D42] Above (N=101,97,95,95,96,97)	0 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	AP [D21] Within (N=101,100,97,97,99,99)	97 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ASAT [D21] Below (N=101,100,97,97,99,99)	0 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BAS [D0] Unknown (N=102,104,102,100,101,102)	0 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BAS [D28] Within (N=101,98,96,98,98,97)	94 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ASAT [D182] Unknown (N=99,91,88,91,93,97)	0 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BAS [D182] Within (N=99,91,88,91,93,97)	96 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL T [D21] Above (N=101,100,97,97,99,99)	1 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL T [D0] Within (N=102,104,102,100,101,102)	101 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL T [D21] Within (N=101,100,97,97,99,99)	97 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	AP [D28] Above (N=101,98,96,98,98,97)	0 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ASAT [D42] Below (N=101,97,95,95,96,97)	0 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ASAT [D7] Unknown (N=102,101,100,99,100,99)	0 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ALAT [D63] Below (N=100,95,95,95,97,97)	0 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	AP [D63] Unknown (N=100,95,95,95,97,97)	2 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL T [D21] Below (N=101,100,97,97,99,99)	0 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BAS [D42] Within (N=101,97,95,95,96,97)	97 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ASAT [D42] Within (N=101,97,95,95,96,97)	97 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	AP [D28] Below (N=101,98,96,98,98,97)	0 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	AP [D21] Unknown (N=101,100,97,97,99,99)	1 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BAS [D42] Below (N=101,97,95,95,96,97)	0 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL T [D21] Unknown (N=101,100,97,97,99,99)	1 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	AP [D21] Below (N=101,100,97,97,99,99)	0 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ASAT [D42] Above (N=101,97,95,95,96,97)	0 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	AP [D7] Unknown (N=102,101,100,99,100,99)	0 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL T [D7] Above (N=102,101,100,99,100,99)	2 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ASAT [D63] Below (N=100,95,95,95,97,97)	0 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ALAT [D42] Unknown (N=101,97,95,95,96,97)	0 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ASAT [D182] Within (N=99,91,88,91,93,97)	97 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BAS [D21] Unknown (N=101,100,97,97,99,99)	4 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	AP [D7] Below (N=102,101,100,99,100,99)	0 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	AP [D0] Within (N=102,104, 102,100,101,102)	101 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BAS [D28] Above (N=101,98,96,98,98,97)	0 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ASAT [D0] Below (N=102,104,102,100,101,102)	0 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ASAT [D182] Below (N=99,91,88,91,93,97)	0 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	AP [D182] Above (N=99,91,88,91,93,97)	0 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ALAT [D63] Unknown (N=100,95,95,95,97,97)	2 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL T [D28] Below (N=101,98,96,98,98,97)	0 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ALAT [D63] Above (N=100,95,95,95,97,97)	3 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BAS [D182] Below (N=99,91,88,91,93,97)	0 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ALAT [D7] Above (N=102,101,100,99,100,99)	1 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ASAT [D21] Unknown (N=101,100,97,97,99,99)	1 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL T [D28] Within (N=101,98,96,98,98,97)	95 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	AP [D182] Unknown (N=99,91,88,91,93,97)	0 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ALAT [D7] Below (N=102,101,100,99,100,99)	0 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ALAT [D0] Above (N=102,101,102,100,101,102)	3 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ALAT [D28] Below (N=101,98,96,98,98,97)	0 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ALAT [D7] Unknown (N=102,101,100,99,100,99)	0 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL T [D28] Above (N=101,98,96,98,98,97)	1 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ALAT [D0] Below (N=102,101,102,100,101,102)	0 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ALAT [D42] Above (N=101,97,95,95,96,97)	2 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ASAT [D28] Above (N=101,98,96,98,98,97)	3 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BAS [D21] Below (N=101,100,97,97,99,99)	0 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BAS [D21] Within (N=101,100,97,97,99,99)	95 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL T [D42] Below (N=101,97,95,95,96,97)	0 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	AP [D7] Above (N=102,101,100,99,100,99)	1 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ASAT [D63] Above (N=100,95,95,95,97,97)	2 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	AP [D21] Above (N=101,100,97,97,99,99)	1 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL T [D63] Unknown (N=100,95,95,95,97,97)	2 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL T [D182] Unknown (N=99,91,88,91,93,97)	0 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL T [D42] Within (N=101,97,95,95,96,97)	95 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ALAT [D21] Unknown (N=101,100,97,97,99,99)	1 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BAS [D7] Above (N=102,101,100,99,100,99)	0 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ASAT [D63] Unknown (N=100,95,95,95,97,97)	2 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ALAT [D28] Within (N=101,98,96,98,98,97)	92 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL T [D28] Unknown (N=101,98,96,98,98,97)	1 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ALAT [D42] Below (N=101,97,95,95,96,97)	0 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL T [D42] Unknown (N=101,97,95,95,96,97)	0 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL T [D63] Within (N=100,95,95,95,97,97)	94 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	AP [D63] Above (N=100,95,95,95,97,97)	1 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BAS [D28] Unknown (N=101,98,96,98,98,97)	3 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	AP [D0] Below (N=102,104, 102,100,101,102)	0 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BAS [D21] Above (N=101,100,97,97,99,99)	0 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	AP [D63] Within (N=100,95,95,95,97,97)	94 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	AP [D28] Unknown (N=101,98,96,98,98,97)	1 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ASAT [D7] Below (N=102,101,100,99,100,99)	0 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	AP [D63] Below (N=100,95,95,95,97,97)	0 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	AP [D42] Above (N=101,97, 95,95,96,97)	1 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BAS [D63] Below (N=100,95,95,95,97,97)	0 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	AP [D42] Within (N=101,97, 95,95,96,97)	96 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ASAT [D63] Within (N=100,95,95,95,97,97)	93 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ASAT [D7] Within (N=102,101,100,99,100,99)	97 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BAS [D7] Unknown (N=102,101,100,99,100,99)	0 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BAS [D63] Above (N=100,95,95,95,97,97)	0 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BAS [D28] Below (N=101,98,96,98,98,97)	0 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ASAT [D0] Unknown (N=102,104,102,100,101,102)	0 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ALAT [D182] Unknown (N=99,91,88,91,93,97)	0 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ASAT [D7] Above (N=102,101,100,99,100,99)	2 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BAS [D42] Unknown (N=101,97,95,95,96,97)	0 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL T [D0] Unknown (N=102,104,102,100,101,102)	0 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BAS [D7] Below (N=102,101,100,99,100,99)	0 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	AP [D42] Below (N=101,97, 95,95,96,97)	0 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ASAT [D21] Within (N=101,100,97,97,99,99)	97 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL T [D182] Within (N=99,91,88,91,93,97)	96 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	AP [D42] Unknown (N=101,97, 95,95,96,97)	0 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BIL T [D7] Unknown (N=102,101,100,99,100,99)	0 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BAS [D182] Above (N=99,91,88,91,93,97)	0 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	AP [D0] Above (N=102,104, 102,100,101,102)	1 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ASAT [D21] Above (N=101,100,97,97,99,99)	1 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ALAT [D0] Within (N=102,101,102,100,101,102)	99 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ASAT [D42] Unknown (N=101,97,95,95,96,97)	0 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	AP [D7] Within (N=102,101,100,99,100,99)	98 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ASAT [D28] Unknown (N=101,98,96,98,98,97)	1 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ASAT [D28] Below (N=101,98,96,98,98,97)	0 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ALAT [D182] Within (N=99,91,88,91,93,97)	95 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	AP [D0] Unknown (N=102,104, 102,100,101,102)	0 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	BAS [D7] Within (N=102,101,100,99,100,99)	99 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed	ASAT [D28] Within (N=101,98,96,98,98,97)	93 Subjects

Secondary

Number of Subjects Reporting Medically Attended Visits (MAEs).

The day 368 was the last contact day for the last subject reporting the event. For each solicited and unsolicited symptom the subject experienced, the subject was asked if they received medical attention defined as hospitalization, an emergency room visit or a visit to or from medical personnel for any reason.

Time frame: During the entire study period (Days 0-368).

Population: The Total Vaccinated Cohort included all vaccinated subjects.

Arm	Measure	Value (NUMBER)
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Medically Attended Visits (MAEs).	51 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Medically Attended Visits (MAEs).	42 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Medically Attended Visits (MAEs).	40 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Medically Attended Visits (MAEs).	42 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Medically Attended Visits (MAEs).	38 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Medically Attended Visits (MAEs).	45 Subjects

Secondary

Number of Subjects Reporting Potential Immune Diseases (pIMDs).

The day 406 was the last contact day with the subjects reporting the event. Potential immune-mediated diseases (pIMDs) are a subset of AEs that include both clearly autoimmune diseases and also other inflammatory and/or neurologic disorders which may or may not have an autoimmune etiology.

Time frame: During the entire study period (Days 0-406).

Population: The Total Vaccinated Cohort included all vaccinated subjects.

Arm	Measure	Value (NUMBER)
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Potential Immune Diseases (pIMDs).	0 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Potential Immune Diseases (pIMDs).	0 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Potential Immune Diseases (pIMDs).	0 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Potential Immune Diseases (pIMDs).	0 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Potential Immune Diseases (pIMDs).	0 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Potential Immune Diseases (pIMDs).	1 Subjects

Secondary

Number of Subjects Reporting Serious Adverse Events (SAEs).

The day 329 was the last contact day with the subjects reporting serious adverse events. SAEs assessed include medical occurrences that results in death, are life threatening, require hospitalization or prolongation of hospitalization, results in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subjects.

Time frame: During the entire study period (Days 0-329).

Population: The Total Vaccinated Cohort included all vaccinated subjects.

Arm	Measure	Value (NUMBER)
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Serious Adverse Events (SAEs).	3 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Serious Adverse Events (SAEs).	1 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Serious Adverse Events (SAEs).	1 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Serious Adverse Events (SAEs).	2 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Serious Adverse Events (SAEs).	1 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Serious Adverse Events (SAEs).	3 Subjects

Secondary

Number of Subjects Reporting Solicited General Symptoms.

Solicited general symptoms assessed were fatigue, headache, joint pain at other location, muscle aches, shivering, sweating and temperature. Temperature is defined as an axillary temperature equal to or above 38.0 degrees Celsius (°C).

Time frame: During a 7-day follow-up period (Days 0-6) post-vaccination period

Population: The Total Vaccinated cohort included all vaccinated subjects

Arm	Measure	Group	Value (NUMBER)
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Solicited General Symptoms.	Temperature (axillary) >=38°C	3 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Solicited General Symptoms.	Shivering	21 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Solicited General Symptoms.	Headache	52 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Solicited General Symptoms.	Fatigue	54 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Solicited General Symptoms.	Muscle aches	38 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Solicited General Symptoms.	Sweating	22 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Solicited General Symptoms.	Joint pain at other location	24 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Solicited General Symptoms.	Shivering	30 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Solicited General Symptoms.	Fatigue	62 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Solicited General Symptoms.	Sweating	21 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Solicited General Symptoms.	Joint pain at other location	34 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Solicited General Symptoms.	Headache	58 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Solicited General Symptoms.	Temperature (axillary) >=38°C	9 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Solicited General Symptoms.	Muscle aches	52 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Solicited General Symptoms.	Fatigue	41 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Solicited General Symptoms.	Headache	51 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Solicited General Symptoms.	Joint pain at other location	24 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Solicited General Symptoms.	Muscle aches	39 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Solicited General Symptoms.	Shivering	19 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Solicited General Symptoms.	Sweating	21 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Solicited General Symptoms.	Temperature (axillary) >=38°C	3 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Solicited General Symptoms.	Headache	51 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Solicited General Symptoms.	Muscle aches	53 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Solicited General Symptoms.	Shivering	24 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Solicited General Symptoms.	Fatigue	58 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Solicited General Symptoms.	Temperature (axillary) >=38°C	2 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Solicited General Symptoms.	Sweating	17 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Solicited General Symptoms.	Joint pain at other location	28 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Solicited General Symptoms.	Sweating	12 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Solicited General Symptoms.	Joint pain at other location	26 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Solicited General Symptoms.	Muscle aches	43 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Solicited General Symptoms.	Temperature (axillary) >=38°C	1 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Solicited General Symptoms.	Shivering	21 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Solicited General Symptoms.	Fatigue	57 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Solicited General Symptoms.	Headache	49 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Solicited General Symptoms.	Temperature (axillary) >=38°C	4 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Solicited General Symptoms.	Shivering	25 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Solicited General Symptoms.	Joint pain at other location	23 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Solicited General Symptoms.	Sweating	25 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Solicited General Symptoms.	Muscle aches	54 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Solicited General Symptoms.	Fatigue	56 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Solicited General Symptoms.	Headache	54 Subjects

Secondary

Number of Subjects Reporting Solicited Local Symptoms.

Solicited local symptoms assessed were pain, redness and swelling

Time frame: During a 7-day follow-up period (Days 0-6) post-vaccination period

Population: The Total Vaccinated cohort included all vaccinated subjects

Arm	Measure	Group	Value (NUMBER)
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Solicited Local Symptoms.	Redness	2 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Solicited Local Symptoms.	Pain	75 Subjects
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Solicited Local Symptoms.	Swelling	2 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Solicited Local Symptoms.	Redness	6 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Solicited Local Symptoms.	Pain	89 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Solicited Local Symptoms.	Swelling	15 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Solicited Local Symptoms.	Redness	1 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Solicited Local Symptoms.	Pain	66 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Solicited Local Symptoms.	Swelling	2 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Solicited Local Symptoms.	Redness	5 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Solicited Local Symptoms.	Pain	94 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Solicited Local Symptoms.	Swelling	9 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Solicited Local Symptoms.	Redness	1 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Solicited Local Symptoms.	Pain	69 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Solicited Local Symptoms.	Swelling	0 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Solicited Local Symptoms.	Pain	95 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Solicited Local Symptoms.	Swelling	16 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Solicited Local Symptoms.	Redness	11 Subjects

Secondary

Number of Subjects Reporting Unsolicited Adverse Events (AEs).

An unsolicited adverse event is any adverse event (i.e. any untoward medical occurrence in a patient or clinical investigation subject, temporally associated with use of a medicinal product, whether or not considered related to the medicinal product) reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms.

Time frame: Within the 84-day (Days 0-83) post-vaccination period.

Population: The Total Vaccinated Cohort included all vaccinated subjects.

Arm	Measure	Value (NUMBER)
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Number of Subjects Reporting Unsolicited Adverse Events (AEs).	68 Subjects
Flulaval/Placebo/Arepanrix Group	Number of Subjects Reporting Unsolicited Adverse Events (AEs).	65 Subjects
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Number of Subjects Reporting Unsolicited Adverse Events (AEs).	57 Subjects
Flulaval/Arepanrix/Placebo Group	Number of Subjects Reporting Unsolicited Adverse Events (AEs).	57 Subjects
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Unsolicited Adverse Events (AEs).	62 Subjects
Arepanrix/Placebo/Flulaval Group	Number of Subjects Reporting Unsolicited Adverse Events (AEs).	63 Subjects

Secondary

Number of Subjects With a Microneutralization Titer Greater Than or Equal to 1:28 for Antibodies Against A/California/7/2009 (H1N1) Strain.

Arepanrix vaccine strain and the unadjuvanted formulation of Arepanrix vaccine strain was A/California/7/2009 (H1N1). The antibody cut-off value assessed was a titer of 1:10 and this value was considered as seropositivity. Seronegative subject is a subject whose antibody titer is below the cut-off value, a seropositive subject is a subject whose antibody titer is greater than or equal to the cut-off value. Microneutralization titers \< 1:28 were considered below the cut-off. Microneutralization testing was cancelled.

Time frame: On Days 0, 21, 42, 63 and 182

Population: Microneutralization testing was cancelled.

Secondary

Seroconversion Factor for Antibodies Against A/California Strain.

Seroconversion factor was defined as the geometric mean of the within-subject ratios of the post-vaccination reciprocal HI titer to the prevaccination reciprocal HI titer.

Time frame: At Day 63 from Day 21 for Flulaval/placebo/unadjuvanted Arepanrix and Flulaval/placebo/Arepanrix Groups; At Day 42 from Day 0 for the 4 other groups

Arm	Measure	Value (MEAN)
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Seroconversion Factor for Antibodies Against A/California Strain.	8.2 Fold
Flulaval/Placebo/Arepanrix Group	Seroconversion Factor for Antibodies Against A/California Strain.	24.6 Fold
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Seroconversion Factor for Antibodies Against A/California Strain.	20.9 Fold
Flulaval/Arepanrix/Placebo Group	Seroconversion Factor for Antibodies Against A/California Strain.	54.9 Fold
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Seroconversion Factor for Antibodies Against A/California Strain.	41.5 Fold
Arepanrix/Placebo/Flulaval Group	Seroconversion Factor for Antibodies Against A/California Strain.	92.4 Fold

Secondary

Seroconversion Factor for Antibodies Against Flulaval Vaccine Strains.

Seroconversion factor of the within-subject ratios of the post-vaccination reciprocal HI titer to the Day 0 reciprocal HI titer. Flulaval vaccines strains were A/Brisbane/59/2007 H1N1, A/Uruguay/716/2007 H3N2 and B/Brisbane/60/2008.

Time frame: On Days 21 and 63 from Day 0 for the first 4 groups and on Days 42 and 63 from Day 0 for the Unadjuvanted Arepanrix/placebo/Flulaval and Arepanrix/placebo/Flulaval Groups

Arm	Measure	Group	Value (MEAN)
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Seroconversion Factor for Antibodies Against Flulaval Vaccine Strains.	Flu A/Uru/716/07 H3N2 [at Day 63 post dose 1]	13.3 Fold
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Seroconversion Factor for Antibodies Against Flulaval Vaccine Strains.	Flu B:Bri/60/08 [Day 21 or 42 post dose 1]	12.6 Fold
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Seroconversion Factor for Antibodies Against Flulaval Vaccine Strains.	Flu A/Uru/716/07 H3N2 [Day 21 or 42 post dose 1]	17.4 Fold
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Seroconversion Factor for Antibodies Against Flulaval Vaccine Strains.	Flu A/Bri/59/07 H1N1 [at Day 63 post dose 1]	6.9 Fold
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Seroconversion Factor for Antibodies Against Flulaval Vaccine Strains.	Flu A/Bri/59/07 H1N1 [Day 21 or 42 post dose 1]	8.4 Fold
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Seroconversion Factor for Antibodies Against Flulaval Vaccine Strains.	Flu B/Bri/60/08 [at Day 63 post dose 1]	9.6 Fold
Flulaval/Placebo/Arepanrix Group	Seroconversion Factor for Antibodies Against Flulaval Vaccine Strains.	Flu A/Bri/59/07 H1N1 [at Day 63 post dose 1]	11.2 Fold
Flulaval/Placebo/Arepanrix Group	Seroconversion Factor for Antibodies Against Flulaval Vaccine Strains.	Flu A/Uru/716/07 H3N2 [at Day 63 post dose 1]	11.7 Fold
Flulaval/Placebo/Arepanrix Group	Seroconversion Factor for Antibodies Against Flulaval Vaccine Strains.	Flu B:Bri/60/08 [Day 21 or 42 post dose 1]	13.9 Fold
Flulaval/Placebo/Arepanrix Group	Seroconversion Factor for Antibodies Against Flulaval Vaccine Strains.	Flu B/Bri/60/08 [at Day 63 post dose 1]	10.0 Fold
Flulaval/Placebo/Arepanrix Group	Seroconversion Factor for Antibodies Against Flulaval Vaccine Strains.	Flu A/Bri/59/07 H1N1 [Day 21 or 42 post dose 1]	12.9 Fold
Flulaval/Placebo/Arepanrix Group	Seroconversion Factor for Antibodies Against Flulaval Vaccine Strains.	Flu A/Uru/716/07 H3N2 [Day 21 or 42 post dose 1]	15.5 Fold
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Seroconversion Factor for Antibodies Against Flulaval Vaccine Strains.	Flu B/Bri/60/08 [at Day 63 post dose 1]	7.9 Fold
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Seroconversion Factor for Antibodies Against Flulaval Vaccine Strains.	Flu A/Uru/716/07 H3N2 [Day 21 or 42 post dose 1]	20.6 Fold
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Seroconversion Factor for Antibodies Against Flulaval Vaccine Strains.	Flu A/Bri/59/07 H1N1 [at Day 63 post dose 1]	8.4 Fold
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Seroconversion Factor for Antibodies Against Flulaval Vaccine Strains.	Flu B:Bri/60/08 [Day 21 or 42 post dose 1]	10.5 Fold
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Seroconversion Factor for Antibodies Against Flulaval Vaccine Strains.	Flu A/Uru/716/07 H3N2 [at Day 63 post dose 1]	15.0 Fold
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Seroconversion Factor for Antibodies Against Flulaval Vaccine Strains.	Flu A/Bri/59/07 H1N1 [Day 21 or 42 post dose 1]	12.0 Fold
Flulaval/Arepanrix/Placebo Group	Seroconversion Factor for Antibodies Against Flulaval Vaccine Strains.	Flu A/Bri/59/07 H1N1 [Day 21 or 42 post dose 1]	9.6 Fold
Flulaval/Arepanrix/Placebo Group	Seroconversion Factor for Antibodies Against Flulaval Vaccine Strains.	Flu A/Uru/716/07 H3N2 [Day 21 or 42 post dose 1]	19.3 Fold
Flulaval/Arepanrix/Placebo Group	Seroconversion Factor for Antibodies Against Flulaval Vaccine Strains.	Flu B/Bri/60/08 [at Day 63 post dose 1]	10.8 Fold
Flulaval/Arepanrix/Placebo Group	Seroconversion Factor for Antibodies Against Flulaval Vaccine Strains.	Flu A/Uru/716/07 H3N2 [at Day 63 post dose 1]	14.6 Fold
Flulaval/Arepanrix/Placebo Group	Seroconversion Factor for Antibodies Against Flulaval Vaccine Strains.	Flu A/Bri/59/07 H1N1 [at Day 63 post dose 1]	7.6 Fold
Flulaval/Arepanrix/Placebo Group	Seroconversion Factor for Antibodies Against Flulaval Vaccine Strains.	Flu B:Bri/60/08 [Day 21 or 42 post dose 1]	14.3 Fold
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Seroconversion Factor for Antibodies Against Flulaval Vaccine Strains.	Flu A/Bri/59/07 H1N1 [Day 21 or 42 post dose 1]	2.3 Fold
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Seroconversion Factor for Antibodies Against Flulaval Vaccine Strains.	Flu A/Uru/716/07 H3N2 [at Day 63 post dose 1]	20.8 Fold
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Seroconversion Factor for Antibodies Against Flulaval Vaccine Strains.	Flu B/Bri/60/08 [at Day 63 post dose 1]	11.4 Fold
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Seroconversion Factor for Antibodies Against Flulaval Vaccine Strains.	Flu A/Uru/716/07 H3N2 [Day 21 or 42 post dose 1]	1.2 Fold
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Seroconversion Factor for Antibodies Against Flulaval Vaccine Strains.	Flu B:Bri/60/08 [Day 21 or 42 post dose 1]	1.3 Fold
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Seroconversion Factor for Antibodies Against Flulaval Vaccine Strains.	Flu A/Bri/59/07 H1N1 [at Day 63 post dose 1]	9.4 Fold
Arepanrix/Placebo/Flulaval Group	Seroconversion Factor for Antibodies Against Flulaval Vaccine Strains.	Flu A/Bri/59/07 H1N1 [at Day 63 post dose 1]	10.1 Fold
Arepanrix/Placebo/Flulaval Group	Seroconversion Factor for Antibodies Against Flulaval Vaccine Strains.	Flu A/Bri/59/07 H1N1 [Day 21 or 42 post dose 1]	3.2 Fold
Arepanrix/Placebo/Flulaval Group	Seroconversion Factor for Antibodies Against Flulaval Vaccine Strains.	Flu A/Uru/716/07 H3N2 [at Day 63 post dose 1]	19.3 Fold
Arepanrix/Placebo/Flulaval Group	Seroconversion Factor for Antibodies Against Flulaval Vaccine Strains.	Flu B/Bri/60/08 [at Day 63 post dose 1]	11.9 Fold
Arepanrix/Placebo/Flulaval Group	Seroconversion Factor for Antibodies Against Flulaval Vaccine Strains.	Flu A/Uru/716/07 H3N2 [Day 21 or 42 post dose 1]	1.7 Fold
Arepanrix/Placebo/Flulaval Group	Seroconversion Factor for Antibodies Against Flulaval Vaccine Strains.	Flu B:Bri/60/08 [Day 21 or 42 post dose 1]	2.4 Fold

Secondary

Seroconversion Factor for Antibodies Against Flulaval Vaccine Strains.

Seroconversion factor was defined as the geometric mean of the within-subject ratios of the post-vaccination reciprocal Hemagglutination Inhibition (HI) titer to the prevaccination reciprocal HI titer. Flulaval vaccines strains were A/Brisbane/59/2007 H1N1, A/Uruguay/716/2007 H3N2 and B/Brisbane/60/2008. For the analysis the Flulaval/placebo/unadjuvanted Arepanrix Group and the Flulaval/placebo/Arepanrix Group were pooled.

Arm	Measure	Group	Value (MEAN)
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Seroconversion Factor for Antibodies Against Flulaval Vaccine Strains.	Flu A/Bri/59/07 H1N1	12.0 Fold
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Seroconversion Factor for Antibodies Against Flulaval Vaccine Strains.	Flu B/Bri/60/08	10.5 Fold
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Seroconversion Factor for Antibodies Against Flulaval Vaccine Strains.	Flu A/Uru/716/07 H3N2	20.6 Fold
Flulaval/Arepanrix/Placebo Group	Seroconversion Factor for Antibodies Against Flulaval Vaccine Strains.	Flu A/Uru/716/07 H3N2	19.3 Fold
Flulaval/Arepanrix/Placebo Group	Seroconversion Factor for Antibodies Against Flulaval Vaccine Strains.	Flu A/Bri/59/07 H1N1	9.6 Fold
Flulaval/Arepanrix/Placebo Group	Seroconversion Factor for Antibodies Against Flulaval Vaccine Strains.	Flu B/Bri/60/08	14.3 Fold
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Seroconversion Factor for Antibodies Against Flulaval Vaccine Strains.	Flu A/Uru/716/07 H3N2	17.3 Fold
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Seroconversion Factor for Antibodies Against Flulaval Vaccine Strains.	Flu A/Bri/59/07 H1N1	4.2 Fold
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Seroconversion Factor for Antibodies Against Flulaval Vaccine Strains.	Flu B/Bri/60/08	8.6 Fold
Arepanrix/Placebo/Flulaval Group	Seroconversion Factor for Antibodies Against Flulaval Vaccine Strains.	Flu A/Bri/59/07 H1N1	3.1 Fold
Arepanrix/Placebo/Flulaval Group	Seroconversion Factor for Antibodies Against Flulaval Vaccine Strains.	Flu B/Bri/60/08	4.9 Fold
Arepanrix/Placebo/Flulaval Group	Seroconversion Factor for Antibodies Against Flulaval Vaccine Strains.	Flu A/Uru/716/07 H3N2	11.6 Fold
Flulaval/Placebo/(Unadjuvanted) Arepanrix Pooled Group	Seroconversion Factor for Antibodies Against Flulaval Vaccine Strains.	Flu A/Uru/716/07 H3N2	16.5 Fold
Flulaval/Placebo/(Unadjuvanted) Arepanrix Pooled Group	Seroconversion Factor for Antibodies Against Flulaval Vaccine Strains.	Flu A/Bri/59/07 H1N1	10.3 Fold
Flulaval/Placebo/(Unadjuvanted) Arepanrix Pooled Group	Seroconversion Factor for Antibodies Against Flulaval Vaccine Strains.	Flu B/Bri/60/08	13.2 Fold

Secondary

Seroconversion Factor for Antibodies Against Flulaval Vaccine Strains.

Time frame: At Day 182 from Day 0

Arm	Measure	Group	Value (MEAN)
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Seroconversion Factor for Antibodies Against Flulaval Vaccine Strains.	Flu A/Bri/59/07 H1N1	4.0 Fold
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Seroconversion Factor for Antibodies Against Flulaval Vaccine Strains.	Flu A/Uru/716/07 H3N2	9.0 Fold
Flulaval/Placebo/Unadjuvanted Arepanrix Group	Seroconversion Factor for Antibodies Against Flulaval Vaccine Strains.	Flu B/Bri/60/08 Victoria	6.7 Fold
Flulaval/Placebo/Arepanrix Group	Seroconversion Factor for Antibodies Against Flulaval Vaccine Strains.	Flu B/Bri/60/08 Victoria	5.7 Fold
Flulaval/Placebo/Arepanrix Group	Seroconversion Factor for Antibodies Against Flulaval Vaccine Strains.	Flu A/Uru/716/07 H3N2	7.2 Fold
Flulaval/Placebo/Arepanrix Group	Seroconversion Factor for Antibodies Against Flulaval Vaccine Strains.	Flu A/Bri/59/07 H1N1	5.2 Fold
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Seroconversion Factor for Antibodies Against Flulaval Vaccine Strains.	Flu B/Bri/60/08 Victoria	5.5 Fold
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Seroconversion Factor for Antibodies Against Flulaval Vaccine Strains.	Flu A/Uru/716/07 H3N2	9.7 Fold
Flulaval/Unadjuvanted Arepanrix/Placebo Group	Seroconversion Factor for Antibodies Against Flulaval Vaccine Strains.	Flu A/Bri/59/07 H1N1	4.7 Fold
Flulaval/Arepanrix/Placebo Group	Seroconversion Factor for Antibodies Against Flulaval Vaccine Strains.	Flu A/Bri/59/07 H1N1	3.7 Fold
Flulaval/Arepanrix/Placebo Group	Seroconversion Factor for Antibodies Against Flulaval Vaccine Strains.	Flu A/Uru/716/07 H3N2	8.5 Fold
Flulaval/Arepanrix/Placebo Group	Seroconversion Factor for Antibodies Against Flulaval Vaccine Strains.	Flu B/Bri/60/08 Victoria	6.8 Fold
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Seroconversion Factor for Antibodies Against Flulaval Vaccine Strains.	Flu B/Bri/60/08 Victoria	6.9 Fold
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Seroconversion Factor for Antibodies Against Flulaval Vaccine Strains.	Flu A/Uru/716/07 H3N2	9.9 Fold
Unadjuvanted Arepanrix/Placebo/Flulaval Group	Seroconversion Factor for Antibodies Against Flulaval Vaccine Strains.	Flu A/Bri/59/07 H1N1	4.4 Fold
Arepanrix/Placebo/Flulaval Group	Seroconversion Factor for Antibodies Against Flulaval Vaccine Strains.	Flu A/Bri/59/07 H1N1	5.0 Fold
Arepanrix/Placebo/Flulaval Group	Seroconversion Factor for Antibodies Against Flulaval Vaccine Strains.	Flu B/Bri/60/08 Victoria	6.4 Fold
Arepanrix/Placebo/Flulaval Group	Seroconversion Factor for Antibodies Against Flulaval Vaccine Strains.	Flu A/Uru/716/07 H3N2	10.6 Fold

Secondary

Vaccine Response Rates (VRR) for Microneutralization Antibody Titers Against A/California/7/2009 (H1N1) Strain.

Arepanrix vaccine strain and the unadjuvanted formulation of Arepanrix vaccine strain was A/California/7/2009 (H1N1). Vaccine Response Rate for microneutralization titers was defined as the incidence rate of vaccinees with at least a 4-fold increase in post vaccination reciprocal titer relative to Day 0. Microneutralization testing was cancelled.

Time frame: On Days 0, 21, 42, 63 and 182

Population: Microneutralization testing was cancelled.

Source: ClinicalTrials.gov · Data processed: Feb 17, 2026

Safety and Immunogenicity of H1N1 Vaccine With Trivalent Inactivated Seasonal Influenza Vaccine in Adults

Conditions

Keywords

Brief summary

Detailed description

Related papers

Interventions

Sponsors

Study design

Eligibility

Inclusion criteria

Exclusion criteria

Design outcomes

Primary

Secondary

Countries

Participant flow

Participants by arm

Withdrawals & dropouts

Baseline characteristics

Adverse events

Outcome results

Hemagglutination Inhibition (HI) Antibody Titers Against A/California/7/2009 H1N1 Vaccine Strain.

Hemagglutination Inhibition (HI) Antibody Titers Against A/California/7/2009 H1N1 Vaccine Strain.

Geometric Mean Antibody Titers (GMTs) for Hemagglutination Inhibition (HI) Antibodies Against Flu A/California H1N1 Strain.

Geometric Mean Antibody Titers (GMTs) for Hemagglutination Inhibition (HI) Antibodies Against Flu A/California H1N1 Strain.

Geometric Mean Antibody Titers (GMTs) for Hemagglutination Inhibition (HI) Antibodies Against Flulaval Vaccine Strains.

Geometric Mean Antibody Titers (GMTs) for Hemagglutination Inhibition (HI) Antibodies Against Flulaval Vaccine Strains.

Hemagglutination Inhibition (HI) Antibody Titers Against A/California/7/2009 H1N1 Vaccine Strain.

Hemagglutination Inhibition (HI) Antibody Titers Against A/California/7/2009 H1N1 Vaccine Strain.

Hemagglutination Inhibition (HI) Antibody Titers Against A/California/7/2009 H1N1 Vaccine Strain.

Hemagglutination Inhibition (HI) Antibody Titers Against Each of the Three Flulaval Strains.

Hemagglutination Inhibition (HI) Antibody Titers Against Each of the Three Flulaval Strains.

Hemagglutination Inhibition (HI) Antibody Titers Against Each of the Three Flulaval Strains.

Hemagglutination Inhibition (HI) Antibody Titers Against Each of the Three Flulaval Strains.

Microneutralization Antibody Titers Against A/California/7/2009 (H1N1) Strain.

Number of Influenza-specific Cluster of Differentiation 4 (CD4) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).

Number of Influenza-specific Cluster of Differentiation 8 (CD8) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).

Number of Seroconverted Subjects for Antibodies Against A/ California Strain.

Number of Seroconverted Subjects for Antibodies Against Flulaval Vaccine Strains

Number of Seroconverted Subjects for Antibodies Against Flulaval Vaccine Strains

Number of Seroconverted Subjects for Antibodies Against Flulaval Vaccine Strains.

Number of Seroprotected Subjects for Antibodies Against A/California Strain.

Number of Seroprotected Subjects for Antibodies Against Flulaval Vaccine Strains

Number of Seroprotected Subjects for Antibodies Against Flulaval Vaccine Strains.

Number of Seroprotected Subjects for Antibodies Against Flulaval Vaccine Strains.

Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed

Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed

Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed

Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed

Number of Subjects Reporting Medically Attended Visits (MAEs).

Number of Subjects Reporting Potential Immune Diseases (pIMDs).

Number of Subjects Reporting Serious Adverse Events (SAEs).

Number of Subjects Reporting Solicited General Symptoms.

Number of Subjects Reporting Solicited Local Symptoms.

Number of Subjects Reporting Unsolicited Adverse Events (AEs).

Number of Subjects With a Microneutralization Titer Greater Than or Equal to 1:28 for Antibodies Against A/California/7/2009 (H1N1) Strain.

Seroconversion Factor for Antibodies Against A/California Strain.

Seroconversion Factor for Antibodies Against Flulaval Vaccine Strains.

Seroconversion Factor for Antibodies Against Flulaval Vaccine Strains.

Seroconversion Factor for Antibodies Against Flulaval Vaccine Strains.

Vaccine Response Rates (VRR) for Microneutralization Antibody Titers Against A/California/7/2009 (H1N1) Strain.